Programs: Recent Episodes
ReachMD
Host: Ezra Cohen, MD, FRCPSC, FASCO
Guest: Petr Szturz, MD, PhD
While key clinical trials inform our management philosophy for patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), the paucity of predictive markers, limited guidance to treatment sequencing, and inherent therapeutic toxicity provide challenges for both clinicians and patients. How can we best stratify our patients to ensure the most optimal outcomes? Join Drs. Ezra Cohen and Petr Szturz as they offer cogent answers to the difficult questions you face in your daily medical practice.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Eric Klein, MD
While the state of cancer screening hasn’t seen too many changes over the years, the results from the PATHFINDER study may offer clinicians a new screening tool. Dr. Eric Klein from the Glickman Urological and Kidney Institute dives into this clinical data and how it might impact cancer screening protocols.
Host: Jennifer Caudle, DO
Guest: Christopher D. Altman, PharmD
Shingles can impact many of our patients 50 years and older, which is why we need to talk to them about their risk. To take a look at counselling strategies, Dr. Jennifer Caudle is joined by Dr. Christopher Altman, Director of Immunization & Clinical Programs.
Sponsored by GSK
Host: Jennifer Caudle, DO
Guest: Christopher D. Altman, PharmD
Joining Dr. Jennifer Caudle to discuss how to talk to vaccine-hesitant patients about shingles vaccination and share insights is Dr. Christopher Altman, Director of Immunization and Clinical programs.
Sponsored by GSK
Host: Jennifer Caudle, DO
Guest: Christopher D. Altman, PharmD
Counseling your patients about their risk of shingles—and encouraging them to get vaccinated—can help better protect them. But how do we do that? To answer this question, Dr. Christopher Altman discusses the risk of shingles with Dr. Jennifer Caudle.
Sponsored by GSK
Host: Jennifer Caudle, DO
Guest: Christopher D. Altman, PharmD
How can we improve rates for shingles vaccination across all ethnicities? To find out how, Dr. Jennifer Caudle is joined by Dr. Christopher Altman to explore discrepancies in vaccination rates.
Sponsored by GSK
Host: Jennifer Caudle, DO
Guest: Christopher D. Altman, PharmD
Joining Dr. Jennifer Caudle to explore how we should approach vaccine hesitancy and address concerns about cost and time constraints for shingles vaccination is Dr. Christopher Altman, Director of Immunization and Clinical Programs.
Sponsored by GSK
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Wendy Wright, DNP, FNP-BC, ANP-BC, FAANP, FAAN, FNAP
Physicians and advanced practice registered nurses (APRNs) may practice differently but they can still get their patient to the same outcome. So where do the conflicts arise? Join Dr. Peter Buch as he walks us through this with Dr. Wendy Wright, nurse practitioner and founder of Wright & Associates Family Healthcare.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Koji Hashimoto, MD, PhD
What facts should we keep in mind when considering liver transplantation? And how do we determine which of our patients are the right candidates? Dr. Peter Buch explores important considerations for liver transplantation with Dr. Koji Hashimoto, the Director of Liver Transplantation at the Cleveland Clinic.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: John Pandolfino, MD, MSCI
From bird beaking to functional lumen imaging probes (FLIP), what do we need to know about the presentation and treatment of achalasia? Dr. Peter Buch speaks with Dr. John Pandolfino from the Feinberg School of Medicine at Northwestern University about the various treatment options available for achalasia.
Host: Jason Liebowitz, MD
Guest: Jonathan Greer, MD
Guest: Karen McKerihan, MSN, NP-C
What do we need to know about providing infusion medication therapies to patients with rheumatologic diseases, and how should we talk to our patients about this treatment option? Joining Dr. Jason Liebowitz to explore rheumatology infusion therapy are Dr. Jonathan Greer and Ms. Karen McKerihan.
Host: Danielle Becker, MD, MS, FAES
Host: Ahmed Abdelmoity, MD
Guest: Deborah Holder, MD
Guest: John Stern, MD
Vagus nerve stimulation (VNS) therapy is an add-on neuromodulation treatment designed for adults and children diagnosed with drug-resistant epilepsy (DRE). The device delivers mild pulses to the brain through the vagus nerve to help prevent seizures before they start and help stop them if they do. Join Drs. Danielle Becker, John Stern, Deborah Holder, and Ahmed Abdelmoity as they discuss best practices for initiating, titrating, and dosing adult and pediatric patients to optimize outcomes.
Host: Frederic Rahbari-Oskoui, MD, MSc
This Expert Exchange webcast is designed to help improve clinicians’ ability to apply pharmacologic and non-pharmacologic strategies in the management of patients with ADPKD.
Host: Mark A. Atkinson, PhD
Guest: Linda DiMeglio, MD, MPH
Autoantibody Screening to Identify Risk for Type 1 DiabetesT1D defines a continuum that begins during an asymptomatic prodrome before the disease manifests clinically. One of the challenges of T1D is identifying persons at high risk before the onset of clinical manifestations by screening for pancreatic β cell autoantibodies. Interventions to delay or prevent the underlying autoantibody-mediated loss of pancreatic β cells are now available to delay or potentially prevent the clinical presentation of T1D as diabetic ketoacidosis and mitigate subsequent, longer-term complications.
Guest: Dr. Timothy Craig
Hereditary angioedema (HAE) is a rare genetic disease that can cause recurrent, unpredictable, and potentially life-threatening attacks of swelling in the body.2 The unpredictability of these attacks is a significant burden on patients.3 Fortunately, preventive treatments like TAKHZYRO® (lanadelumab-flyo) can help reduce the frequency and severity of HAE attacks.1 Here to share key information and data on this treatment option is Dr. Timothy Craig, Professor of Pulmonary, Allergy, and Critical Care Medicine at Pennsylvania State University.
IndicationTAKHZYRO® (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.
Important Safety InformationHypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.
Adverse Reactions: The most commonly observed adverse reactions (≥10% and higher than placebo) associated with TAKHZYRO were injection site reactions consisting mainly of pain, erythema, and bruising at the injection site; upper respiratory infection; headache; rash; myalgia; dizziness; and diarrhea. Less common adverse reactions observed included elevated levels of transaminases; one patient discontinued the trial for elevated transaminases.
Use in Specific Populations: The safety and efficacy of TAKHZYRO in pediatric patients <12 years of age have not been established.
No data are …
Host: Jennifer Caudle, DO
Guest: William Lumry, MD
Hereditary angioedema (HAE) is a rare, genetic disease that can cause recurrent, unpredictable, and potentially life-threatening attacks of swelling in the body.1 These swelling attacks can be both painful and debilitating, which is why prevention is so important.1 So what are the treatment options available that can help prevent HAE attacks? Joining Dr. Jennifer Caudle to discuss the importance of long-term prevention for HAE and the role of the treatment option TAKHZYRO (lanadelumab-flyo) is Dr. William Lumry, Clinical Professor of Internal Medicine at the University of Texas Southwestern Medical School.
IndicationTAKHZYRO® is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.
Important Safety InformationHypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.
Adverse Reactions: The most commonly observed adverse reactions (≥10% and higher than placebo) associated with TAKHZYRO were injection site reactions consisting mainly of pain, erythema, and bruising at the injection site; upper respiratory infection; headache; rash; myalgia; dizziness; and diarrhea. Less common adverse reactions observed included elevated levels of transaminases; one patient discontinued the trial for elevated transaminases.
Use in Specific Populations: The safety and efficacy of TAKHZYRO in …
Host: John Buse, MD, PhD
Guest: Sue Pedersen, MD, FRCPC
New guidelines published by Obesity Canada take a deep dive into pharmacotherapy and feature the latest recommendations on comorbidities and decision tools. To better understand the impact of these guidelines, Dr. John Buse speaks with one of the guidelines authors, Dr. Sue Pedersen, a specialist in endocrinology and metabolism.
Host: Ethan Craig, MD, MHS
Guest: Dr. Lianne Gensler, MD
To figure out how to improve the detection of fibromyalgia and axial spondyloarthritis, Dr. Ethan Craig is joined by Dr. Lianne Gensler from the UCSF Spondylitis Clinic at the University of California San Francisco Medical Center.
Dr. Craig and Dr. Gensler are Novartis consultants.
11/22
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Guest: Marilyn J. Wooley PhD
Due to the nature of their work, first responders may be at a higher risk for developing posttraumatic stress disorder (PTSD). So how can clinicians help their front-line patients with PTSD? Dr. Andrew Wilner will discuss this with Dr. Marilyn Wooley, Clinical Psychologist who specializes in treating first responders and author of the book, How Heroes Heal: Stories of First Responders and the Journey from Posttraumatic Stress Injury to Posttraumatic Growth.
Host: Jennifer Caudle, DO
Guest: Diane M. Harper, MD, MPH, MS
There are several testing methods available for cervical cancer screening, such as co-testing and primary HPV testing. So what are some of the most prominent benefits and limitations of these and other testing approaches? Joining Dr. Jennifer Caudle to break down the latest advancements in cervical cancer screening is Dr. Diane Harper, a Professor in the Departments of Family Medicine and Obstetrics and Gynecology at the University of Michigan.
Host: Bradley Torphy, MD
Learn more about the efficacy and other clinical data for this preventive migraine treatment option. Dr. Brad Torphy highlights clinical data on this treatment option.
Host: Jennifer Caudle, DO
Guest: Majed Refaai, MD
While VKA-related GI bleeds are common, clinicians need to be aware of the severity of the bleed, especially in cases of hemodynamic instability. To get a better understanding of the impact of this severity, Dr. Majed Refaai from the University of Rochester Medical Center shares insights on these life-threatening bleeds.
Host: Wade Cooper, DO
For patients with chronic or episodic migraine, what treatment options should we consider? To help answer that question, Dr. Wade Cooper discusses a treatment option for migraine.
Host: Fouad T. Chebib, MD
Guest: Pranav S. Garimella, MD
This Expert Exchange webcast is designed to help improve clinicians’ ability to apply pharmacologic and non-pharmacologic strategies in the management of patients with ADPKD.
Host: John Buse, MD, PhD
Guest: Silva Arslanian, MD
New research on once-daily semaglutide for adolescent patients with obesity may alter clinicians’ approach to care. What do we need to know? Dr. John Buse speaks with one of the study’s investigators, Dr. Silva Arslanian, from the University of Pittsburgh to dive into this clinical data and explore how these results may change the treatment landscape.
Host: Ethan Craig, MD, MHS
Guest: Sara S. McCoy, MD, PhD
Because Sjogren's disease has no calculable disease activity scores or established guidelines, how do clinicians monitor disease activity?
Dr. Ethan Craig is joined by Dr. Sara S. McCoy, MD, PhD who runs the Sjögren’s Clinic at the University of Wisconsin to discuss activity monitoring for Sjögren’s disease.
Dr. Craig and Dr. McCoy are Novartis consultants.
247548 11/22
Guest: Narjust Duma, MD
Guest: David J. Feller-Kopman, MD
Guest: Bruce E. Johnson, MD
Guest: Razelle Kurzrock, MD, FACP
Guest: Ignacio Wistuba, MD
Lung cancer incidence is decreasing due in part to reduced smoking rates, and new trends are emerging as things change. But despite these advancements, some challenges remain to be solved. Explore those challenges and key strategies for overcoming them in this four-part series.
PP-US-8201a-1520 12/22
Host: Jillian Ziemanski, OD, PhD, FAAO
Guest: Cynthia Matossian, MD, FACS
How can more advanced measures improve meibomian gland function to relieve dry eye symptoms and improve refraction? Listen as Dr. Cynthia Matossian and Dr. Jillian Ziemanski discuss additional approaches you can try with your patients.
Host: Thomas F. Patterson, MD, FACP, FIDSA
Guest: George Thompson III, MD, FIDSA
The changing epidemiology of invasive fungal infections, ongoing antifungal resistance, drug-drug interactions, and few oral agents leave patients with limited viable treatment options. While the antifungal pipeline has been essentially dry for the past 2 decades, several antifungal drugs are now in late-stage clinical development and poised to address these unmet needs. But take heed: They will need to be treated as precious commodities lest they, too, become ineffective due to resistance.
For patients with ER+/HER2- advanced breast cancer, current treatment guidelines recommend the use of endocrine therapy plus a CDK 4/6 inhibitor as a first-line treatment. And while the guidelines recommend sequential endocrine therapy for disease progressions, this progression can lead to ESR1 mutations and resistance to endocrine therapy. Could a novel oral selective estrogen receptor have more efficacy in preventing ESR1 mutations associated with endocrine resistance? That’s the exact question the EMERALD trial sought to answer, and what this study found in its subgroup analyses is the focus of this Audio Abstract.
Host: Jason Liebowitz, MD
Guest: Laura Coates, MBChB, MRCP, PhD
Different domains of psoriatic arthritis can look different in each of our patients. How should that factor into our evaluation and treatment approach for this disease? Dr. Jason Liebowitz sits down with Dr. Laura Coates, an Associate Professor at Oxford University, to explore a domain-based approach to care.
Dr. Liebowitz and Dr. Coates are Novartis consultants.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: John Mascarenhas, MD
Guest: Raajit Rampal, MD, PhD
What do we need to know about the therapeutic landscape and management of myelofibrosis-related anemia? Here to share their perspectives with Dr. Charles Turk are Dr. Raajit Rampal from the Memorial Sloan Kettering Cancer Center and Dr. John Mascarenhas from Mount Sinai.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Paul Hunter, MD
It’s important to recognize that older adults are more susceptible to influenza infection—as well as increased severity of infection—than younger, healthier populations.1 Fortunately, there are vaccines available that can help prevent influenza in this aging population. But do the relative benefits and harms of higher-dose and adjuvanted vaccines, compared with one another and with other influenza vaccines, favor the use of any one or more of these vaccines over other age-appropriate options for people 65 and older?2 That's the exact question the CDC’s Advisory Committee on Immunization Practices (ACIP) sought to answer and what Dr. Charles Turck discusses with Dr. Paul Hunter, Associate Professor in the Department of Family Medicine and Community Health at the University of Wisconsin School of Medicine and Public Health.
References:
1. Centers for Disease Control and Prevention. Fly & People 65 Years and Older. Accessed August 16, 2022. https://www.cdc.gov/flu/highrisk/65over.htm.
2. National Center for Immunization & Respiratory Diseases. Advisory Committee on Influenza Practices. Influenza Vaccines for Older Adults: GRADE Summary. Accessed August 16, 2022.
USA-FLUD-22-0056 December 2022
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Kenneth Cusi, MD, FACP, FACE
From noninvasive tests to liver biopsies—what do we need to know about current diagnostic tools for nonalcoholic steatohepatitis (NASH)? Dr. Charles Turck joins Dr. Kenneth Cusi to dive into diagnostic guidelines and share the latest updates on these tools.
Host: Wui-Jin Koh, MD
Join our top experts from around the world as they discuss evidence- and consensus-based recommendations from The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), as well as the latest emerging clinical evidence in the optimal treatment of cancer. This multi-format, multispecialty, and multiregional educational initiative is designed to support your knowledge, competence, and skills across multiple solid tumor types.
Host: Sara W. Koblitz
Guest: Michael J. Thorpy, MD
While most clinicians are aware of a drug being either “approved” or “not approved” by the FDA, many are not familiar with the term “tentative approval.” Leading experts, attorney Sara Koblitz, JD, and Dr. Michael Thorpy, review the FDA approval process, explore how “tentative approval” is currently impacting treatment in the field of sleep medicine, and discuss how “non-drug” issues are related to delayed FDA approval. Review the latest safety and efficacy pivotal trial data associated with once-nightly sodium oxybate and find out if we’re truly on the cusp of a new awakening in sleep medicine.
Host: Jason Liebowitz, MD
Guest: Jonathan Greer, MD
Guest: Karen McKerihan, MSN, NP-C
What are some ways we can incorporate shared decision-making into the treatment of rheumatologic diseases? To answer that question, Dr. Jason Liebowitz joins Dr. Jonathan Greer and Ms. Karen McKerihan.
Host: Warner K. Huh, MD
Guest: Leigh Anne Cantrell, MD, MSPH
Guest: Mark H. Stoler, MD
Experts discuss the ACS and ASCCP CCV screening guidelines and review the benefits of primary screening and the latest data driven testing options. Is Pap cytology a thing of the past? Find out more about harmonization of guidelines from leading experts, Drs. Cantrell, Stoler and Huh. You might just transform your clinical practice.
Host: Caron A. Jacobson, MD
Guest: Matthew Lunning, DO
Guest: Loretta J. Nastoupil, MD
Since the first chimeric antigen receptor (CAR) T-cell therapy was approved by the US Food and Drug Administration (FDA) for the treatment of large B-cell lymphoma (LBCL) in the third or later line of therapy, there has been significant development in the field. There are now three approved CAR T-cell therapies for various subtypes of LBCL, and these immunotherapies are now moving into earlier treatment, with axi-cel and liso-cel both FDA approved in the second-line setting. At the same time, researchers have made tremendous strides in managing the hallmark toxicities of CAR T-cell therapy like cytokine release syndrome (CRS) and neurologic events, opening the possibility for this therapy to move safely beyond academic medical centers and into outpatient settings.
The educational activity features an expert roundtable panel discussion on real-world clinical practice experiences with CAR T-cell therapy for the treatment of diffuse large B-cell lymphoma (DLBCL) from the esteemed panelists, with a focus on the second-line setting. The faculty panel will evaluate the most recent clinical data and provide their expert insights on how new emerging evidence can and should be considered for real-world clinical practice. The discussion will also include a summary of second-line clinical trials, differentiation factors among …
Host: Martin Pollak, MD
Guest: Susanne Nicholas, MD, MPH, PhD
End-stage kidney disease (ESKD) is at least 3x higher among African Americans compared to Americans of European descent. Carriers of APOL1 variants with chronic kidney disease (CKD) are associated with more rapid disease progression and an increased risk of kidney failure. Join Drs. Martin Pollak and Susanne Nicholas as they discuss the epidemiology and possible mechanisms of APOL1 kidney disease, as well as recent clinical evidence for therapies in development that can potentially prevent rapid disease progression.
Host: Ethan Craig, MD, MHS
Guest: Dr. Lianne Gensler, MD
To help us understand how axial spondyloarthritis (axSpA) and inflammatory back pain (IBP) differ, Dr. Ethan Craig is joined by Dr. Lianne Gensler from the UCSF Spondylitis Clinic at the University of California San Francisco Medical Center.
Dr. Craig and Dr. Gensler are Novartis consultants.
249165 11/22
Host: Andrea Singer, MD, FACP, CCD
Guest: Susan V. Bukata, MD, FAOA, FAAOS
Life-altering secondary fractures are a harsh reality, but Medicare studies show, and orthopedic surgeons agree, that knowledge has not translated into prevention. Why is there clinical inertia in providing preventative interventions related to secondary fragility fractures? Join Drs. Andrea Singer and Susan Bukata as they provide a cogent medical approach to preventing these fractures and a roadmap for when and how to use available therapies based on their mechanisms of action.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Masja de Haas, MD, PhD
Program Chairman:
Roberto Romero, MD, DMedSci
Chief, Perinatology Research Branch
Division of Maternal-Fetal Medicine and Obstetrics
Division of Intramural Research
NICHD/NIH/DHHS
Editor-in-Chief for Obstetrics
The American Journal of Obstetrics and Gynecology
Neonatal alloimmune neutropenia (NAIN or NIN) is a neutrophil blood group antagonism similar to HDFN and FNAIT. Its presentation varies clinically and ranges from asymptomatic to severe manifestations such as sepsis and meningitis. Listen in as Drs. Masja de Haas and Lee Shulman discuss clinical clues that should catch your eye. Discover novel yet simple ways to be vigilant and make the right clinical calls.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Eugenia Shmidt, MD
The pregnancy inflammatory bowel disease and neonatal outcomes (PIANO) registry is the largest US-based study that examines pregnant women who have inflammatory bowel disease (IBD). So how can clinicians use the takeaways from this study in their practice? Join Dr. Peter Buch as he discusses IBD in pregnant women with Dr. Eugenia Shmidt, Assistant Professor in the Division of Gastroenterology, Hepatology, and Nutrition at the University of Minnesota.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: John Mascarenhas, MD
There are several challenges and limitations associated with the current therapeutic options available for myelofibrosis-related anemia, leading to a recent push to transform the treatment paradigm. Joining Dr. Charles Turck to share strategies for optimizing the care of patients with myelofibrosis-related anemia is Dr. John Mascarenhas, Director of the Center of Excellence for Blood Cancers and Myeloid Disorders at the Mount Sinai Tisch Cancer Center.
Host: Aaron Gerds, MD
There are two key unmet needs in the treatment of myelofibrosis. Here to share what those are and how we can work to address them is Dr. Aaron Gerds from the Cleveland Clinic.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Miguel Regueiro, MD
The horizon for patients with Crohn’s disease is looking promising as new treatments are expected to come out in the next few years. So what are the best practices for treating fistulizing Crohn’s disease? Explore the treatment landscape with Dr. Peter Buch and Dr. Miguel Regueiro, Chair of the Digestive Disease and Surgery Institute at Cleveland Clinic.
Host: William J. Gradishar, MD
Guest: Javier Cortes, MD, PhD
Guest: Hope S. Rugo, MD
New data for sequencing antibody-drug conjugates (ADCs) in HER2 metastatic breast cancer have hit the conference circuit. Listen as Drs. William Gradishar, Javier Cortés, and Hope Rugo dissect the data surrounding ADCs in different types of HER2 metastatic breast cancer. Make sure you’re up to date and offering your patients the best care.
Host: John Buse, MD, PhD
Guest: Jennifer B. Green, MD
What does the latest research on glycemia reduction show us about the impact of glucose-lowering medication in combination with metformin on microvascular and cardiovascular outcomes in patients with type 2 diabetes? Dr. John Buse speaks with one of the study’s investigators, Dr. Jennifer Green, a Professor of Medicine at Duke University, about this emerging data.
Host: Andrew J. S. Coats, MD
Host: Clara Bonanad Lozano, MD, PhD
Host: Aaron Wong, MD
Optimizing RAASi therapy in patients with heart failure, while managing hyperkalemia can be challenging. Three experts talk about this clinical dilemma and present new therapeutic options that could achieve better outcomes in patients with heart failure.
This course consists of the following:
- Guidelines, RAASi and hyperkalemia: the clinical dilemmas in heart failure - Prof. Andrew Coats, MD - Coventry, UK
- Hyperkalemia in heart failure: Why should we care? - Clara Bonanad Lozano, MD, PhD - Valencia, Spain
- Potassium binding as RAASi enabling therapy: applying recent insights into practice - Aaron Wong, MD - Bridgend, UK
Host: Antonis Pantazis, MD
Host: Dr. M. (Michelle) Michels, MD
Host: Iacopo Olivotto, MD
Hypertrophic cardiomyopathy (HCM) is more than just a thickened heart. This series of three presentations provides insights into the etiology and pathogenesis of this complex disease, how to make the diagnosis, and the therapeutic options.
Dr. Antonis Pantazis starts his presentation off with a scientific definition of HCM and explains what distinguishes it from other conditions that feature a “thick heart.” Dr. Michelle Michels highlights the importance of a thorough work-up in patients with LV hypertrophy to make the correct diagnosis. Prof. Iacopo Olivotto discusses the study results of mavacamten, a drug specifically designed for treating HCM.
This course consists of the following:
- Unhiding hypertrophic cardiomyopathy, a call for action - Antonis Pantazis, MD - London, UK
- Hypertrophic cardiomyopathy: making the diagnosis - Michelle Michels, MD, PhD - Rotterdam, the Netherlands
- Managing patients with hypertrophic cardiomyopathy: what is the therapeutic landscape? - Prof. Iacopo Olivotto, MD - Florence, Italy
Host: John McMurray, MD
Host: Carolyn Lam, MD
Host: Scott Solomon, MD
What are the benefits of SGLT2 inhibitors (SGLT2i) in heart failure? What clinical challenges can physicians face when initiating guideline recommended therapy in heart failure? And what unanswered questions with SGLT2i in heart failure remain? Three speakers present the guidelines, evidence of studies and tell us what we can expect in the near future with regard to SGLT2i in heart failure.
This course consists of the following:
- The clinical challenges of initiating guideline recommended therapy in HF - Prof. John McMurray, MD - Glasgow, UK
- Benefits and evolving insights on SGLT2i in the spectrum of LVEF - Prof. Carolyn Lam, MD, PhD - Singapore
- Expanding evidence on SGLT2i: Where are we now and what can we expect? - Prof. Scott Solomon, MD - Boston, MA, USA
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Bryson Katona, MD, PhD
Lynch syndrome is the most common cause of inherited colon cancer and is often underdiagnosed. How can we improve detection of these patients? To find out more, Dr. Peter Buch joins Dr. Bryson Katona from the Hospital of the University of Pennsylvania to explore some key detection strategies.
Guest: Lisa Nodzon PhD, ARNP, AOCNP
No matter whether you’re using venetoclax for chronic lymphocytic leukemia in the first-line or relapsed/refractory setting, there are some important considerations to keep in mind, like its dose ramp-up as well as the importance of hydration and tumor lysis syndrome prophylaxis. Tune in as Dr. Lisa Nodzon, advanced oncology certified nurse practitioner in the Department of Malignant Hematology at Moffitt Cancer Center, reviews those key considerations and more.
Guest: Ilene Galinsky BSN,MSN,ANP-C
Patients with acute myeloid leukemia (AML) are at high risk for febrile neutropenia or profound, protracted neutropenia. So how can we monitor for the risk of neutropenia in AML patients starting venetoclax therapy? That’s what Ilene Galinsky, Senior Program Research Nurse Practitioner for the Leukemia Program at Dana Farber Cancer Institute, is here to explain.
Host: Charles P. Vega, MD
Guest: Alvaro E. Galvis, MD, PhD
How does a patient's culture impact their health behaviors? Find clues in a case highlighting how cultural responsiveness leads to open patient-clinician communication that is the cornerstone of good clinical care.
Listen in as 2 leading experts address disparities by breaking down barriers and building better communication with Latino patients. Will you evolve your clinical approach by taking the necessary (easy) steps to help overcome medical mistrust?
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Nancy S. Reau, MD
The most common liver disease caused by pregnancy is intrahepatic cholestasis of pregnancy (ICP). So what do clinicians need to know to best treat their patients? Explore the impact of liver disease on pregnancy as Dr. Peter Buch is joined by Dr. Nancy S. Reau, Professor in the Department of Internal Medicine at Rush Medical College.
Guest: Ilene Galinsky BSN,MSN,ANP-C
Here to review the ramp-up and dosing for venetoclax therapy in patients with newly diagnosed acute myeloid leukemia is Ilene Galinsky, Senior Program Research Nurse Practitioner for the Leukemia Program at Dana Farber Cancer Institute.
Host: Charles P. Vega, MD
Guest: Kareen Y. Espino, MD
What is cultural humility, and how can it be incorporated into clinical practice? How does a patient's culture impact their health behaviors, and why does your own culture and your “practice” approach matter?
Listen in as 2 leading experts navigate concerns surrounding cultural humility and emphasize the importance of empathy while they review tips for improved communication with Latino patients. There are easy ways to integrate small but meaningful changes into your clinical practice to help bridge communication gaps and enable your patients to live healthier lives.
Host: Charles P. Vega, MD
Guest: Alejandra Hurtado
National trends highlight the necessity of a diverse workforce that can better meet the needs of underserved Latino communities. Hear about the real impact being made by training programs designed to meet community needs through the eyes of a medical student as she discusses her cultural background and future aspirations to give back to the health of her community. Will you be inspired to offer mentorship opportunities and diversify your staff to provide culturally appropriate care?
Guest: Lisa Nodzon PhD, ARNP, AOCNP
Both the disease itself and the treatments for chronic lymphocytic leukemia (CLL) can cause neutropenia, which is why Dr. Lisa Nodzon from the Moffitt Cancer Center is here to discuss neutropenia in relation to CLL treatment with venetoclax.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Harry Paul Erba, MD, PhD
Guest: Uma Borate, MD, MS
With the development of technologies paired with an enhanced understanding of the AML genomic landscape, it’s become possible to further the development of AML therapies. Joining Dr. Charles Turck to explore venetoclax and its role in current AML treatment paradigms are Drs. Uma Borate and Harry Erba.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Lauren Williams, MCN,RD,LD
Kids with dyslipidemia don’t have much different nutritional needs than other young kids their age. However, there are a few key things to be aware of. So how can clinicians meet families where they are to improve their diet? Dive into the unique needs of youth with dyslipidemia as Dr. Mary Katherine Cheeley is joined by Lauren Williams, Class II Clinical Dietician at Cook Children’s Health System.
Host: Jacob Sands, MD
Guest: Tomasz Beer, MD, FACP
Multi-cancer early detection tests are designed to detect multiple cancers from a single blood test. Could these tests help address some of the most common limitations associated with current cancer screening methods, like a lack of adherence and access? Joining Dr. Jacob Sands to discuss how multi-cancer early detection tests work and their potential impact on cancer screening is Dr. Tom Beer, Adjunct Professor of Medicine at the OHSU Knight Cancer Institute and the Chief Medical Officer for Multi-Cancer Early Detection at Exact Sciences Corporation.
Host: Jason Liebowitz, MD
Guest: Laura Coates, MBChB, MRCP, PhD
Given that recommendations for treatment are constantly evolving, how should we adjust our therapeutic approach to provide optimal care? To answer that question, Dr. Jason Liebowitz is joined by Dr. Laura Coates, an Associate Professor at Oxford University.
Dr. Liebowitz and Dr. Coates are Novartis consultants.
245473 11/22
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: David Mohr, PhD
In addition to potentially improving access to mental health care, digital tools have also been shown to improve symptoms in many types of mental illness1 and can serve as an adjunct to psychotherapy or pharmacotherapy. Despite this, these tools have not yet been widely adopted in the United States. So what are some strategies we can use to implement these tools and develop an improved framework? Joining Dr. Charles Turck to discuss mental health treatments and their application in clinical practice is Dr. David Mohr, a Professor in the Department of Preventive Medicine at Northwestern University Feinberg School of Medicine in Chicago.
Reference:
- Mohr DC, Azocar F, Bertagnolli A, et al. Banbury Forum Consensus Statement on the Path Forward for Digital Mental Health Treatment. Psychiatr Serv. 2021;72(6):677-683.
December 2022 US.UNB.X.22.00074
Guest: John Anderson, MD
HAE is a rare, autosomal dominant genetic disease that can cause recurrent, unpredictable, and potentially life-threatening attacks of swelling in the body.1 There are approximately 6,000 patients living with HAE in the U.S. alone,2 and it’s not uncommon for patients to go undiagnosed for years after they start experiencing symptoms.1 Since early diagnosis is vital to creating a management plan that meets each patient’s individual needs,2 Dr. John Anderson is here to share key information on how we can better diagnose HAE in our patients.
References:
- Banerji A. Hereditary Angioedema: Classification, Pathogenesis, and Diagnosis. Allergy Asthma Proc. 2011;32:403–407.
- Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, Craig T, Davis-Lorton M, Frank MM, Li HH, Lumry WR, Zuraw BL. US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema. J Allergy Clin Immunol Pract. 2021 Jan;9(1):132-150.
©2022 Takeda Pharmaceutical Company Limited. All rights reserved.
US-NON-7744v1.0 10/22
Host: Lee Shulman MD, FACOG, FACMG
Guest: Andrea S. Lukes, MD, MHSc, FACOG
Are you currently considering GnRH antagonists as first-line therapy, or are you waiting for patients to fail other endometriosis treatment approaches first? Drs. Andrea Lukes and Lee Shulman discuss how the advent of effective GnRH antagonists is evolving the care of endometriosis. Are you ready to provide patients with the clinical outcomes they seek while balancing the benefits of medical and surgical approaches?
Host: Jenny S. Sauk, MD
It is estimated that only 20% to 30% of patients with Crohn’s disease (CD) have a non-progressive or indolent course. While most patients with CD present with non-penetrating or non-stricturing disease, 50% of patients develop intestinal complications within 20 years of diagnosis. In this interactive CME activity, Dr. Sauk presents the case of a patient with CD, highlighting the importance of early recognition of disease complications and considerations for surgical management. This real-world patient case offers you an opportunity to test your clinical skills for the successful management of inflammatory bowel disease (IBD) and learn more from an IBD expert faculty.
Host: Sushila R. Dalal, MD
The management of inflammatory bowel disease (IBD) remains challenging, owing to variable clinical presentations and ever-changing therapeutic options. In this interactive CME activity, Dr. Sushila Dalal presents the case of a newly diagnosed patient with IBD, highlighting the importance of prompt diagnosis and aggressive medical treatment. This real-world patient case offers you an opportunity to test your clinical skills for the successful management of IBD and learn more from IBD expert faculty.
Host: John Buse, MD, PhD
Guest: Deborah Wexler, MD
The GRADE study demonstrated the efficacy of different treatment options for patients with type 2 diabetes. To learn more about these treatment options, Dr. John Buse joins one of the study’s investigators, Dr. Deborah Wexler from Harvard Medical School and the Massachusetts General Hospital Diabetes Center, to dive into this study.
Host: Hugh S. Taylor, MD
Endometriosis is challenging to diagnose, with approximately 6 to 11 years from symptom onset to definitive diagnosis and treatment. Many medical providers are not adequately familiar with the disease, and this, coupled with historically limited medical options, has resulted in surgical approaches often being considered as the first treatment option. Join us as Dr. Hugh Taylor discusses how this landscape is changing to one in which safe and effective medical options can now offer improved outcomes for our patients with endometriosis.
Host: Jennifer L. Payne, MD
Optimizing the management of comorbid depression and menopause is a significant clinical challenge. When the darkness begins to set in, are you able to hear your patients’ needs and deliver life-changing treatment?
Join Dr. Jennifer Payne as she provides concrete tips and explores the latest guidelines and research on therapies that improve vasomotor symptoms, mood, and perimenopausal depression. Get ready to offer new hope to your patients as you help them cool off and begin to see the dawn of a new day.
Host: Andrew M. Kaunitz, MD, FACOG
By the age of 50, ultrasound imaging demonstrates that 70%-80% of women have fibroids. Uterine fibroids are associated with disability similar to other chronic diseases. They can even lead to lower vitality and social function than are experienced by women with breast cancer. Fibroid-related hysterectomies account for 45% of all US hysterectomies, but a surgical approach is no longer one size fits many. Join Dr. Andrew Kaunitz as he describes the clinical presentations of fibroids and how newly emergent medical options greatly improve fibroid-related symptoms, provide time to consider other alternatives, and can be used to bridge the transition to menopause.
Host: Anita H. Clayton, MD
Guest: Jennifer L. Payne, MD
This animated Women’s Health 2022 lecture features a discussion between Drs. Jennifer Payne and Anita Clayton who clearly highlight the importance of screening for perinatal and postpartum depression (PPD). Our experts delve into the critical importance of proactively diagnosing and treating women during the various stages of pregnancy and review the latest therapies that specifically target PPD. Find out how these therapies compare to traditional antidepressants and how PPD treatment can improve the health and quality of life for patients and their families. What changes can you implement into your clinical practice to improve maternal and infant health?
Host: David L. Eisenberg, MD, MPH, FACOG
Intrauterine devices and contraceptive implants, also called long-acting reversible contraceptives (LARCs), are the most effective reversible contraceptive methods. The major advantage of LARCs compared with other reversible contraceptive methods is that they do not require ongoing effort on the part of the patient for long-term, effective use. In addition, after the device is removed, the return of fertility is rapid. Join Dr. David Eisenberg has he discusses when LARCs should be recommended as a first-line contraceptive choice and when they should not. He further details how to approach a shared decision-making discussion with patients about their contraceptive options.
Host: Michael Krychman, MD
For affected women, acute vulvovaginal candidiasis (VVC) brings with it a significant health burden, and the substantial morbidity and poor quality of life associated with recurrent disease (RVVC) requires improved diagnosis, management, and quality of care. Join Dr. Michael Krychman as he dissects the barriers to managing VVC and RVVC and provides insights on diagnosis and management based on guidelines, plus an overview of innovative therapeutic agents. The unique qualities of the current and emerging therapeutic interventions may well represent a significant step forward in how you manage these challenging infections.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Namrata Chandhok, MD
Underrepresentation is widespread in hematological clinical trials. To learn more about the challenges preventing representation—and possible solutions—Dr. Charles Turck joins Dr. Namrata Chandhok from the Sylvester Comprehensive Cancer Center at the University of Miami to share insights on inclusion in clinical trials from the American Society of Hematology annual Meeting.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Arnold Wald, MD
The American Gastroenterological Association released updated guidelines for patients with irritable bowel syndrome with constipation (IBS-C). To find out more about the latest updates in treatment, Dr. Peter Buch dives into these guideline recommendations with Dr. Arnold Wald, a Professor of Medicine at the University of Wisconsin.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Paul Feuerstadt MD, FACG, AGAF
In the United States, about 80 percent of tests used to diagnose C. difficile are PCR assays. So what are the best options to diagnose and treat patients with this infection? To discuss the evolving treatment and evaluation landscape for C. difficile, Dr. Peter Buch is joined by Dr. Paul Feuerstadt, Assistant Clinical Professor at Yale New Haven Hospital.
Host: Jason Liebowitz, MD
Guest: Bella Mehta, MBBS, MS, MD
Treatment for monogenic autoinflammatory disease can look different for our pediatric patients and our adult patients. What do we need to know? Dr. Jason Liebowitz sits down with Dr. Bella Mehta from Cornell Medical College to discuss treating these diseases.
Host: Matthew Sorrentino, MD
Guest: Luke Laffin, MD
Six commonly used supplements thought to improve patients’ cholesterol may be doing more harm than good. So what do we need to know about these supplements? To walk us through the results of the SPORT trial, Dr. Matthew Sorrentino is joined by Dr. Luke Laffin, Co-Director of the Center for Blood Pressure Disorders at the Cleveland Clinic.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Robert Battat, MDCM, FRCPC
A kay cofounder in managing postoperative Crohn’s disease, bile acid diarrhea can be challenging to diagnose. What tests are currently available? To discuss this cofounder and how to diagnose it, Dr. Peter Buch sits down with Dr. Robert Battat, the Director of the Center for Clinical and Translational Research for Inflammatory Bowel Disease at the University of Montreal.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Robert Battat, MDCM, FRCPC
What confounders do we face when managing postoperative Crohn’s disease, and what tools do we have available to us? Dr. Peter Buch dives into this topic with Dr. Robert Battat, the Director of the Center for Clinical and Translational Research for Inflammatory Bowel Disease at the University of Montreal.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Daniel Strand, MD
Acute pancreatitis can be tricky to diagnose and treat. To help us understand how to better manage this condition, Dr. Peter Buch is joined by Dr. Daniel Strand, the Director of Pancreatobiliary Endoscopy at UVA Health in Charlottesville and an Associate Professor of GI Hepatology to share management updates for patients with recurrent acute and chronic pancreatitis.
Host: Kara B. Markham, MD
What are the essential steps in managing hemolytic disease of the fetus and newborn (HDFN)? How soon after “the cord has been cut” does newborn care transfer from the maternal-fetal medicine specialist and ob-gyn to the pediatric team? At a recent satellite symposium of the American Academy of Pediatrics, Dr. James Bussel, Dr. Kara Markham, and Bethany Weathersby presented the latest data regarding current and emerging practice patterns and highlighted the critical need for improved understanding and multidisciplinary collaboration in the area of HDFN. Tune in to hear Dr. Markham summarize how diagnosis, care, and treatment have evolved—plus insights on how these might change the way you practice.
Host: Neilanjan Nandi, MD
Guest: Andres Yarur, MD
Irritable bowel disease (IBD) often requires a personalized approach to treatment. So what does the current therapeutic drug monitoring landscape look like? Dr. Neil Nandi speaks with Dr. Andres Yarur, Associate Professor of Medicine at Cedars-Sinai in Los Angeles, about therapeutic drug monitoring for IBD.
Host: Kevin J. Harrington, MBBS, PhD
Guest: Barbara Burtness, MD
Guest: Ari Rosenberg, MD
There is an unmet clinical need for more durable responses in many patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). Advances in delineating the anti-apoptotic signaling mechanisms are guiding the development of novel therapeutic options for these patients. Join Drs. Kevin Harrington, Barbara Burtness, and Ari Rosenberg as they discuss challenges in treating patients with LA SCCHN and focus on the latest clinical data surrounding an antagonist of inhibitor of apoptosis proteins in this patient population.
Host: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
Guest: Kamyar Kalantar‐Zadeh, MD
Guest: Pieter Martens, MD, PhD
Patients with heart failure are at increased risk for iron deficiency which leads to poor outcomes and quality of life. Several intravenous iron formulations are available to clinicians, yet iron deficiency remains undertreated. Join Dr. Giuseppe Rosano, Dr. Pieter Martens, and Dr. Kamyar Kalantar-Zadeh as they discuss differing iron formulations and the current body of evidence for managing iron deficiency in patients with heart failure.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Piotr Kowalski, PhD
mRNA technology may have a potential role in several areas of gene editing. But are there any barriers to its application in clinical practice? Dr. Piotr Kowalski from the University College Cork explores mRNA technology in gene editing.
Host: David Schulman, MD, MPH, FCCP
Guest: William Lago, MD
Guest: Tejaswini Kulkarni, MD, MPH, FCCP
What are some of the barriers to early diagnosis for idiopathic pulmonary fibrosis (IPF)? Joining Dr. David Schulman to share their perspectives on the latest diagnostic challenges and provide strategies to combat them are Drs. Tejaswini Kulkarni and William Lago.
This is a non-promotional, non-CME disease state educational podcast produced in partnership with the American College of Chest Physicians and is supported by Three Lakes Foundation.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Aline Charabaty, MD
Given what medications are currently available, inflammatory bowel disease (IBD) can be difficult to manage. What do we need to know about them, and how do we know which of our patients are the right candidates for them? To answer this question, Dr. Peter Buch speaks with Dr. Aline Charabaty from the Sibley Memorial Hospital.
Host: Jason Liebowitz, MD
Guest: Sara Tedeschi, PA
As advancements in imaging continue to emerge, what does that mean for the management of gout, calcium pyrophosphate deposition, and crystalline arthritis? To answer this question, Dr. Jason Liebowitz is joined by Dr. Sara Tedsechi from Harvard Medical School.
Dr. Liebowitz and Dr. Tedeschi are Novartis consultants.
10/22
Guest: Matt Birnholz, MD
Could an oral compound represent a new class of psychotropic agent with a non-D2-receptor binding mechanism of action for the treatment of psychosis in schizophrenia? That’s what the authors of a recent study wanted to find out, and it’s what Dr. Matt Birnholz explores in this Audio Abstract.
To review the full abstract, please click here.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: James B. Bussel, MD
Program Chairman:
As the platelet equivalent of hemolytic disease of the fetus and newborn, fetal and neonatal alloimmune thrombocytopenia (FNAIT) is an uncommon yet complex and life-threatening bleeding disorder that results from incompatibility between mother and baby for platelet-specific antigens. Despite relatively normal platelet function, in the setting of severe thrombocytopenia, intracranial hemorrhage is a consequence. Drs. Shulman and Bussel discuss advances in management strategies and concrete steps you can take to lower the risk and stop the progression of this disorder in your patients.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Ira M. Jacobson, MD
What do the guidelines recommend for hepatitis B vaccination? Dr. Peter Buch joins Dr. Ira Jacobson, Director of Hepatology and Professor of Medicine at NYU Langone Health and NYU Grossman School of Medicine, to explore challenges and guidelines for hepatitis B vaccination.
Host: Lee Shulman MD, FACOG, FACMG
Guest: Ayman Al-Hendy, MD
GnRH antagonists are revolutionizing the medical management of uterine fibroids. Drs. Al-Hendy and Shulman discuss how medical myomectomy with GnRH antagonists is revolutionizing care by bridging gaps during 3 different stages of patients’ lives.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Aasma Shaukat, MD, MPH
Adenoma detection rate (ADR) may help us better detect our patients’ risk of developing colorectal cancer. To explore what we need to know about this quality indicator, Dr. Peter Buch joins Dr. Aasma Shaukat from the New York University Grossman School of Medicine to talk about ADR.
Host: Yelena Janjigian, MD
Guest: Sam Klempner, MD
HER2 is an essential biomarker to be assessed in all patients with gastric/GEJ cancer. Its importance is not only related to its role as a therapeutic target for pathway inhibition, but also to its ability to anchor the application of non-HER2 pathway therapeutic strategies with direct and bystander impact in the tumor microenvironment. Join Drs. Janjigian and Klempner as they delve into historical and exciting emerging data that may well bring new hope to your patients with gastric/GEJ cancers.
Guest: Professor Christopher Brightling, PhD, FMedSci
Guest: Professor Bruce Levy, MD
Host: Charles Turck, PharmD, BCPS, BCCCP
For an asthma patient with active airway hyperresponsiveness, what kind of role do airway structural changes and mast cells play? And why is airway hyperresponsiveness so important? Professor Chris Brightling and Professor Bruce Levy share their clinical perspectives on airway hyperresponsiveness.
©2022 Amgen and AstraZeneca. All rights reserved. US-69836 Last Updated 10/22
Host: Marat Fudim, MD, MHS
Despite the use of guideline-directed medical therapy (GDMT), many heart failure (HF) patients may experience worsening symptoms and disease progression. There is now an FDA-approved device that works with GDMT and uses the baroreflex to improve HF-related physiological effects and clinical consequences. Tune in to keep up with baroreflex activation therapy, its mechanism of action, and the associated improved patient outcomes.
Host: Kevin Cleveland, PharmD, ANP
Older adults face a variety of unique challenges that increase their risk of serious influenza infections. But fortunately, vaccinations can help address these challenges. Learn more with Dr. Kevin Cleveland, Associate Professor at the Idaho State University College of Pharmacy.
Host: Jennifer Caudle, DO
Guest: Joseph Aloi, MD
The rate of chronic kidney disease (CKD) in patients with type 2 diabetes (T2D) continues to rise. What can we do to slow this progression of CKD? Dr. Joseph Aloi from the Wake Forest School of Medicine explores this growing epidemic and discusses how a new tool may aid in early risk assessment of early stage 1-3b CKD.
Host: Christina Madison, BS, PharmD, BCACP, AAHIVP
In the midst of a potential tridemic between COVID-19, RSV, and influenza, it’s now more critical than ever to raise awareness among patients about the importance of flu vaccines. Here to provide counseling strategies for educating patients about flu vaccines is Dr. Christina Madison, Associate Professor of Pharmacy Practice at Roseman University of Health Sciences.
Host: Jennifer Caudle, DO
Guest: Carolyn Bridges, MD
We all know that influenza vaccinations can help prevent serious infections and save lives. But how often do you consider the underrecognized benefits of these vaccines—like how influenza vaccinations can be a cost-effective solution for both patients and the entire healthcare system? Joining Dr. Jennifer Caudle to discuss these underrecognized benefits and how we can educate patients about the benefits of influenza vaccination is Dr. Carolyn Bridges, Director of Adult Immunizations at Immunize.org.
Host: Jennifer Caudle, DO
Guest: Jennifer Shu, MD, FAAP
Why is are we currently facing a tripledemic? Joining Dr. Jennifer Caudle to uncover what has led to this dramatic increase in COVID-19, RSV, and the flu—and share strategies to combat this tripledemic—is ReachMD Host Dr. Jennifer Shu, a pediatrician at Children’s Medical Group in Atlanta, Georgia.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Sara Horst, MD, MPH
Ulcerative colitis (UC) has an evolving treatment landscape, which has made it difficult for clinicians to position treatment options for their patients. What’s currently available? Dr. Peter Buch dives into this rapidly changing treatment landscape with Dr. Sara Horst, an Associate Professor at Vanderbilt University.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Philip D. Harvey, PhD
The current therapies we have available for schizophrenia are very effective at reducing psychotic symptoms in most patients, but for about 30 percent of patients, adverse events and suboptimal treatment responses can take a heavy toll. Could emerging therapies help us address these unmet needs? Learn more about the efficacy and tolerability limitations of current treatment options and what’s on the horizon with Dr. Charles Turck and Dr. Philip Harvey from the University of Miami Miller School of Medicine.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Craig Chepke, MD, FAPA
Trace amine-associated receptor type 1 (TAAR1) is thought to be the most important receptor for treating neuropsychiatric disorders, and it could provide more benefits and medications to patients with these illnesses. To discover more, Dr. Charles Turck, is joined by Dr. Craig Chepke, Clinical Assistant Professor of Psychiatry at SUNY Upstate Medical University.
Host: Jose Rubio, MD
If clinicians can better understand the pathophysiology of schizophrenia, it could lead to more therapeutic options for this illness. So which potential mechanisms could be involved in its pathophysiology and in the discovery of more treatments for schizophrenia? Learn more about this illness with Dr. Jose Rubio, Assistant Professor at the Institute for Behavioral Science at the Feinstein Institutes for Medical Research.
Host: Mario R. Nacinovich, Jr., MSc
Guest: Walter Koroshetz, MD
Amyotrophic lateral sclerosis (ALS) is a rare neurogenerative disease, and organizations including the FDA and NIH are working to accelerate potential therapies. What’s on the horizon for the treatment landscape? Mario Nacinovich joins Dr. Walter Koroshetz, who is the Director of the National Institute of Neurological Disorders and Stroke, to explore these new developments.
Host: Benjamin Levy, MD
Guest: Rebecca Heist, MD, MPH
Guest: Peter Bela Illei, MD
Antibody-drug conjugates (ADCs) have promising clinical data in the treatment of advanced non-small cell lung cancer. Listen in as Drs. Benjamin Levy, Rebecca Heist, and Peter Illei discuss current data on TROP2 ADCs and what this means for our patients.
Host: Maria Fleseriu, MD, FACE
Guest: Irina Bancos, MD
Cushing’s disease is complex, and individualized approaches require the consideration of many patient factors. You and your patient also need to know what to expect in terms of therapeutic response and speed of recovery. Tune in as Drs. Maria Fleseriu and Irina Bancos address these challenges and more!
Host: Javed Butler, MD, MBA, MPH
Guest: Scott Solomon, MD
Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction (DELIVER trial) is a study designed to assess the effectiveness of SGLT2 inhibitors in patients with higher left ventricular ejection fraction. To help lead the discussion on the results of this study, Dr. Javed Butler is joined by Dr. Scott Solomon, lead study author and Director of the Clinical Trials Outcomes Center and the Edward D. Frohlich Distinguished Chair at Harvard Medical School.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Fatima, Adhi, MD
Guest: Mei Chang, PharmD
Collaborative care is fundamental for critically ill patients, especially when it comes to medication dosing. To explore key considerations on dosing and share insights from their presentations at IDWeek 2022, Dr. Charles Turck is joined by Dr. Adhi Fatima from the Baylor College of Medicine and Mei Chang from the Montefiore Medical Center at the Weiler Division Einstein Campus.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Eamonn Quigley, MD
New recommendations about the pharmacological management of irritable bowel syndrome (IBS) with diarrhea by the American Gastroenterological Association (AGA) was published in Gastroenterology 2022. So what do we need to know about these updates, and which medications should we be using? To provide insight, Dr. Peter Buch is joined by Dr. Eamonn Quigley, the David M Underwood Chair of Medicine in Digestive Disorders and Professor of Medicine at the Academic Institute.
Guest: Marc Riedl, MD, MS
Prior to 2008, there were limited approved treatment options for hereditary angioedema (HAE) available in the United States, but today, there are several medications approved by the U.S. Food and Drug Administration for preventing and treating HAE attacks.1 In light of the number of therapies that have been approved in recent years and continued clinical advancements in HAE research, what do we need to consider when discussing these treatment options with our patients? Here to share those key considerations and important information on the HAE treatment landscape is Dr. Marc Riedl.
References:
- Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, Craig T, Davis-Lorton M, Frank MM, Li HH, Lumry WR, Zuraw BL. US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema. J Allergy Clin Immunol Pract. 2021 Jan;9(1):132-150.e3.
©2022 Takeda Pharmaceutical Company Limited. All rights reserved.
Host: John Buse, MD, PhD
Guest: Martin de Bock, PhD FRACP
Recent research has explored the efficacy of open source automated insulin delivery devices for patient with type 1 diabetes. What did these results tell us? Dr. John Buse speaks with Dr. Martin de Bock, a pediatric endocrinologist at the University of Otago in Christchurch, New Zealand, to dive deeper into this research.
Host: Aparna R. Parikh, MD
Guest: Dustin Deming, MD
Guest: Scott Kopetz, MD, PhD
In this chapterized panel discussion, Drs. Aparna Parikh, Dustin Deming, and Scott Kopetz take us through NCCN recommended guidelines and best practices for identifying biomarkers. Armed with this knowledge, you’ll be able to select systemic therapies more accurately for your patients with MSI-high disease, as well as patients with HER2-amplified CRC.
Host: Brian Barry
Guest: Amos Katz
Meet Susan and Mary, two real-world patients with different manifestations of progression in their RMS who were treated with the therapy option MAYZENT. So why was MAYZENT the appropriate choice for these patients, and how did they get started on this treatment option? Here to walk us through these two real-world patient cases and their perspectives on RMS management are Dr. Brian Barry and Dr. Amos Katz.
Host: Ethan Craig, MD, MHS
Guest: Alexis Ogdie, MD, MSCE
What are some way we can overcome the challenges that come with monitoring response to therapy for patients with psoriatic arthritis (PsA)? Dr. Ethan Craig is joined by Dr. Alexis Ogdie-Beatty from the Perelman School of Medicine at the University of Pennsylvania to discuss the importance of monitoring and share strategies.
Dr. Craig and Dr. Ogdie-Beatty are Novartis consultants.
221663 7/22
Host: Jyoti D. Patel, MD, FASCO
Join us as Dr. Jyoti Patel illustrates her approach to treating a 75-year-old patient who was recently diagnosed with stage IV NSCLC harboring a MET exon 14 skipping mutation—then put these tips to use in your own practice!
Host: Risa Kagan, MD, FACOG, CCD, NCMP
Guest: Ekta Kapoor, MBBS
Guest: Genevieve Neal-Perry, MD, PhD
This activity addresses disparities in the treatment of vasomotor symptoms faced by menopausal women of diverse racial and ethnic backgrounds. Faculty discussion covers overcoming these disparities, guideline recommendations, a novel mechanism for controlling vasomotor symptoms, and strategies to educate patients. First-hand patient testimonials complement the discussion.
Current and Emerging Treatment Approaches
Host: Risa Kagan, MD, FACOG, CCD, NCMP
Guest: Ekta Kapoor, MBBS
Guest: Genevieve Neal-Perry, MD, PhD
This activity addresses disparities in the treatment of vasomotor symptoms faced by menopausal women of diverse racial and ethnic backgrounds. Faculty discussion covers overcoming these disparities, guideline recommendations, a novel mechanism for controlling vasomotor symptoms, and strategies to educate patients. First-hand patient testimonials complement the discussion.
Addressing Patient Needs
Host: Risa Kagan, MD, FACOG, CCD, NCMP
Guest: Ekta Kapoor, MBBS
Guest: Genevieve Neal-Perry, MD, PhD
This activity addresses disparities in the treatment of vasomotor symptoms faced by menopausal women of diverse racial and ethnic backgrounds. Faculty discussion covers overcoming these disparities, guideline recommendations, a novel mechanism for controlling vasomotor symptoms, and strategies to educate patients. First-hand patient testimonials complement the discussion.
Overview of Disparities
Guest: Patrick Forde, MD
Guest: Jesús García-Foncillas, MD, PHD
Immune checkpoint inhibitors, or ICIs, have improved the prognosis for patients with many different types of cancer. Drs. Forde and García-Foncillas outline current biomarkers and the importance of testing to optimize patient outcomes. Your patients will thank you for tuning in!
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: A. Mark Fendrick, MD
With the relaunch of the Cancer Moonshot initiative, implementing strategies to overcome disparities in cancer screening is critical to reducing the rate of cancer mortality. Dr. Charles Turck joins Dr. Mark Fendrick to explore these disparities, and discuss the role of multicancer detection tests.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Musaddiq Khan
Clinical data continues to emerge on mRNA therapeutics and their applications. What do we need to know about this data, and are there any barriers to the broader application of these therapeutics? Dr. Charles Turck is joined by Musaddiq Khan, the Vice President of Therapeutic Area Solutions in the Customer Value Team at Medable, to dive into clinical trials for mRNA therapeutics.
Host: Javed Butler, MD, MBA, MPH
Guest: William T. Abraham, MD, FACP, FACC, FAHA, FESC, FRCPE
Cardiac contractility modulation (CCM) is a novel, approved, implantable device that significantly improves heart failure symptoms, exercise tolerance, and quality of life while reducing the rate of heart failure hospitalizations. Find out why you should consider sending your patients with NYHA Class III heart failure who are not responding to guideline-directed medical therapy directly to an electrophysiologist for device implantation.
Host: Roger A. Goldberg, MD
Guest: Peter A. Campochiaro, MD
Can we apply the new, more durable treatments in diabetic macular edema and neovascular age-related macular degeneration to the treatment of our patients with diabetic retinopathy? Join Dr. Peter Campochiaro and Dr. Roger Goldberg as they discuss ways these new approaches could benefit even more patients.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jason Zucker, MD
The monkeypox outbreak has taken the nation by storm, leading to an increase in diagnostic and vaccination resources. But has this virus prepared us for future infectious disease outbreaks? Joining Dr. Charles Turck to share lessons we’ve learned from the monkeypox outbreak is Dr. Jason Zucker from the Columbia University Irving Medical Center.
Host: Pavani Chalasani MD, MPH
Guest: Hope S. Rugo, MD
Results from the TROPiCS-02 trial may impact survival for patients with receptor–positive/HER2-negative breast cancer. To find out why, Dr. Hope Rugo from the University of California San Francisco Comprehensive Cancer Center joins Dr. Pavani Chalasani to talk about the study and how it might impact the future of breast cancer treatment.
Host: John Buse, MD, PhD
Guest: Matthew Crowley, MD
Can telehealth change the way we manage persistently controlled type 2 diabetes (PPDM)? Dr. John Buse speaks with Dr. Matt Crowley, an Associate Professor of Medicine in the Department of Medicine in the Division of Endocrinology, Metabolism and Nutrition at Duke University, to explore some of the research on different methods of telehealth.
Host: John Buse, MD, PhD
Guest: Seth Berkowitz, MD, MPH
Food assistance programs like the Supplemental Nutrition Assistance Program (SNAP) can help relieve food insecurity. But can they also lower healthcare spending? To answer this question, Dr. John Buse sits down with Dr. Seth Berkowitz from the Division of General Medicine and Clinical Epidemiology at the University of North Carolina School of Medicine.
Host: Jennifer Caudle, DO
Guest: Francesca Taraballi, PhD
Guest: John J. Russell, MD
As mRNA therapeutics continue to emerge, what do our patients know about them? Joining Dr. Jennifer Caudle to explore knowledge gaps and discuss tactics to educate patients are Drs. John Russell and Francesca Taraballi.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Kenneth J. Moise Jr., MD
Program Chairman:
How well do you understand the biology of hemolytic disease of the fetus and newborn (HDFN)? What about its connection to the FcRn receptor pathway and IgG? Drs. Lee Shulman and Ken Moise go beyond the basics taught in medical school immunology and look more closely at FcRn’s role in protecting IgG. With an improved understanding of these mechanisms, we can expand therapeutic targets beyond the fetus and newborn and finally put the needles away.
Host: Jason Liebowitz, MD
Guest: Sara Tedeschi, PA
What do we need to know about the epidemiology and pathogenesis of calcium pyrophosphate deposition? Dr. Jason Liebowitz is joined by Dr. Sara Tedeschi from Harvard Medical School to share key insights on CPPD.
Dr. Liebowitz and Dr. Tedeschi are Novartis consultants
10/22 236268
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Deborah L. Korn, PsyD
Eye movement desensitization and reprocessing (EMDR) therapy is an interactive psychotherapy used to relieve stress and reduce symptoms of trauma. It is most commonly associated with the treatment of posttraumatic stress disorder (PTSD). But can this therapy also treat other stress-related disorders? To go into further detail, Dr. Charles Turck is joined by Dr. Deborah Korn, a clinical psychologist in private practice in Cambridge, Massachusetts and co-author of the book titled Every Memory Deserves Respect: EMDR, the Proven Trauma Therapy with the Power to Heal.
Host: John Buse, MD, PhD
Guest: Ashok Balasubramanyam, MD
Researchers from the GRADE study zeroed in on islet autoimmunity in beta cell dysfunction for patients with type 2 diabetes. What did various treatment options show us? Dr. John Buse speaks with Dr. Ashok Balasubramanyam, a Professor in the Department of Endocrinology, Diabetes and Metabolism at Baylor College of Medicine.
Host: Janani Reisenauer, MD
Host: Septimiu Murgu, MD, FCCP
Host: Eric Edell, MD, FCCP
Lung cancer screenings have shown to be effective in detecting lung cancer earlier. So what are the current guidelines? To discuss this question and give their own experiences with lung cancer screenings and the management of early-stage lung cancer are expert pulmonologists, Drs. Septimiu Murgu and Janani Reisenauer. Dr. Murgu is from the University of Chicago, and Dr. Reisenauer is from the Mayo Clinic.
Host: John Buse, MD, PhD
Guest: Jose C. Florez, MD, PhD
Precision medicine may be the future of diabetes treatment. But what’s needed to implement this approach into practice? Here to explore this concept with Dr. John Buse is Dr. Jose Florez, Chief of the Endocrine Division and Diabetes Unit at the Massachusetts General Hospital.
Host: John Buse, MD, PhD
Guest: Carolyn Bramante
Emerging research has shed light on the possibility of generic drugs being repurposed for the treatment of COVID-19. Dr. John Buse discusses metformin, ivermectin, and fluvoxamine with Dr. Carolyn Bramante, an Assistant Professor in the Division of Geriatrics, Palliative and Primary Care at the University of Minnesota Medical School.
Host: Ajay K. Singh, MBBS, FRCP, MBA
Guest: Kirsten L. Johansen, MD
Anemia in chronic kidney disease (CKD) is persistently undermanaged because current treatments have been linked with an increased risk for major cardiovascular events. They are also injectable or intravenous and definitely invasive, which no doubt limits patient acceptance.
Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are a novel class of small-molecule oral drugs in late-phase development and under review by the FDA that are poised to provide an alternative treatment paradigm for patients with CKD-related anemia. Physicians and other clinicians who manage patients with anemia in CKD will need to be familiar with these novel agents and the data supporting their use in appropriately selected patients.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Linda Bradley, MD
Join Drs. Linda Bradley and Lee Shulman as they discuss factors contributing to disparities in care for patients with endometriosis and/or uterine fibroids. They offer practical tips to overcome the disproportionate disease burden that especially impacts women of color. Cut through the noise to clearly hear each patient’s voice. Your clinical impact may be profound.
Host: Torie Comeaux Plowden, MD, MPH, FACOG
Guest: Sateria Venable
Do you want to be part of the solution? Pain and pelvic pressure, heavy menstrual bleeding, and dysmenorrhea should not be considered “normal” in a woman’s history. Diagnosing uterine fibroids or endometriosis early can help women improve their quality of life, preserve their uterus, and preserve their future fertility. Medical management can achieve this, but too often a hysterectomy is the only intervention offered. Tune in to hear from Dr. Torie Comeaux Plowden and Sateria Venable talk about the need for widespread educational efforts to address proper diagnosis and appropriate treatment, that can minimize the physical, mental, and socioeconomic effects of endometriosis and uterine fibroids.
Host: Matthew Sorrentino, MD
Guest: Michael A. Solomon, MD, MBA
Guest: Sean Agbor-Enoh, MD, PhD
Pulmonary arterial hypertension (PAH) is a rare, and even fatal, condition that can impair the chest and lungs. But could a new blood test help us better assess disease severity and survivability in patients with PAH? To dive deeper into this topic, Dr. Matthew Sorrentino is joined by Dr. Michael Solomon and Dr. Sean Agbor-Enoh from the National Institutes of Health.
Host: Theodora A. Potretzke, MD
Guest: Fouad T. Chebib, MD
This Expert Exchange webcast is designed to help improve clinicians’ understanding of the role radiologic imaging plays in the diagnosis and management of ADPKD.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Marc E. Agronin, MD
Guest: Anton Porsteinsson, MD
From expert specialists like internists and geriatric neuropsychiatrists to the patient themselves and their loved ones, there are a lot of individuals involved in an Alzheimer’s disease care team. So what are some best practices for collaborating and coordinating a patient’s care across all members of the team? Joining Dr. Charles Turck to share their perspectives are Dr. Marc Agronin from MIND Institute and Dr. Anton Porsteinsson from the University of Rochester.
Host: Paul Paik, MD
Guest: Catherine Shu, MD
Take a deep dive into current and ongoing clinical trials related to MET inhibitors and discover the key distinctions between these agents, such as dosing differences. Our experts also have recommendations on appropriate therapy selection for your patients with advanced NSCLC harboring MET exon 14 skipping mutations.
Host: Pam R. Taub, MD, FACC, FASPC
Guest: George L. Bakris, MD
Guest: Gerasimos S. Filippatos, MD, FESC, FHFA, FHFSA(h)
The FIDELITY pooled analysis findings demonstrated benefits in cardiovascular and kidney outcomes when nonsteroidal mineralocorticoid receptor antagonists (MRAs) were added to the mix. Tune in to hear Drs. Pam Taub, Gerasimos Filippatos, and George Bakris discuss the risk factors of chronic kidney disease, the importance of measuring eGFR and UACR, and how finerenone improves outcomes.
Host: Jacob Sands, MD
Guest: Edward B. Garon, MD, MS
Recently approved capmatinib may be a new treatment for patients with metastatic non-small cell lung cancer who have MET exon 14 skipping mutations. To learn more about this emerging treatment option, Dr. Jacob Sands speaks with Dr. Edward Garon from the David Geffen School of Medicine at the University of California in Los Angeles to explore data from the GEOMETRY Mono-1 study.
Host: Charles P. Vega, MD
Guest: David J. Cennimo, MD, FACP, FAAP, FIDSA
Clinicians treating patients in outpatient, urgent care, and emergent care settings who encounter patients with mild to moderate disease are tasked with providing optimal care to prevent disease progression. Drs. Charles Vega and David Cennimo take us through the spectrum of COVID-19 disease and identify available treatment options for your high-risk patients.
Host: Charles P. Vega, MD
Guest: Paul G. Auwaerter, MD, MBA
Newer therapeutic options are now available to treat COVID-19. Don’t panic! Drs. Charles Vega and Paul Auwaerter are here to help you successfully integrate these therapeutics into your practice. Find out how to identify patients that are at risk for severe disease and select the appropriate treatment for the patient in front of you.
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Guest: Sean Lawler, PhD
The STING protein is a novel treatment pathway for cancer. How might it affect our patients’ immune response to diseases such as brain cancer? Dr. Sean Lawler, an Associate Professor in the Department of Pathology and Laboratory Medicine at Brown University in Providence, Rhode Island. joins Dr. Andrew Wilner to explore the role of the STING pathway.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: David Leiman, MD, MSHP
Proton pump inhibitors (PPIs) are among the most commonly prescribed class of medication for acid-related disorders. But what are the long-term consequences of PPIs? And how have they changed the prescribing pattern among gastroenterologists? To help us better understand this topic, Dr. David Leiman, Assistant Professor of Medicine at Duke University School of Medicine, joins Dr. Peter Buch to discuss how we should be utilizing PPIs with our patients.
Host: Jennifer Caudle, DO
Guest: Sandra P. Reyna, MD
Spinal muscular atrophy (SMA) is a challenging rare disease that requires a diagnosis and access to treatment as early as possible. To help us understand the importance of early treatment, Dr. Sandra Reyna from Novartis Gene Therapies shares key considerations for optimizing outcomes and gives us some insight into available SMA treatment options, focusing on the gene therapy ZOLGENSMA.
© 2022 Novartis Gene Therapies, Inc.
US-ZOL-22-0129 08/22
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Benjamin L. Cohen, MD
Guest: Stefan Holubar, MD, MS
New data suggests that the use of anti-TNF therapy early in the treatment course can be effective for patients with inflammatory bowel disease (IBD). However, some of them may still require surgery. But is anti-TNF therapy safe in the perioperative period? To answer this question, Dr. Peter Buch is joined by Drs. Benjamin Cohen and Stefan Holubar from the Cleveland Clinic to discuss the findings from the PUCCINI study.
Host: Piotr Ponikowski, MD, PHD, FESC, FHFA
Guest: Adrian F. Hernandez, MD, MHS
Guest: Professor Andrew Sindone
Despite being an important and common comorbid condition in patients with heart failure, iron deficiency remains underdiagnosed and undertreated. Join Dr. Piotr Ponikowski, Dr. Andrew Sindone, and Dr. Adrian Hernandez as they discuss using guideline-directed medical therapy to overcome the morbidity, mortality, and very poor quality of life experienced by patients with heart failure and iron deficiency.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Victoria Gomez, MD
Endoscopic sleeve gastroplasty may be an effective option for weight loss. But which of our patients are the right candidates—and what do they need to know about before and after the procedure? Dr. Peter Buch dives into this procedure with Dr. Victoria Gomez, an Associate Professor of Medicine at the Mayo Clinic in Florida.
Host: Mario R. Nacinovich, Jr., MSc
Guest: Richard Kojan, MD
As the fight against Ebola continues, can a new biosecure emergency care unit (CUBE) and therapeutic guidelines from the World Health Organization (WHO) help combat this disease? Mario Nacinovich joins study Dr. Richard Kojan, President of the Alliance for International Medical Action, to discuss these new guidelines.
Host: Mario R. Nacinovich, Jr., MSc
Guest: Siwen Wang, MD
Have our patients experienced anxiety, depression, and stress following a COVID-19 infection? Joining Mario Nacinovich to dive into emerging research on post-COVID-19 psychological distress is Dr. Siwen Wang, a researcher in the Department of Nutrition at Harvard T.H. Chan School of Public Health.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Michel Kahaleh, MD
Endoscopic ultrasound-guided gallbladder drainage (ESU) is used to treat patients with cholecystitis and infection of the gallbladder. So when should we be utilizing ESU, and what are some common challenges associated with this procedure? Joining Dr. Peter Buch to explore this topic is Dr. Michel Kahaleh, Chief of Endoscopy, Director of the Pancreas Program, and Medical Director of the Advanced Endoscopy Research Program at Robert Wood Johnson Medical School.
Host: Courtney DiNardo, MD
Guest: Marina Y. Konopleva, MD, PhD
Developments over the last few years have brought dramatic changes to the treatment landscape of acute myeloid leukemia (AML). While new therapies mean more opportunities to individualize care, clinicians are also faced with new challenges and must quickly evaluate patients, order appropriate molecular tests, assess risk, and differentiate the efficacy, safety, and applicability of novel treatments and combinations. Join Drs. Courtney DiNardo and Marina Konopleva for a discussion of how to untangle the data to determine which treatment is right for each patient in the increasingly complex clinical setting of AML.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Marc E. Agronin, MD
Over five million Americans currently suffer from Alzheimer’s disease, and that number is only expected to double in the next several decades. But what do we first need to understand about its pathophysiology so that we can better care for our patients with Alzheimer’s disease? To give us an in-depth look, Dr. Charles Turck is joined by Dr. Marc Agronin, Chief Medical Officer for MIND Institute and President of the American Association for Geriatric Psychiatry.
Host: Robert J. Mentz, MD, FHFSA, FACC, FAHA
Guest: Peter van der Meer, MD, PhD
Iron deficiency in patients with heart failure remains underdiagnosed, undertreated, and commonly overlooked in non-anemic patients and has a significant impact on patient outcomes and quality of life. Join Dr. Robert Mentz and Dr. Peter van der Meer as they discuss approaches to identifying and treating iron deficiency in patients with heart failure and comorbidities such as diabetes.
Host: Matt Birnholz, MD
Guest: David Canaday, MD
As we age, our immune system becomes weaker and is therefore unable to ward off infection as easily as in our younger years.1 This is particularly troublesome during flu season. In fact, the CDC’s Advisory Committee on Immunization Practices (ACIP) recently looked at flu vaccine data for adults aged 65 years and older, and they now recommend that this age group preferentially receive higher dose or adjuvanted vaccines over standard dose unadjuvanted vaccines when available.2 So what was the data that led to these updated recommendations? Joining Dr. Matt Birnholz to share those key findings and the role of adjuvanted vaccines like FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted) in preventing influenza in older adults is Dr. David Canaday, Professor in the Division of Infectious Diseases & HIV Medicine at Case Western Reserve University in Cleveland.
Avoid use in patients who have experienced any severe allergic reactions to any component of the vaccine. For more risk information please see below or consult the Full US Prescribing Information for FLUAD® QUADRIVALENT here.
References:
1. Gavazzi G, Krause KH. Ageing and infection. Lancet Infect Dis. 2002;2(11):659-666.
2. Centers for Disease Control and Prevention. Past seasons estimated influenza disease …
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Kenneth J. Moise Jr., MD
Program Chairman:
Are you taking the right steps to consistently ensure all of your patients at risk of alloimmune disorders of pregnancy, specifically HDFN, receive a helping hand plus timely and appropriate clinical care? Despite having considerable clinical consequences, this area of medicine is not fully understood by many clinicians. Drs. Shulman and Moise provide expert insight on red blood cell alloimmunization, highlighting essential pathophysiology and current and evolving management strategies. Join us to learn new ways to approach this complicated and rare clinical condition.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Sharon Sha, MD, MS
Guest: Anton Porsteinsson, MD
Alzheimer’s disease is considered to have a long preclinical course, meaning that changes in the brain occur without the presentation of any clinical symptoms. But unfortunately, diagnostic delays continue to exist even after symptoms appear. So what are the factors contributing to diagnostic delays, and how can we reduce this gap? Joining Dr. Charles Turck to discuss key strategies for early intervention in Alzheimer’s disease are Drs. Sharon Sha and Anton Porsteinsson.
Host: Robert L. Coleman, MD, FACOG, FACS
Guest: Kathleen Moore, MD, MS
The global burden of cervical cancer is immense, especially for patients who have failed first-line therapy. Second-line interventions have historically had low response rates of short duration. But the landscape is changing with new and emerging agents in late-stage clinical trials, including antibody-drug conjugates, immunotherapy regimens, and tumor-infiltrating lymphocyte therapies. Join Drs. Robert Coleman and Kathleen Moore as they discuss and distill the “need to know” findings about these more effective therapies—therapies destined to improve outcomes for patients whose cervical cancer has failed first-line therapy.
Host: Ethan Craig, MD, MHS
Guest: Alexis Ogdie, MD, MSCE
For patients with oligoarticular arthritis, how can imaging features help us distinguish psoriatic arthritis from other inflammatory processes? Joining Dr. Ethan Craig to answer that question is Dr. Alexis Ogdie-Beatty from the Perelman School of Medicine at the University of Pennsylvania.
Dr. Craig and Dr. Ogdie-Beatty are Novartis consultants.
221663 7/22
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Madhu Grover, MBBS
Gastroparesis is a complex disease that has limited treatment options. What do we need to know about it? Dr. Mandu Grover, an Associate Professor of Medicine at the Mayo Clinic, joins Dr. Peter Buch to discuss gastroparesis.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Madhu Grover, MBBS
Gastroparesis can be a complex disease to understand—and treat. What therapeutics are currently available? Dr. Peter Buch is joined by Dr. Mandu Grover, an Associate Professor of Medicine at the Mayo Clinic, to take a look at current treatment options.
Host: Donna Ryan, MD
Guest: Juan Pablo Frías, MD
There are now multiple medical therapies available to facilitate weight loss in patients with type 2 diabetes (T2D). Learn who is the right patient, when these therapies should be started, and the right combinations and intensification strategies to sustain meaningful weight loss that can lower the risk of complications.
Host: Christina Y. Weng, MD, MBA
Guest: Margaret A. Chang, MD, MS
What are the critical steps to implantation and refill of the PDS? Join Dr. Margaret Chang and Dr. Christina Weng to discover the nuances that retina surgeons need to know about to optimize success and minimize patient risk.
Guest: Benjamin Izar, MD
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Brain metastases are common in patients with advanced melanoma and are a leading cause of cancer-related death. However, little is known as to why melanoma spreads to the brain, but new research from Columbia University may provide some answers. To discuss this recent discovery, Dr. Andrew Wilner is joined by Dr. Benjamin Izar, Assistant Professor of Medicine at Columbia University Vagelos College of Physicians and Surgeons.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Ehab L. Atallah, MD
New longer-term outcome data for chronic lymphocytic leukemia (CLL) has recently emerged with some interesting results. To dive into the key findings of these trials and other current CLL treatments available, Dr. Charles Turck is joined by Dr. Ehan Atallah, Professor of Medicine and the Section Head of Hematological Malignancies at the Medical College of Wisconsin Division of Hematology and Oncology.
Guest: Peter Whitehouse, MD, PhD
What kind of impact can Alzheimer’s disease have on our patients, their caregivers, and the healthcare system as a whole? Here to help answer that key question is Dr. Peter Whitehouse, Professor of Neurology at Case Western Reserve University.
Guest: Kostas Lyketsos
The risk of Alzheimer’s disease increases substantially with age. In fact, about one in three adults aged 85 and older have dementia. So how do we screen for it, and what kind of impact can early detection have on our patients? Here to break down essential cognitive screening strategies for Alzheimer’s disease is Dr. Constantine Lyketsos, the Elizabeth Plank Althouse Professor for Alzheimer’s Research and Chair of Psychiatry at the Johns Hopkins Bayview Medical Center.
Guest: Peter Whitehouse, MD, PhD
Although obtaining specific statistics about the prevalence of Alzheimer’s disease can be difficult, what we do know is that its prevalence is increasing worldwide. With that in mind, Dr. Peter Whitehouse from Case Western Reserve University joins us to help uncover the unmet needs of patients, caregivers, and clinicians.
Host: David Eichenbaum, MD
Guest: Mark R. Barakat, MD
Several novel treatment options are now available for DME, but do you know how which patients to treat with these agents to prolong durability and improve access? Join Dr. David Eichenbaum and Dr. Mark Barakat as they discuss patient management approaches based on the latest clinical data.
Guest: Neera Dahl, MD, PhD
Guest: Craig E. Gordon, MD
This Expert Exchange webcast is designed to help improve clinicians’ ability to apply pharmacologic and non-pharmacologic strategies in the management of patients with ADPKD.
Host: Anisha Dua, MD, MPH
Guest: Michael Putman, MD, MSci
What does the therapeutic landscape look like for patients with giant cell arthritis (GCA)? Joining Dr. Anisha Dua to highlight the need for more targeted therapies is Dr. Mike Putman from the Medical College of Wisconsin.
Dr. Dua and Dr. Putman are Novartis consultants.
199849 6/22
Guest: Francesca Taraballi, PhD
As mRNA therapeutics continue to evolve, what do we know about its potential in the treatment of infectious diseases? Dr. Francesca Taraballi from the Center for Musculoskeletal Regeneration at the Houston Methodist Hospital explores emerging mRNA therapeutics.
Guest: Rishi D. Naik, MD, MSCI
Colorectal cancer may be more prevalent than you think, underscoring the importance of colorectal cancer screening. Join us as we explore the latest screening recommendations and available modalities with Dr. Rishi Naik, Assistant Professor of Medicine in the Department of Gastroenterology, Hepatology, and Nutrition at Vanderbilt University Medical Center in Nashville, Tennessee.
Host: Jennifer Caudle, DO
Guest: Daniel R. Karlin, MD, MA
Digital tools have emerged as one of the newest therapeutic modalities for behavior modification in several chronic psychiatric diseases,1 such as major depressive disorder, chronic insomnia, and substance use disorders. But what exactly are these digital tools, and what does their use look like in practice? Joining Dr. Jennifer Caudle to answer those and other key questions regarding the use of digital tools in psychiatry is Dr. Daniel Karlin, Assistant Professor of Psychiatry at Tufts University in Boston and Chief Medical Officer at MindMed in New York City.
References:
- Patel NA, Butte AJ. Characteristics and challenges of the clinical pipeline of digital therapeutics. NPJ Digit Med. 2020;3:159.
August 2022 US.UNB.X.22.00018
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Craig Chepke, MD, FAPA
Curious about how the 2022 Psych Congress came together? Tune in to hear Steering Committee member Dr. Craig Chepke give us a behind-the-scenes look at the conference. Dr. Chepke is also the Medical Director of Excel Psychiatric Associates.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Craig Chepke, MD, FAPA
Although we’ve made some progress in the treatment of schizophrenia, unmet needs still remain. So what are the new mechanism of actions being explored in the treatment of this disease? To learn more about the updates featured at the 2022 Psych Congress, Dr. Charles Turck speaks with Dr. Craig Chepke, Medical Director of Excel Psychiatric Associates and member of the Psych Congress Steering Committee.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Matthew N. Brams, MD
Since the use of digital tools in psychiatry and mental health treatment is already a reality, it’s important to know how to find the digital tool that best suits your and your patients’ needs and—perhaps even more importantly—how to encourage patients to use the tool. That’s why Dr. Charles Turck speaks with Dr. Matthew Brams, who shares the benefits of digital tools, the data he’s able to gain from them, how he talks to patients, and more.
July 2022 US.UNB.X.22.00009
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: William Schaffner, MD
Before recommending the new COVID-19 booster, what do we need to know about this vaccine, and which of our patients fit the criteria for it? To learn the latest on what experts have to say about the new COVID-19 booster, Dr. Charles Turck speaks with Dr. William Schaffner from the National Foundation for Infectious Diseases.
Host: Ethan Craig, MD, MHS
Guest: Alexis Ogdie-Beatty, MD, MSCE
How does preclinical psoriatic arthritis (PsA) progress into chronic PsA? To dive into this path of progression, Dr. Ethan Craig is joined by Dr. Alexis Ogdie-Beatty from the Perelman School of Medicine at the University of Pennsylvania.
Dr. Craig and Dr. Ogdie-Beatty are Novartis consultants.
221663 7/22
Host: Suzanne J. Baron, MD
Guest: Jonathan A. Bradlow, MD, FACC
Guest: Kendra J. Grubb, MD
Data are limited on the incidence and factors associated with structural valve deterioration (SVD) after transcatheter aortic valve replacement (TAVR) and surgery for severe aortic stenosis in patients of all risk levels. The lifetime management of these patients requires an understanding of bioprosthetic valve durability and failure. Tune in for new evidence evaluating the 5-year incidence, outcomes, and predictors of hemodynamic SVD in patients undergoing TAVR and surgery that will support best practices for treatment selection.
Host: John Kitchens, MD
Guest: SriniVas R. Sadda, MD
Whether you’re a medical or surgical retina specialist, the port delivery system (PDS) is a practice-changing treatment modality. How can you smoothly incorporate continuous anti-VEGF delivery technology into your clinical practice? Join Dr. SriniVas Sadda and Dr. John Kitchens as they discuss how the PDS fits into our treatment arsenal.
Host: Cem Akin, MD, PhD
Guest: Jason Gotlib, MD, MS
It could take up to 7 years for a patient to be accurately diagnosed with systemic mastocytosis. Drs. Jason Gotlib and Cem Akin take us through the guidelines, diagnostic criteria, signs and symptoms, and the most important diagnostic tests for high-suspicion patients.
Host: Donna Ryan, MD
Guest: Juan Pablo Frías, MD
Dropping 15% or more of body weight has a greater disease-modifying effect than any other glucose-lowering intervention. Join Drs. Donna Ryan and Juan Pablo Frias as they discuss implementing an upstream intervention to weight loss and newer drugs (GIP agonists, GLP-1 receptor agonists, SGLT2 inhibitors) to help your patients experience improved effects earlier and for a longer duration. Tune in to find out how the novel dual GIP and GLP-1 receptor antagonist tirzepatide could fit into your therapeutic strategies.
Host: Charles P. Vega, MD
Guest: Rajeev Raghavan, MD, M.Ed, FASN
Clinicians have a critical need for up-to-date knowledge related to anemia of CKD. Provide better care for your patients by learning about the importance of assessing and treating while considering the burdens of the disease, advances in our understanding of the pathophysiology of the disease, ways to fill the unmet needs of treatment with ESAs, and the status of potential new therapies. Tune in to keep up!
Host: John J. Russell, MD
Guest: Paul Craddock, PhD
Beginning in the mid-16th century up until present day, medicine has evolved tremendously. How did transplant surgery play an important role in doing so? Dive into the teachings with Dr. Paul Craddock, author of the book titled, Spare Parts: The Story of Medicine Through the History of Transplant Surgery, as he joins Dr. John Russell to dissect the surprising history of modern medicine.
Host: Mario R. Nacinovich, Jr., MSc
Guest: Charles P. Gerba, MD
A recent case of polio emerging in New York City have clinicians questioning whether or not we need to be concerned about a spread. What do we need to know about this case—and our potential risk—of polio? Joining Mario Nacinovich to take a look at this case is microbiologist Dr. Charles Gerba, a Professor of Environmental Science at the University of Arizona.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Eamonn Quigley, MD
What factors affect the microbiome? And who should we be prescribing probiotics to? Find out the answers to those and other key questions with Dr. Peter Buch and returning guest Dr. Eamonn Quigley, Professor of Medicine and Chief of the Division of Gastroenterology and Hepatology at Weill Cornell Medical College at Houston Methodist Hospital.
Host: Carl Danzig, MD
Guest: Arshad M. Khanani, MD, MA
With the availability of multiple novel treatment options, how do we decide which is best for each patient with neovascular age-related macular degeneration? Join Dr. Arshad Khanani and Dr. Carl Danzig as they discuss their approach to treatment based on the latest clinical evidence.
Host: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Patrick Rossignol, MD, PhD
In heart failure, the use of MRAs is often delayed despite being a crucial part of medical therapy. The evidence is clear that clinical inertia and the suboptimal use of these therapies leads to poorer outcomes for our patients. Join Dr. Ileana Piña and Dr. Patrick Rossignol as they discuss approaches to the clinical stigma surrounding the use of MRAs, as well as management strategies to better ensure the best medical therapy possible for our patients with heart failure.
Host: Michael Greenberg, MD
Guest: Jonathan S. Weiss, MD
Physician assistants (PAs) are licensed to practice medicine to provide many of the same services as a physician. And they may even train in dermatology. But what do we need to take into consideration when bringing a PA into a dermatology practice? Joining Dr. Michael Greenberg to discuss the ethics of this all-too-common situation is Dr. John Weiss, President and Co-Managing Partner at Georgia Dermatology Partners.
Host: Anisha Dua, MD, MPH
Guest: Michael Putman, MD, MSci
What are some imaging factors we should consider when monitoring giant cell arthritis (GCA) and the medication prescribed for it? Dr. Anisha Dua is joined by Dr. Mike Putman to explore these factors.
Dr. Dua and Dr. Putman are Novartis consultants.
199849 6/22
Host: Guillermo Garcia-Manero, MD
Guest: Rami Komrokji, MD
Lower-risk MDS is an acquired bone marrow disorder that manifests with symptomatic anemia. Over time, many of these patients become dependent on red cell transfusions. Erythropoiesis-stimulating agents (ESAs) are first-line treatment, but not all lower-risk MDS patients respond to ESA and many eventually become refractory to ESAs. Join Drs. Guillermo Garcia-Manero and Rami Komrokji as they discuss the diagnostic and prognostic imperatives associated with lower-risk MDS, when to initiate and move on from ESA therapy, and an approach for patients in whom ESAs are no longer effective.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Sarah McGill, MD, MSc
Alpha-gal allergy is a recently identified food allergy to red meat and other products made by mammals. So what more do we need to know about this new allergy, and which of our patients are at risk for anaphylaxis? To dive into this topic, Dr. Peter Buch is joined by Dr. Sarah McGill, Associate Professor of Medicine at the University of North Carolina, to discuss her recent research on alpha-gal allergy.
Host: Paul G. Auwaerter, MD, MBA
Guest: Timothy E. Albertson, MD, MPH, PhD
Our understanding of the spectrum of COVID-19 as well as optimal management tactics continue to develop. In light of the ever-changing data and clinical recommendations surrounding COVID-19, clinicians are challenged to stay abreast of current treatment-related information with the potential to impact clinical decision-making. To mitigate the overall health burden associated with this devastating pandemic, healthcare professionals must be up to date on the latest practice-changing information regarding recommended therapeutic strategies, which include monoclonal antibodies, for high-risk patients in the outpatient setting. As such, an educational initiative surrounding COVID-19 outpatient treatments is warranted.
Host: Timothy E. Albertson, MD, MPH, PhD
Unknown: Paul G. Auwaerter, MD, MBA
Normal functions of the immune system include defense against infections. As the immune system ages and these capabilities decline, however, there is increased susceptibility to infections. Individuals of any age can acquire SARS-CoV-2 infection, although adults of middle age and older are most commonly affected, and older adults are more likely to have severe disease. Older age is also associated with increased COVID-19-related mortality. There is a need for knowledge regarding the harmful effects of the aging immune system (immunosenescence) and the role of chronic inflammation among elderly populations to facilitate enhanced clinical monitoring of at-risk patients. As such, an educational activity is needed to provide up-to-date coverage of the knowledge regarding immunosenescence in the context of COVID-19 to help optimize patient outcomes.
Guest: Timothy E. Albertson, MD, MPH, PhD
Unknown: Paul G. Auwaerter, MD, MBA
Like other viruses, SARS-CoV-2 evolves over time. Certain variants have gained widespread attention because of their rapid emergence within populations and evidence for transmission or clinical implications; per the CDC, these are considered variants of concern. Clinicians may be challenged to optimize use of COVID-19 vaccines and therapeutics in the clinical context of SARS-CoV-2 variants given the complex nature of the variants and the ever-evolving data surrounding them. Because of the significance associated with SARS-CoV-2 variants, clinicians require education on the latest data and clinical recommendations regarding these variants.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: William Chey, MD
The role of diet and nutrition in irritable bowel syndrome (IBS) has long been established, but clinical updates are always evolving. That’s why Dr. Peter Buch welcomes Dr. William Chey, Professor of Medicine and Chief of Gastroenterology at the University of Michigan, to talk about the latest clinical updates from the American Gastroenterological Association.
Host: Anisha Dua, MD, MPH
Guest: Elaine Husni, MD, MPH
The risk of developing cancer may be higher in patients with spondyloarthritis, or SpA for short.1-6 What do we need to know about the risk of cancer, as well as other malignancies in these patients? Dr. Anisha Dua joins Dr. Elaine Husni from the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to explore malignancies in SpA.
Dr. Dua and Dr. Husni are Novartis consultants.
- Deng C, Li W, Fei Y, Li Y, Zhang F. Risk of malignancy in ankylosing spondylitis: a systematic review and meta-analysis. Sci Rep. 2016;6:1-6.
- Gross R, Schwartzman-Morris J, Krathen M, et al. A comparison of malignancy incidence among psoriatic and rheumatoid arthritis patients in a large US cohort. Arthritis Rheumatol. 2014;66(6):1472-1481.
- Chiesa Fuxench ZC, Shin DB, Ogdie Beatty A, Gelfand JM. The risk of cancer in patients with psoriasis: a population-based cohort study in the health improvement network. JAMA Dermatology. 2016;152(3):282-290.
- Moon H-I, Chang H-J, Kim J-E, Ko H-Y, Ann S-H, Min C-K. The association between multiple myeloma and ankylosing spondylitis: a report of two cases. Korean J Hematol. 2009;44(3):182-187.
- Chang CC, Chang CW, Nguyen PAA, et al. Ankylosing spondylitis and the risk of cancer. Oncol Lett. 2017;14(2):1315-1322.
- Karmacharya P, Shahukhal …
Host: Dixon W. Wilde, PhD, FAHA
Guest: Ioana Preston, MD
Unexplained dyspnea may have many causes, which is why patients must have a complete diagnostic work-up to rule out pulmonary hypertension (PH) as a root cause. The differential diagnosis of PH is multifaceted and should be a collaborative effort between the community healthcare provider and the PH specialist at the PH center. Many diagnostic evaluations may be performed outside of the PH center, but right heart catheterization, which is the definitive procedure, and adjoining tests should be performed at the center. Newer and emerging diagnostic imaging techniques may also prove helpful, particularly in diagnosing chronic thromboembolism leading to chronic thromboembolic pulmonary hypertension. This program reviews the diagnostic approach to determining whether PH is the root cause of patients’ dyspnea and considers when community physicians, having created an index of suspicion for PH, should immediately refer their patients to the PH center for a full work-up.
Host: Rami Komrokji, MD
Guest: Michael R. Savona, MD
Guest: Jamile Shammo, MD, FASCP, FACP
Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid neoplasms associated with cytopenias, suboptimal production of mature erythrocytes, and substantial risk for progression to acute myeloid leukemia.
The classification of MDS and MDS/myeloproliferative neoplasm (MPN) overlap syndromes continue to evolve, making them difficult for clinicians to define and raising important new considerations for diagnosis, assessment, risk stratification, and treatment. The presence of ring sideroblasts (RS) and mutations in the SF3B1 gene correlate with favorable outcomes and help define specific disease subtypes.
In this video-based educational activity, an interview-style expert faculty panel will provide their perspectives and insights on the latest trends and emerging research in low-risk MDS, including guideline-directed diagnostic workup, RS evaluation and SF3B1 testing and their implications, currently approved and novel emerging treatment strategies for managing lower risk MDS, and strategies to mitigate and manage treatment-related adverse events.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Javier Morales, MD, FACP, FACE
Out of the 32 million patients with diabetes in the United States, 40 percent also have chronic kidney disease. But what’s even more alarming is that only 10 percent of these patients know they have chronic kidney disease. So what strategies can we use to address the unmet needs and barriers faced when managing patients with chronic kidney disease and type 2 diabetes? Joining Dr. Charles Turck to answer this and other key questions is Dr. Javier Morales, Associate Clinical Professor of Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell on Long Island.
Host: Mario R. Nacinovich, Jr., MSc
Guest: Charles P. Gerba, MD
With rates of monkeypox continuing to rise, what do we need to know about this disease? And how easily can it spread from one person to another? Tune in to hear from renowned microbiologist, Dr. Charles Gerba, a Professor of Environmental Science at the University of Arizona as he explores these topics with Mario Nacinovich.
Guest: Mikhail Kosiborod, MD
Patients with diabetes-related chronic kidney disease (CKD) are at high risk for a number of adverse events over a relatively short period of time. So what do we have in terms of efficacious therapies that can help make a positive impact in that regard? Here to share what we need to know about non-steroidal mineralocorticoid receptor antagonists (MRAs) for the treatment of diabetes-related CKD is Dr. Mikhail Kosiborod, Director of Cardiometabolic Research and Co-Director of the Haverty Cardiometabolic Center of Excellence at Saint Luke’s Mid America Heart Institute.
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Guest: Jason Barton, MD, PhD, FRCP(C)
Prosopagnosia, also known as face blindness, is a rare cognitive disorder. Joining Dr. Andrew Wilner to share his insights on this condition is Dr. Jason Barton, a Professor of Neurology, Ophthalmology and Visual Sciences, and Psychology at the University of British Columbia in Vancouver, Canada.
Host: Ayse Tuba Kendi, MD
Guest: A. Oliver Sartor, MD
Prostate cancer–specific antigen (PSMA) is highly expressed on prostate cancer (PC) cells and can be detected in tumors using positron emission tomography imaging. Even though clinical features predict different stages of PC progression, the application of imaging to guide treatment is still evolving but gaining substantial evidence for the targeting of PSMA. With clinical research shifting paradigms for the treatment of metastatic castration-resistant prostate cancer (mCRPC), novel treatment options require adoption and effective application into clinical practice. PSMA has become an appealing target for diagnostic agents for imaging and therapeutic agents to treat mCRPC. Radionuclide emitters are being used for both cell surface expression of PSMA and the tumor microenvironment, and research has proven the therapeutic efficacy of PSMA-directed radioligand therapy (RLT).
In this educational activity, two experts will examine the role and rationale for PSMA targeted therapies and diagnostics—jointly known as theragnostics—as a revolutionary new approach to treating patients with advanced prostate cancer and will evaluate clinical trial data for PSMA-targeted RLT.
Guest: Gates B. Colbert, MD, FASN
Approximately 34 million patients live with diabetes in the United States, and up to 40 percent of those patients also have chronic kidney disease (CKD). That’s why it’s so important to know how to identify and prevent CKD progression in patients with diabetes, and here to share key strategies is Dr. Gates Colbert, Assistant Clinical Professor at Texas A&M College of Medicine.
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Guest: Sanjay Kumar, PhD
Temporal lobe epilepsy (TLE) is the most common form of focal epilepsy. Due to recent research from Florida State University, we might have a better understanding of the potential link between a specific protein and increased vulnerability to neurodegeneration among patients with this disorder. Dr. Andrew Wilner is joined by Dr. Sanjay Kumar, Professor of Biomedical Sciences and Neuroscience at Florida State University, to discuss this new discovery.
Host: William Mencia, MD, FACEHP, CHCP
Guest: Julie Blatt, MD
Guest: Taizo Nakano, MD
PIK3CA-related overgrowth spectrum (PROS) refers to various clinical entities that share the same pathogenetic mechanism. These disorders are caused by somatic gain-of-function PIK3CA mutations. Diagnosis of PROS is often challenging and requires DNA sequencing of the affected tissue. PIK3CA genetic mutations vary greatly depending on the tissue being tested. PROS is not considered an inherited disease.
The road to a diagnosis of a rare disease can be a long, winding process. Because of its rarity, a wide spectrum of symptoms, and disease heterogeneity, patients may feel alone and as though they are the only ones with the disease. Management of PROS currently involves symptomatic treatment of its manifestations; an unmet need exists for targeted, systemic therapies.
Currently, there is no cure for PROS. This educational activity will assist the interprofessional care team to better understand, apply, and interpret advances in current and emerging evidence that will help bridge the gap toward faster adoption into patient care.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Reena Chokshi, MD
Gastric emptying tests may be used for patients with gastroparesis and functional dyspepsia. But when it comes to assessing patients with symptoms, is it time to discard these tests? Find out with Dr. Peter Buch as he speaks with Dr. Reena Chokshi, Assistant Professor at Baylor College of Medicine and author of an editorial on this topic, titled Is It Time to Abandon Gastric Emptying in Patients With Symptoms of Gastroparesis and Functional Dyspepsia?, which was published in the Clinical Gastroenterology and Hepatology journal in May 2021.
Host: Anisha Dua, MD, MPH
Guest: Michael Putman, MD, MSci
With several guidelines available—what imaging considerations should we keep in mind when it comes to diagnosing giant cell arthritis (GCA)? Joining Dr. Anisha Dua to walk us through the guidelines and make recommendations is Dr. Mike Putman.
Dr. Dua and Dr. Putman are Novartis consultants.
199849 6/22
Host: Jason D. Bloom, MD, FACS
Guest: Carolyn I. Jacob, MD, FAAD
The injection of botulinum toxin type A products can diminish unwanted facial wrinkles and improve appearance. Do you fully understand how to use these products? Tune in as Dr. Jason Bloom and Dr. Carolyn Jacob take us through the pharmacologic similarities, differences, and duration of effect for the 4 FDA-approved neuromodulators and demonstrate specific injection techniques for the masseter, platysma bands, “bunny lines,” and the glabellar complex.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Maurizio Bonacini, MD
What non-invasive techniques are available to assess liver fibrosis? Joining Dr. Peter Buch to give us insight on this key question, along with how we can incorporate these treatments into our patient care, is Dr. Maurizio Bonacini. Dr. Bonacini is an Associate Professor of Clinical Medicine at the University of California, San Francisco and CEO of Mission Gastroenterology and Hepatology.
Host: Mario R. Nacinovich, Jr., MSc
Guest: Julia Bilinska, MD
Guest: Aatish Patel, MD
Monkeypox continues to spread around the globe, and its clinical manifestations can differ from what we’ve seen. What are the newest symptoms of this disease? Learn more about these manifestations from Drs. Aatish Patel and Julia Bilinska from Guy's and St. Thomas' NHS Foundation Trust in London as they talk about their research with Host, Mario Nacinovich.
Host: Anisha Dua, MD, MPH
Guest: Elaine Husni, MD, MPH
The estimates of prevalence of depression across the axial spondyloarthritis spectrum ranges from 11% to 64%. How we can help these patients manage their mental health? To find out more, Dr. Anisha Dua is joined by Dr. Elaine Husni from the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.
Dr. Dua and Dr. Husni are Novartis consultants.
Zhao SS, Thong D, Miller N, et al. The prevalence of depression in axial spondyloarthritis and its association with disease activity: a systematic review and meta-analysis. Arthritis Res Ther. 2018;20(1):1-9.
196466 6/22
Host: John Buse, MD, PhD
Guest: Ania Jastreboff, MD, PhD
In the ongoing battle against obesity, what does the SURMOUNT-1 study tell us about the role of tirzepatide? Dr. Ania Jastreboff, who is an Associate Professor of Medicine and the co-director of Weight Management and Obesity Prevention Program at Yale School of Medicine, chats with Dr. John Buse and this study’s findings.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Robert Wong, MD
What are our treatment options for hepatitis B, and do they have any limitations? Here to walk us through the challenges treatment landscape for hepatitis B is Dr. Robert Wong, who is a Clinical Associate Professor at Stanford University.
Host: John Buse, MD, PhD
Guest: Rodica Pop-Busui, MD, PhD
The American Diabetes Association (ADA) published a new consensus report with the American College of Cardiology on heart failure in patients with diabetes. What does this report recommend—and how will these recommendations impact clinical practice? Dr. John Buse speaks with Dr. Rodica Pop-Busui from the University of Michigan about these updated heart failure recommendations.
Host: Mikhail Kosiborod, MD
Optimizing GDMT for patients with heart failure and concomitant kidney dysfunction and/or diabetes continues to be a challenge despite the overwhelming clinical evidence and recent updates to the guidelines for heart failure management. Recent evidence from clinical trials with SGLT2 inhibitors and mineralocorticoid receptor antagonists and the use of novel potassium binders provide new therapeutic opportunities for these patients. This activity will review the current challenges in initiating and maintaining patients on optimal RAASi therapy and approaches to improve cardiorenal outcomes.
Host: Pavani Chalasani MD, MPH
Guest: Prof. David Cameron
A groundbreaking clinical study on patients with HER2-low breast cancer may impact they way we provide treatment. Dr. David Cameron from the University of Edinburgh in Scotland joins Dr. Pavanai Chalasani to share key results from the DESTINY Breast04 trial.
Host: John J. Russell, MD
Guest: Vallerie V. Mclaughlin, MD
Join Dr. John Russell as he speaks about diagnosing and treating pulmonary arterial hypertension using the latest pharmacologic and medical management strategies with Dr. Valerie McLaughlin, Director of the Pulmonary Hypertension Program at the University of Michigan.
Host: John Buse, MD, PhD
Guest: Kenneth Cusi, MD, FACP, FACE
The American Association of Clinical Endocrinology (AACE) released new recommendations for the diagnosis and management of NAFLD and NASH. To learn more about these updates, Dr. John Buse speaks with Dr. Kenneth Cusi, who is the Chief of the Division of Endocrinology, Diabetes and Metabolism in the Department of Medicine at the University of Florida.
Host: John Buse, MD, PhD
Guest: David Spence, MD
Pioglitazone was studied in the Insulin Resistance Intervention after Stroke trial, or IRIS for short. What do we need to know about it? Joining Dr. John Buse to share background and clinical data of the impacts observed is Dr. David Spence, a Professor Emeritus of Neurology and Clinical Pharmacology at Western University and the Director of the Stroke Prevention and Atherosclerosis Research Center in London, Ontario.
Host: Matthew S. Keller MD
Guest: Natasha Mesinkovska, MD, PhD
Alopecia areata affects more than 300,000 people in the United States each year, causing hair loss to the scalp, eyebrows, and eyelashes. But recent studies have shown that the Janus kinase inhibitor drug baricitinib can help significantly regrow hair for patients. To find out more about what this first-ever FDA approval of a systemic treatment could mean for patients with alopecia areata, Dr. Matthew Keller speaks with Dr. Natasha Mesinkovska, Associate Professor of Dermatology and Vice Chair for Clinical Research of Dermatology at University of California Irvine.
Host: Hector O. Chapa, MD, FACOG
Guest: Erin D. Michos, MD, MHS, FACC, FAHA, FASE
Polycystic ovary syndrome (PCOS) affects approximately 5 to 13 percent of women in the general population. And although previous research has shown its link to cardiovascular (CV) risk factors later in life, a new study has revealed that PCOS can increase the risk of heart complications during delivery. So what do these findings mean when it comes to caring for pregnant patients with PCOS? Find out with Dr. Hector Chapa as he’s joined by lead author of the study Dr. Erin Michos, who's the Director of Women’s Cardiovascular Health and an Associate Professor of Medicine at Johns Hopkins School of Medicine.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Mark Pimentel, MD
Hydrogen breath tests can help clinicians determine if a patient has conditions that can affect their digestive health, and they’re especially important for the diagnosis of carbohydrate maldigestion and small intestinal bacterial overgrowth. That’s why Dr. Peter Buch takes an in-depth look at breath testing with Dr. Mark Pimentel, Professor of Medicine at the David Geffen School of Medicine at UCLA and Associate Professor at Cedars-Sinai Medical Center.
Host: Anisha Dua, MD, MPH
Guest: Grace C Wright, MD, PhD
Guest: Irene Blanco, MD, MS
How can we improve diversity in the rheumatology workforce? Joining Dr. Anisha Dua to explore underrepresentation in the workforce are Dr. Grace Wright and Dr. Irene Blanco.
Drs. Dua, Blanco, and Wright are Novartis consultants.
194889 4/22
Host: Shanu Modi, MD
This Clinical Case Challenge is designed to help improve clinical decision making for providers caring for patients with HER2+ breast cancer.
Host: Shanu Modi, MD
Guest: Sara A. Hurvitz, MD, FACP
This Expert Exchange webcast is designed to help improve clinicians’ ability to implement appropriate treatment strategies for patients with HER2+ breast cancer.
Host: Gerasimos S. Filippatos, MD, FESC, FHFA, FHFSA(h)
Guest: Javier Morales, MD, FACP, FACE
Guest: Angela Yee-Moon Wang, MD, FACP, FACE
Diabetic nephropathy is one of the leading causes of end-stage renal disease (ESRD) and is associated with mortality and morbidity worldwide. Recent data on the use of nonsteroidal MRAs were presented at the European Society of Cardiology and other major meetings and were simultaneously published in major journals. Join our experts to explore these data and find out how you can better prevent the deterioration of renal function and improve cardiovascular outcomes in your patients across the spectrum of renal decline.
Host: Dixon W. Wilde, PhD, FAHA
Guest: Jean M. Elwing, MD
Many pulmonary arterial hypertension (PAH) patients remain undiscovered, undiagnosed, and underserved. The reasons for this are many-fold, but central to the treatment of these patients is a need to make PAH care more accessible, affordable, and attractive. The COVID-19 pandemic has further exacerbated the need to connect with not only undiscovered PAH patients, but even those currently under physician care. That’s why this program explores myriad aspects of finding means to discover, connect with, and manage the disease of these underserved PAH patients in our general population. Key explorations brought to light in the program include the burdens many patients and physicians face with the financial costs to care, the prejudices many experience or perceive, and the lack of education and awareness of patients and healthcare providers alike. Part of the solution to these modern-day issues centers on the education of physicians, reducing medical and ancillary costs to patients, and making the most of the developing practices of telemedicine.
Guest: Elaine Husni, MD, MPH
Host: Anisha Dua, MD, MPH
Physical activity has shown to have many benefits for patients with spondyloarthritis, or SpA for short. What kind of role does it have in the treatment of these patients? To answer this question, Dr. Anisha Dua is joined by Dr. Elaine Husni from the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Dr. Dua and Dr. Husni are Novartis consultants.
O’Dwyer T, O’Shea F, Wilson F. Physical activity in spondyloarthritis: a systematic review. Rheumatol Int. 2015;35(3):393-404.
196466 6/22
Host: Pavani Chalasani MD, MPH
Guest: Erika Hamilton, MD
A new treatment option for breast cancer may alter the treatment landscape for patients with HER2-positive metastatic breast cancer. Joining Dr. Pavani Chalasani to share data from the DESTINY Breast03 trial is Dr. Bethany Hamilton, the Director of the Breast Cancer and Gynecologic Cancer Research Program at Sarah Cannon Research Institute at Tennessee Oncology.
Host: Neilanjan Nandi, MD
Guest: Parambir Dulai, MD
In contrast to traditional monoclonal antibodies or small molecules, hyperbaric oxygen therapy involves a different type of treatment. But is this therapeutic option effective for our ulcerative colitis patients? To better understand this, Dr. Neil Nandi speaks with Dr. Parambir Dulai from Northwestern University to share his research on hyperbaric oxygen therapy.
Host: Anisha Dua, MD, MPH
Guest: Grace C Wright, MD, PhD
Guest: Irene Blanco, MD, MS
What are some of the social determinants that can impact patient outcomes? Joining Dr. Anisha Dua to share strategies to improve these inequities are Dr. Grace Wright and Dr. Irene Blanco.
Drs. Dua, Blanco, and Wright are Novartis consultants.
194889 4/22
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Eamonn Quigley, MD
Have you ever wondered what the practice of gastroenterology will look like in 10 years? If so, you’re not alone. And to help clear up that crystal ball, Dr. Peter Buch speaks with Dr. Eamonn Quigley about what’s to come in gastroenterology.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Paul Kwo, MD
The treatment landscapes for alcoholic hepatitis and acute kidney injury in cirrhosis are evolving. So how are we now defining acute kidney injury with cirrhosis, and how should we treat these two conditions based on the latest therapeutic updates? To find out, Dr. Peter Buch speaks with Dr. Paul Kwo, Professor of Medicine and Director of Hepatology at Stanford University.
Host: Javed Butler, MD, MBA, MPH
Guest: Alice White, PhD
Guest: Christopher Chen, MD, PhD
There is currently no safe way to get a close-up view of the human heart, which is exactly why a team of Boston University researchers created a device to mimic the human organ. So how does the new device called miniPUMP work, and how was it developed? To discuss this, Dr. Javed Butler is joined by Dr. Alice White and Dr. Christopher Chen from Boston University.
Host: Septimiu Murgu, MD, FCCP
Host: Eric Edell, MD, FCCP
Guest: Narjust Duma, MD
Guest: Janani Reisenauer, MD
Guest: Colleen Channick, MD, FCCP, DAABIP
A multidisciplinary panel including a medical oncologist, a thoracic surgeon, and an interventional pulmonologist will discuss the role of lung cancer teams in their thoracic oncology practices. The panelists will review their management of patients with lung cancer during the COVID-19 pandemic, including the impact of delayed procedures and telemedicine on patient outcomes.
Host: Mark Socinski, MD
Guest: Jennifer Marie Suga, MD, MPH
There are new targeted therapies that are now approved for the treatment of advanced non-small cell lung cancer. Dr. Mark Socinski & Dr. Marie Suga discuss evolving diagnostic approaches and best practices for selecting the right therapy for patients with NSCLC.
Host: Jason Liebowitz, MD
Guest: Michael Putman, MD, MSci
Shared treatment decisions can help guide patient care—but how can we implement them in our practice? Drs. Jason Liebowitz and Michael Putman share tips and strategies to implement shared decision-making (SDM) in rheumatology.
Dr. Liebowitz and Dr. Putman are Novartis consultants.
194889 4/22
Guest: Todd H. Baron, MD
What do we need to know about esophageal perforations? Dr. Todd H. Baron from the University of North Carolina School of Medicine shares how he treats patients with esophageal perforations.
Host: Pavani Chalasani MD, MPH
Guest: Kevin Kalinsky MD, MS
CDK4/6 inhibitors have changed the treatment landscape for hormone receptor-positive/HER2-negative metastatic breast cancer. But if the disease progresses, should we switch our patients to endocrine therapy? Joining Dr. Pavanai Chalasani to answer this question and share the most recent research from the MAINTAIN trial is lead researcher, Dr. Kevin Kalinsky from the Winship Cancer Institute at Emory University.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Brennan Spiegel, MD, MSHS
Diverticular disease is a common condition for which clinical therapies continue to evolve. So what has changed in the treatment paradigm? Joining Dr. Peter Buch to discuss everything from the role of colonoscopy, diverticular bleeding, long-term complications, and more is Dr. Brennan Spiegel, Director of Health Services Research at Cedars-Sinai and Professor of Medicine at UCLA.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Nicholas Shaheen, MD, MPH
For patients with Barrett’s esophagus with dysplasia, endoscopic surveillance is recommended to monitor the progression of the condition. But with the release of an updated guideline from the ACG, which of our patients are the right candidates for endoscopic treatment, and when should we be stopping surveillance? To discuss these and other key questions stemming from the updated guideline, Dr. Peter Buch is joined by Dr. Nicholas Shaheen, Professor of Medicine and Epidemiology and Chief of the Division of Gastroenterology and Hepatology at the University of North Carolina School of Medicine.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Todd H. Baron, MD
Treating benign esophageal strictures can be challenging. How can we avoid mistakes and improve care? Dr. Peter Buch joins Dr. Todd Baron, Professor of Medicine and Director of Advanced Therapeutic Endoscopy at the Division of Gastroenterology and Hepatology at the University of North Carolina School of Medicine to share common therapeutic mistakes and discuss how to treat esophageal strictures.
Host: Anisha Dua, MD, MPH
Guest: Elaine Husni, MD, MPH
Patients with spondyloarthritis, or SpA for short, can be at an increased cardiovascular risk.1,2 To learn how we can better understand and manage this risk, Dr. Anisha Dua is joined by Dr. Elaine Husni from the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.
Dr. Dua and Dr. Husni are Novartis consultants.
- Zhao SS, Robertson S, Reich T, Harrison NL, Moots RJ, Goodson NJ. Prevalence and impact of comorbidities in axial spondyloarthritis: systematic review and meta-analysis. Rheumatol (United Kingdom). 2020;59:iv47-iv57.
- Papagoras C, Markatseli TE, Saougou I, et al. Cardiovascular risk profile in patients with spondyloarthritis. Jt Bone Spine. 2014;81(1):57-63.
196466 6/22
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Kathryn Peterson, MD, MSci
As rates of eosinophilic esophagitis continue to rise, how should we adjust our approach to management? To answer that question, Dr. Peter Buch is joined by Dr. Kathryn Peterson, an Associate Chief of the Division of Gastroenterology at the University of Utah Health.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Kenneth Cusi, MD, FACP, FACE
Not only is nonalcoholic steatohepatitis (NASH) the most common chronic liver condition worldwide, but it’s also becoming the number one cause of liver transplantation beyond hepatitis C. And with its growing prevalence and burden having no end in sight, Dr. Charles Turck speaks with Dr. Kenneth Cusi about how we can better recognize the symptoms of NASH in high-risk patient groups.
Host: Ian W. Flinn, MD, PhD
Guest: William Wierda, MD
Preventing or mitigating adverse events (AEs) when utilizing small molecule inhibitors of BTK and Bcl-2 in the management of CLL is critical to improving patient outcomes. Coupling each agent’s unique side-effect profile with the appropriate patient makes the decisions even more complex. Join Drs. Ian Flinn and William Wierda as they deep dive into these issues and offer actionable guidance backed by key clinical trials.
Host: Jerome Lisk, MD
Guest: Mark Mintz, MD
Recent developments in artificial intelligence (AI) technology have shown to aid with neurological disease diagnosis, risk stratification, treatment response, and more. So what are the newest AI applications? And perhaps even more importantly, what’s to come in the future? To find out the answer to these and other key questions, Dr. Jerome Lisk speaks with Dr. Mark Mintz, Chief Medical Officer and Founder of NeurAbilities Healthcare, to discuss emerging AI tools in the field of neurology.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Andrew Ong MBChB, MRCP, FAMS
Irritable bowel syndrome (IBS) varies by geography, culture, and environment. So to learn more about IBS in the Asian population, Dr. Peter Buch welcomes Dr. Andrew Ong, who discusses the differences between IBS in the Asian population compared to North America and the importance of considering cultural differences when confronting IBS.
Host: Jacob D. Soumerai, MD
Guest: Andrew H. Lipsky, MD
The landscape of treatment for CLL is rapidly evolving, with promising results from trials examining chemotherapy-free regimens in the frontline setting. While these targeted approaches utilizing BTK or BCL-2 inhibitors have largely displaced chemoimmunotherapy in frontline management of CLL, there remains a clinically significant fraction of patients who will require subsequent therapy after developing drug intolerance or progressive disease. Join Drs. Andrew Lipsky and Jacob Soumerai as they strategize which targeted therapeutic options for relapsed/refractory CLL likely offer each individual patient the safest and most effective clinical outcome.
Host: Susan O’Brien, MD
Guest: Timothy Call, MD
The process of matching the most optimal first-line therapy to patients with CLL has recently undergone a paradigm shift. Along with a widening focus on targeted agents, untangling key patient- and disease-centric parameters adds complexity to this shared decision. Join Drs. Susan O’Brien and Timothy Call as they offer clarity to this first-line decision process—a clarity that you can readily take into the clinic.
Host: Jennifer Caudle, DO
Guest: Maitreyi Raman , MD, MSc, FRCPC
Diet and nutrition is known to play a large role in the onset and treatment of IBD. So what were some of the trending sessions focusing on diet and nutrition at the 2022 Crohn’s & Colitis Congress? Join Dr. Jennifer Caudle as she speaks with Dr. Maitreyi Raman to explore the latest research advancements in diet therapies.
Guest: Amy Mgonja, PharmD, BCGP, CPPS
Training pharmacists to administer vaccines can reduce barriers to immunizations and improve patient care. Here to discuss the ApHA Pharmacy-Based Immunization Delivery Program and the important role that pharmacists play in educating and vaccinating patients is Dr. Amy Mgonja, clinical consultant pharmacist at Dawa Rx Consulting.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Vershalee Shukla, MD
Tools like MCED can help us detect cancer early, but how can we implement it in practice? Dr. Charles Turck joins Dr. Vershalee Shukla, a board-certified radiation oncologist and co-founder of the Vincere Cancer Center to discuss the clinical implementation of multi-cancer early detection screening.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Nick Kusnezov, MD
Can you balance locum tenens with a full-time career? To answer that question, Dr. Charles Turck is joined by board-certified orthopedic surgeon, Dr. Nicholas Kusnezov, to walk us through his journey from joining the military to locum tenens.
Host: Septimiu Murgu, MD, FCCP
Host: Eric Edell, MD, FCCP
Guest: Narjust Duma, MD
Guest: Andreas Rimner, MD
Two internationally known medical and radiation oncologists will discuss ongoing and recent clinical trials and offer their perspectives on how they will impact thoracic oncology practice. The panelists will also discuss current guidelines for managing patients with advanced lung cancer and emphasize the role of tissue and blood biomarkers.
Host: Jason Liebowitz, MD
Guest: Michael Putman, MD, MSci
Social media is often used as a tool to network and connect to people around the world—but can rheumatologists use it to connect with their patients? Drs. Jason Liebowitz and Michael Putman share how rheumatologists can use it to improve care.
Dr. Liebowitz and Dr. Putman are Novartis consultants.
194889 4/22
Host: Shaji K. Kumar, MD
Guest: María-Victoria Mateos, MD, PhD
A plethora of new data for multiple myeloma were presented at ASCO 2022. Hear Dr. Shaji Kuman and Dr. Maria-Victoria Mateos discuss the most relevant findings and which emerging strategies look promising for patients.
Guest: Amrita Krishnan, MD
Guest: Morie Gertz, MD, MACP
Patients with multiple myeloma inevitably experience disease relapse, which is challenging. Rapid therapeutic advances have heralded an increasing number of efficacious targeted strategies and combination therapies for patients after a first relapse or in those with heavily pretreated disease. However, selecting the optimal regimen requires a individualized approach. Hear how Dr. Amrita Krishnan and Dr. Morie Gertz translate the evolving clinical data into their clinical practices and what factors influence their choices to improve durable responses and outcomes for patients with relapsed/refractory multiple myeloma.
Guest: Monique Hartley-Brown, MD, MMSc
Guest: Shonali Midha, MD
Significant progress has been made with induction and initial treatment of multiple myeloma, leading to longer and deeper remissions for patients. Yet, how do you decide which regimen is best? Hear how Dr. Monique Hartley-Brown and Dr. Shonali Midha navigate the treatment of their newly diagnosed patients and what factors they consider when selecting a regimen.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Naim Alkhouri, MD
Non-alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease in the United States and affects about one-quarter of the population. So what are the risk factors for developing NAFLD, and how can we monitor its progression and manage our patients? Joining Dr. Peter Buch to answer these and other key questions is Dr. Naim Alkhouri, Chief of Transplant Hepatology and the Director of the Fatty Liver Program at Arizona Liver Health.
Guest: Amrita Krishnan, MD
Guest: Cesar Rodriquez Valdes, MD
There is an unmet clinical need for more durable responses in patients with multiple myeloma because of their inevitable relapses. Advances in our ability to delineate the molecular pathobiology of the disease are guiding impressive new therapeutic options for this patient population. Join Dr. Cesar Rodriguez Valdes and Dr. Amrita Krishnan as they discuss the latest data around emerging agents targeting BCL-2 and BCMA for multiple myeloma and the investigational targets on the horizon.
Host: Pavani Chalasani MD, MPH
Guest: Nan Chen, MD
Immunotherapy is starting to make its way in breast cancer, especially triple-negative breast cancer. So how do we identify which of our patients are good candidates for this treatment? Joining Dr. Pavani Chalasani to share the most recent research on immunotherapy is Dr. Nan Chen, an Assistant Professor of Medicine at the University of Chicago.
Guest: Caitlin Costello, MD
Guest: Ravi Vij, MD
Frontline management of patients with newly diagnosed multiple myeloma is complicated by a multitude of current and newer agents, and navigating the guidelines can be confusing. Tune in as Drs. Caitlin Costello and Ravi Vij provide insight into the newer agents and different administration modalities so that you can address your patients’ questions.
Eosinophils are part of a complex set of allergic mechanisms in eosinophilic asthma. But eosinophils are far from the only component or driver of disease. Here to share key insights on the role of eosinophils along with genetic and environmental factors in the pathophysiology of eosinophilic asthma is pulmonary and critical care physician Dr. Praveen Akuthota.
The treatment landscape for eosinophilic asthma is a rapidly changing field, with new therapies arriving on a regular basis. One of the newer therapeutic approaches available is biologics. But how do they work to treat eosinophilic asthma? And which of our patients should be prescribed biologics and when? Tune in to hear Dr. Ian Pavord answer those and other key questions about the role of biologics in the eosinophilic asthma treatment landscape with Dr. Charles Turck.
Host: Pavani Chalasani MD, MPH
Guest: Seema A. Khan, MD
Dr. Pavani Chalasani meets with Dr. Seema Khan, a Professor of Surgery and Interim Co-Vice Chair of Research at Northwestern Feinberg School of Medicine, to explore the role of surgery in metastatic breast cancer and take a look at the current treatment landscape.
Host: Jacob Sands, MD
Guest: Maya Leiva, PharmD, BCOP
What causes drug shortages in the U.S.? Joining Dr. Jacob Sands to answer this question and dive in to what physicians and pharmacists can do to prepare for future shortages is Dr. Maya Leiva, an Associate Professor of Pharmacy Practice at West Coast University and a board certified board certified hematology and oncology clinical pharmacy specialist at Inova Schar Cancer Institute.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Michel Kahaleh, MD
Per-oral endoscopic myotomy (POEM) is a specialized endoscopic procedure to treat motility disorders of the esophagus. But what’s the procedure’s specific use in treating achalasia and other esophageal dysmotilities? To help answer that key question, Dr. Peter Buch is joined by Dr. Michel Kahaleh, Professor of Medicine and Director of the Pancreas Program in the Department of Medicine at Robert Wood Johnson Medical School, to discuss which patients to consider for POEM and key limitations of the procedure that clinicians should be aware of.
Host: Neilanjan Nandi, MD
Guest: Anita Afzali MD, MPH, FACG, AGAF
Guest: Aline Charabaty, MD
Although the rate of females in gastroenterology has increased, gender disparities such as equal pay and leadership positions still persist. That’s why Drs. Aline Charabaty and Anita Afzali co-founded Scrubs & Heels, a leadership organization working to foster professional growth for women in gastroenterology. And now, they join Dr. Neil Nandi to discuss Scrubs & Heels’ mission and how we can close gender disparities and promote women in the field of gastroenterology.
Host: Jennifer Caudle, DO
Guest: Wendy Wright, DNP, FNP-BC, ANP-BC, FAANP, FAAN, FNAP
Guest: Gary Marshall, MD
It's well understood that annual vaccination is the best way to help reduce the high burden associated with influenza. And while most influenza vaccines available in the United States are produced in eggs, this presents some inherent challenges, which can lead to reduced vaccine effectiveness. Fortunately, alternative production processes can help us overcome those challenges, and to learn more, Dr. Jennifer Caudle speaks with Dr. Wendy Wright and Dr. Gary Marshall.
USA-CRP-22-0018 May 2022
Host: Jacob Sands, MD
Guest: Maya Leiva, PharmD, BCOP
Recognizing bias and improving diversity is critical for patient outcomes, especially within the field of oncology. To explore how we can improve care for both LGBTQ+ patients and employees within healthcare, Dr. Jacob Sands is joined by Dr. Maya Leiva, an Associate Professor of Pharmacy Practice at West Coast University and a board certified board certified hematology and oncology clinical pharmacy specialist at Inova Schar Cancer Institute.
HER2 (ERBB2) mutations may increase receptor internalization and lead to hyperactive downstream signaling, uncontrolled cell growth, and tumorigenesis. Learn more about how HER2 mutations affect several types of cancer, including non-small cell lung cancer (NSCLC).
Intended for US Healthcare Professions only
©2022 Daiichi Sankyo, Inc. and AstraZeneca. PP-US-8201a-1332 06/22
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Nanette F. Santoro, MD
Tune out the noise and get to the heart of managing menopause and associated vasomotor symptoms. This program provides highlights from the 2022 American College of Obstetricians and Gynecologists Annual Clinical and Scientific Meeting. Join Drs. Nanette Santoro and Lee Shulman as they dive into the latest research, which could alter your current practice patterns and help your patients cool off.
Host: John J. Russell, MD
Guest: Heidi Skolnik, MS, CDN, FACSM
For older adults, losing weight can be an almost impossible task…which then begs the question: have we been giving the wrong advice? And can stopping age-related weight gain and muscle loss be done in six simple steps? To find out, Dr. John Russell speaks with nutritionist and exercise physiologist Ms. Heidi Skolnik, co-author of The Whole Body Reset.
Host: Dixon W. Wilde, PhD, FAHA
Guest: Vallerie V. Mclaughlin, MD
In the management of the pulmonary arterial hypertension (PAH) patient, the use of risk assessment algorithms has become de rigueur for the regular determination of disease progression and the effectiveness of treatment. However, based on the registries, from which the modern risk assessment models have been developed, it’s clear that the majority of patients fall into the intermediate-risk category. And yet, within this broad category, there’s a spectrum of disease severity, medical treatment need, and survivorship. Using risk assessment effectively in the modern era will rely on a rethinking of how to use risk assessment and adjusting disease management strategies appropriately. This program explores new ideas in the use and application of risk assessment protocols and the impact these have on the use of multimodal, combination therapy and lung transplantation.
Host: Ayman Al-Hendy, MD
Despite its profound impact, endometriosis remains critically undermanaged. This program provides highlights from a live symposium at the annual meeting for obstetrics and gynecology professionals and is based on patient & provider surveys. Join Dr. Ayman Al-Hendy to explore management gaps, the role of GnRH antagonists in addressing deficits, and the latest research, which he presented with Drs. Andrea Lukes and Lee Shulman—you might just alter your current practice patterns.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Neena Abraham, MD, MS
Join Dr. Peter Buch as he explores the management of acute gastrointestinal bleeding and the periendoscopic period with anticoagulants and with Dr. Neena Abraham, Associate Medical Director at the Mayo Clinic Center for the Science of Health Care Delivery in Arizona and lead author of the joint “American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline.”
Host: Michael Greenberg, MD
Guest: Lynn McKinley-Grant, MD, FAAD
Psoriatic disease looks and feels different for people of color, and these differences may affect their diagnosis, treatment, and—by extension—quality of life. In fact, more than 50 percent of people with psoriatic arthritis experience a 2-year delay in diagnosis and a lower quality of life compared to white patients. So how can we help close the diagnostic gap and provide better care for our patients of color with psoriatic arthritis? To find out, Dr. Michael Greenberg is joined by Dr. Lynn McKinley-Grant, Associate Professor of Dermatology at Howard University College of Medicine.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Laura Targownik, MD
Proton pump inhibitors (PPIs) are among the 10 most widely prescribed medications, but PPI overuse has been associated with adverse events. So what is the best advice for de-prescribing PPIs, and which of our patients should remain on PPIs? Find out the answers to these and other key questions with Dr. Peter Buch and Dr. Laura Targownik, who’s the lead author of the American Gastroenterological Association’s Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Frances Onyimba, MD
Over the last two decades, up to 20 percent of the population in industrialized nations have reported an abnormal physical response to food ingestion, also known as an adverse reaction to food. So what key information do we need to know about food allergies and intolerances amid this recent rise around the world? To find out, Dr. Peter Buch is joined by Dr. Frances Onyimba, Assistant Professor of Medicine at the University of Maryland School of Medicine. Together, they’ll discuss how we can better identify and diagnose food allergies and intolerances.
Host: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Adrian F. Hernandez, MD, MHS
Recent clinical trial data and subsequent approval of novel therapies have expanded the treatment armamentarium. These advances have the potential to improve long-term patient outcomes, but also make the choice of therapy more complex. This activity aims to educate clinicians managing patients with HFrEF already on guideline-directed medical therapy (GDMT) who continue to be at high risk of rehospitalization to recognize the clinical characteristics of worsening heart failure and to select appropriate HF treatment strategies including novel classes of agents in heart failure.
Host: Anisha Dua, MD, MPH
Guest: Grace C Wright, MD, PhD
Guest: Irene Blanco, MD, MS
How can we improve representation in rheumatology clinical trials? To share strategies, Dr. Anisha Dua joins Dr. Grace Wright and Dr. Irene Blanco to discuss diversity in clinical trials.
Drs. Dua, Blanco, and Wright are Novartis consultants.
194889 4/22
Host: John J. Russell, MD
Guest: Randy Young, MD
As Monkeypox continues to spread across non-endemic countries more and more, how can we detect it in our patients? And what’s being done to stop the spread? Guest and fellow ReachMD Host Dr. Randy Young, a Pulmonary Disease and Critical Care Medicine physician, joins Dr. John Russell to discuss what physicians should be looking out for, and how this virus has impacted public health.
Host: Mitchell D. Creinin, MD
In-office delivery of sexual and reproductive healthcare (SRH) services was markedly restricted for 2 years during the COVID-19 pandemic. Now, in-office access to these services has begun to improve. What have we learned since 2020 that can prepare us for future periods of reduced access? Join Dr. Mitchell Creinin as he discusses SRH service strategies initiated during the pandemic that remain useful even in times of full in-office access.
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Guest: Craig Chepke, MD, FAPA
Schizophrenia is a chronic mental disorder characterized by symptoms that negatively affect a patient’s mental and emotional behaviors. And although there are current treatment options including first and second-generation antipsychotics, treatment challenges still persist. That’s why Dr. Andrew Wilner speaks to psychiatrist Dr. Craig Chepke from Excel Psychiatric Associates to discuss clinical strategies that can help optimize outcomes for our patients.
Host: Carol Wysham, MD
From newly approved treatments to emerging clinical trial data, Dr. Carol Wysham shares some of the highlights from the American Diabetes Association’s 82nd Scientific Sessions, exploring developments in GLP-1 receptor agonists, barriers to patient use, and more.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: David Graham, MD
H. pylori testing is accessible now more than ever before. Why is this development so important? To help us understand why, Dr. David Graham, a Professor of Medicine and Gastroenterology at the Baylor College of Medicine, joins Dr. Peter Buch to discuss this availability and dive into “Antimicrobial Susceptibility Testing for Helicobacter pylori Is Now Widely Available: When, How, Why."
Host: John Buse, MD, PhD
The American Diabetes Association and European Association for the Study of Diabetes recently published guidance on the management of hyperglycemia in type 2 diabetes. What does this consensus statement tell us? Tune in to hear from Dr. John Buse about how we should adapt our approach to management.
Host: Michael Greenberg, MD
Guest: Esther Freeman, MD, PhD
Guest: Steven Chen, MD, MPH, MHPEd
With the recent rise of monkeypox cases around the world, dermatologists will be some of the first to evaluate and diagnose patients with the disease. So to help those on the frontlines, Dr. Esther Freeman, Director of Global Health Dermatology at Massachusetts General Hospital and Dr. Steven Chen, Assistant Professor of Dermatology at Harvard Medical School, share what dermatologists need to know about monkeypox.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Jasmohan Bajaj, MD
In patients with cirrhosis and chronic liver disease, acute-on-chronic liver failure is emerging as a major cause of mortality. That’s why an update on precipitating factors and essential management strategies is the basis of Dr. Peter Buch’s discussion with Dr. Jasmohan Bajaj, Professor of Medicine at the Richmond VA Medical Center and lead author of the article “Acute-on-Chronic Liver Failure Clinical Guidelines,” which was published in the American Journal of Gastroenterology in February 2022.
Host: Barry A. Singer, MD
Patients living with MS can experience hidden or invisible symptoms that may not be apparent to others but can affect how they feel and function. In this podcast, Dr. Barry Singer, the Director at the Multiple Sclerosis Center for Innovations in Care, and Rosario, a patient who has been living with MS for 10 years, discuss their clinical and personal experiences with MS, and the impact that MS can have on a patient's QoL.
In the 2-year AFFIRM pivotal trial: Relapsing MS patients received 300 mg TYSABRI every 28 days (n=627) or placebo (n=315). Patients with PPMS, SPMS, and PRMS were excluded.2,3
83% of patients taking TYSABRI had no sustained disability progression for 12 weeks vs 71% with placebo (primary endpoint: 17% vs 29%; p<0.001).2,3
Dr. Singer reviews the results of a recent publication from Hersh et al, which describes the effect of TYSABRI® (natalizumab) on various aspects of a patient’s QoL. In the study, 164 patients reported their experience after starting TYSABRI using a standard Quality of Life in Neurological Disorders (Neuro-QoL) assessment of 12 domains, which included anxiety, depression, positive affect and well-being, emotional and behavioral dyscontrol, stigma, cognitive function, sleep disturbance, fatigue, participation and satisfaction with social …
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Brian Smith, MD, MPH
Guest: Charlie Strange, MD
Screening for alpha-1 antitrypsin deficiency in patients with chronic obstructive pulmonary disease (COPD) plays an integral role in modern care algorithms. But screening is only the first step, however, as primary care physicians and pulmonologists must then work together to coordinate a patient’s care. Joining Dr. Charles Turck to share their perspectives on how we can better collaborate to detect and treat alpha-1 in patients with COPD are primary care physician Dr. Brian Smith and pulmonologist Dr. Charlie Strange.
Host: Javed Butler, MD, MBA, MPH
Guest: Pam R. Taub, MD, FACC, FASPC
Guest: Marc S. Sabatine, MD, MPH
Two lipid experts will 1) provide an overview of the landscape of nonstatin, LDL-C-lowering therapy, 2) explain current guideline recommendations, 3) describe the evidence with ezetimibe and PCSK9 inhibitors in patients with atherosclerotic cardiovascular disease (ASCVD), 4) discuss cardiovascular risk reduction with PCSK9 inhibitors in a variety of very high risk ASCVD patient populations, and 5) emphasize the need to incorporate PCSK9 inhibition early in acute coronary syndrome patients to facilitate best patient outcomes.
Host: Eric Edell, MD, FCCP
Host: Septimiu Murgu, MD, FCCP
Guest: Narjust Duma, MD
Guest: Christopher Hartley, MD
Guest: Jeffrey Mueller, DO
Expert pathologists and a medical oncologist will discuss current guidelines and their own practices regarding the role of liquid biopsy and comprehensive genetic and PD-L1 testing in the management of advanced lung cancer. The panelists will also explore various strategies for optimizing the quantity and quality of cytology and small volume biopsy specimens.
Host: William Boden, MD, FACC, FAHA
Patients with ASCVD and a history of MI are at especially high risk for repeat adverse cardiac events. Listen in as Dr. Bill Boden summarizes a post hoc analysis of such patients from the REDUCE-IT trial. Can icosapent ethyl plus a statin provide improved carioprotection by reducing recurrent events in this population? Tune in to learn more!
REDUCE-IT is a landmark trial that examined the coadministration of icosapent ethyl and statins in patients for secondary and primary prevention of recurrent events and demonstrated a significant reduction in the key primary and secondary endpoints. This discussion relates to a post hoc analysis of a subset of patients who had prior myocardial infarction, as part of the REDUCE-IT study, and comprised about 45% of the patients with established atherosclerotic coronary disease. The results of this post-MI analysis bring into clear focus that treating hypertriglyceridemia is a critical variable in terms of reducing dyslipidemic risk and overall risk.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Harish Gagnejam MD
What are some ways we can strike the perfect balance when it comes to treating our patients with GERD? To help us answer this question, Dr. Harish Gagneja from the Dell Medical School at the University of Texas joins Dr. Peter Buch to explore balanced treatment options for these patients.
Host: Peter Buch, MD, FACG, AGAF, FACP
The COVID-19 pandemic has entirely transformed the educational community, especially for medical students. To find out more about this impact, Dr. Peter Buch is joined by two fourth-year medical school students, Miss Sheila Eghbali and Mr. Kyle Glose, to discuss their experiences.
Host: John J. Russell, MD
Guest: Amesh Adalja, MD
Monkeypox is not something we’re used to seeing in non-endemic countries like North America and Europe. Yet its spreading has some experts scratching their heads. Dr. Amesh Adalja, a Senior Scholar at the Johns Hopkins Center for Health Security at the Bloomberg School of Public Health, shares with Dr. John Russell what clinicians need to know about monkeypox amid the global outbreak in non-endemic countries.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Brennan Spiegel, MD, MSHS
Let’s escape our busy day for a moment to imagine the future of gastroenterology and to ask ourselves: How can technology make us better clinicians? Explore that very question with Drs. Peter Buch and Brennan Spiegel as they discuss the latest advances in artificial intelligence and virtual reality that are aiding both clinical practice and research efforts.
Host: Luis Paz-Ares, MD, PhD
Guest: Kristen Marrone, MD
In the first-line management of non-small cell lung cancer, the use of immune checkpoint inhibitors (ICI) as monotherapy, as dual ICI, in combination with chemotherapy, or not at all is broadly dependent on which biomarkers are identified. While the choice of therapy is generally based on the level of expression of 1 or more biomarkers (eg, PD-L1, TMB), other factors often complicate this decision. Join us as Drs. Luis Paz-Ares and Kristen Marrone tackle these complexities by providing both foundational and clinical guidance to help you help your patients.
Host: Elizabeth Smyth, MD
Guest: Jaffer Ajani, MD
HER2 expression is a crucial biomarker when selecting treatment for patients with advanced gastric and gastroesophageal junction (GEJ) cancers. Until recently, there were limited therapeutic options. Join this lively conversation to enhance your knowledge related to emerging data and optimal treatment selection for patients with HER2-positive gastric and GEJ cancers.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Alexander Perelman, D.O.
Small intestinal bacterial overgrowth (SIBO) has been recognized for years, yet the optimal method of diagnosis remains controversial. So to help clear up the controversy, Dr. Peter Buch welcomes back returning guest Dr. Alexander Perelman to talk about diagnosing and treating SIBO.
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Guest: Zachary Marcum, PharmD, PhD
Hypertension affects nearly half of adults in the United States and is associated with cognitive decline and dementia. A wide variety of antihypertensive medications are prescribed to millions of people to control blood pressure and prevent vascular dementia. Could it be that certain medications are better than others in preventing brain injury from chronic hypertension? Dr. Andrew Wilner is joined by Dr. Zachary Marcum, Associate Professor in the School of Pharmacy-University of Washington, to discuss his recent study investigating the association between certain hypertension medications and reduced cognitive impairment.
Host: John Buse, MD, PhD
Guest: Samuel Dagogo-Jack, MD, DSc
Intensive lifestyle interventions have shown to, if not prevent, significantly delay the onset of diabetes. But what do we need to know about these interventions? Joining Dr. John Buse to share clinical data and unravel the impacts of interventions in prediabetic patients is Dr. Samuel Dagogo-Jack from the University of Tennessee Health Sciences Center.
Host: Septimiu Murgu, MD, FCCP
Host: Eric Edell, MD, FCCP
Guest: Nichole Tanner, MD, MS, FCCP
Guest: Fabien Maldonado, MD, FCCP
Two internationally known interventional pulmonologists will discuss current guidelines and their own experiences regarding sampling of lung lesions and mediastinal adenopathy. Specifically, the panelists will discuss the pros and cons of various diagnostic strategies and sampling techniques, including transcutaneous and bronchoscopic biopsies. This interactive webinar will offer the opportunity for learners to ask questions prior to and during the event. Learning is augmented by a few follow-up quizzes weeks after the webinar, a strategy proven to improve knowledge gain and retention.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Adam S. Cheifetz, MD
Therapeutic drug monitoring has emerged as an important tool to optimize therapy for patients with inflammatory bowel disease (IBD). To help us learn more about this tool, Dr. Peter Buch is joined by Dr. Adam Cheifetz of Beth Israel Deaconess Medical Center and Professor of Medicine at Harvard Medical School.
Host: Charles Turck, PharmD, BCPS, BCCCP
Over the course of the COVID-19 pandemic, the healthcare field has been hit hard—facing employment challenges, increased burnouts, and more. Yet salaries have been slow to rise, and conditions haven't improved. Dr. Thuy Nguyen from the University of Michigan School of Public Health joins Dr. Charles Turck to share how employment in the healthcare field has changed over the course of the COVID-19 pandemic.
Host: Jennifer Caudle, DO
Guest: Alireza Atri, MD, PhD
Guest: Brad Dickerson, MD
Guest: Sharon J. Sha, MD, MS
Alzheimer’s Disease (AD) is a progressive disease that presents challenges when it comes to the early diagnosis and treatment of patients. That’s why this two-part series will help answer your specific questions while providing expert insights into these challenges.
In this first activity, a panel of esteemed faculty will examine the case of a patient who was diagnosed early with mild cognitive impairment (MCI) due to AD, prior to dementia. Using this patient case, faculty will delve into both the importance of early identification of AD and how to detect it early. The panel will then discuss the pathobiology of AD and potential treatments in development to target this pathology. Finally, the panel will explore current treatment options, including the appropriate use of anti-amyloid monoclonal antibody (mAb) treatment. Throughout this activity, we will gather questions from clinicians like you who care for patients living with dementia, and then in part two of this series, we will answer some of the questions generated from this first activity.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Andrew Chan, MD
Increasing evidence indicates the involvement of B cells in the pathogenesis of multiple sclerosis (MS), but their exact role is unclear. Despite that uncertainty, B-cell depletion therapies have shown to ease symptoms, prevent relapses, and even slow the course of the disease. So how exactly do B-cell therapies work, and how do we know if they’re right for our patients? Joining Dr. Charles Turck to talk about the role of b-cell therapies for our MS patients is Dr. Andrew Chan.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Charles P. Vega, MD
We now have evidence-based options to reduce atherosclerotic cardiovascular disease (ASCVD) event burden beyond any previously available therapy. A pragmatic approach that addresses residual cardiovascular (CV) risk across a variety of risk factors and that goes beyond LDL-C lowering therapies is needed to optimally manage patients with or at high risk of ASCVD. Pharmacists treating these patients require review of recent data and guidelines so they can incorporate these findings into clinical practice. Join us to ensure you’re keeping up with the science and giving your patients the best care.
Host: Pavani Chalasani MD, MPH
Guest: Kevin Kalinsky MD, MS
Chemotherapy is one of the most commonly used treatments for cancer—but it can lead to challenging side effects. So do all of our patients really need it? Joining Dr. Pavani Chalasani to discuss whether or not chemotherapy is the right choice for patients with hormone receptor-positive HER2-negative, node-positive breast cancer is Dr. Kevin Kalinsky from Emory University.
Guest: David C. Mares, MD
Since alpha-1 antitrypsin deficiency is prevalent among patients with chronic obstructive pulmonary disease (COPD), screening for alpha-1 is absolutely critical. However, diagnosing alpha-1 in patients with COPD can be challenging. That’s why pulmonologist and critical care specialist Dr. David Mares is here to share how we can overcome those challenges and the impact screening for alpha-1 may have on our patients with COPD.
Host: David Schulman, MD, MPH, FCCP
Guest: Andrew H. Limper, MD
Guest: Timothy A. Hernandez, MD
There are many barriers to reaching a definitive diagnosis for idiopathic pulmonary fibrosis (IPF). To learn more about these obstacles—and how we can overcome them—Dr. David Schulman from the American College of Chest Physicians joins Dr. Tim Hernandez from the University of Texas Health Sciences Center and Dr. Andrew Limper from the Mayo Clinic to discuss the diagnosis of IPF.
This is a non-promotional, non-CME disease state educational podcast produced in partnership with the American College of Chest Physicians and is supported by Three Lakes Foundation.
https://info.chestnet.org/bridging-specialties-timely-diagnosis-for-ild-patients
Host: John Buse, MD, PhD
Guest: Domenica M. Rubino, MD
The obesity epidemic affects millions of patients around the world, but a new treatment option may be a game-changer for the treatment landscape. Lead author of the STEP 8 clinical trial, Dr. Domenica Rubino, joins Dr. John Buse to share the insights from this drug trial and how these key clinical findings may impact the obesity treatment landscape.
Host: Javed Butler, MD, MBA, MPH
Guest: Justin Ezekowitz, MD, MBBCh, MSc
The Study of Dietary Intervention under 100 millimole in Heart Failure (SODIUM-HF) trial was designed to assess the effects of a low-sodium diet on adverse cardiovascular events. So what were the study’s findings, and what do they mean for our patients with heart failure? Dr. Javed Butler is joined by Dr. Justin Ezekowitz, who shared the SODIUM-HF trial results at the 2022 American of Cardiology Annual Scientific Meeting.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Asma Khapra, MD
Over the last few years, we've only started to gain an understanding of how gender affects our approach to GI illnesses. And since a greater awareness of these differences will help us become better clinicians, Dr. Peter Buch speaks with Dr. Asma Khapra about how we can optimize our approach to managing common GI illnesses in our female patients.
Host: Jacob Sands, MD
Guest: Marie Wood, MD
Can our breast cancer patients benefit from chemoprevention? Joining Dr. Jacob Sands to share treatment options for chemoprevention and which patients may benefit the most is Dr. Marie Wood, the Director of Breast Medical Oncology and Director of the Cancer Clinical Trials Office at the University of Colorado Anschutz Medical Center.
Host: Marco Metra, MD
Guest: Adrian F. Hernandez, MD, MHS
Since the 2017 AHA/ACC/HFSA guidelines, considerable research has been conducted in the care of patients with heart failure, including the impact of iron deficiency. The new 2022 guidelines have considerable updates based on the totality of current evidence. Join Dr. Adrian Hernandez and Dr. Marco Metra as they discuss key highlights from the guidelines and make sure you’re staying up to date with the evolving data and best practices.
Host: Mikhail Kosiborod, MD
Guest: Michael Böhm, MD, FESC
The 2022 updates to the ACC/AHA guidelines for heart failure are the first since 2017. In the interim, considerable research has been conducted on the impact of optimal RAASi therapy and the management of hyperkalemia in patients with heart failure. Join Dr. Mikhail Kosiborod and Dr. Michael Böhm as they discuss key highlights from the guidelines and make sure you’re staying up to date with the evolving data and best practices.
Host: Jennifer Caudle, DO
Guest: Brian Smith, MD, MPH
Primary care physicians play a critical role in screening for alpha-1 antitrypsin deficiency in patients with chronic obstructive pulmonary disease (COPD). But who should they be screening, and how? And what are some of the diagnostic challenges they should be aware of? Here to help answer those and other key questions for primary care physicians is Dr. Brian Smith, who’s in private practice at Versailles Family Medicine in Kentucky.
Guest: Joel Neal, MD, PhD
Guest: Alexander Spira, MD, PhD, FACP
With the recent approvals of mobocertinib and amivantamab, we now have targeted therapies for EGFR exon 20 insertion–positive locally advanced or metastatic NSCLC, following progression on or after platinum-based chemotherapy. To learn more about mobocertinib, Dr. Joel Neal (Stanford) speaks with Dr. Alexander Spira (Virginia Cancer Specialists Research Institute) about the historical unmet need for this patient population, how mobocertinib is different from classical EGFR TKIs, and the clinical data that led to its FDA approval.
All trademarks are property of their respective owners.
Host: William Schaffner, MD
Guest: Monica M. Farley, MD
Pneumococcal disease can cause pneumonia, meningitis, and sepsis, and can be a serious complication of influenza. Pneumococcal disease is serious and can be deadly; in the US, more than 150,000 adults are hospitalized with pneumococcal pneumonia each year, and about 1 in 20 individuals who get pneumococcal pneumonia will die. According to the 2017 National Health Interview Survey, pneumococcal vaccination coverage among adults age 65 years and older was 69%, well below US public health goals. The changing recommendations for pneumococcal vaccination in adults can make the vaccination assessment process challenging for healthcare professionals. This activity is based on the latest CDC recommendations and includes practical strategies to implement pneumococcal vaccination.
Host: Jeffery D. Dunn, PharmD, MBA
Guest: Gary M. Owens, MD
Guest: Anita L. Nelson, MD
Are you ready to see what is on the horizon to more effectively navigate vasomotor symptoms (VMS)? Join Drs. Dunn, Owens, and Nelson as they discuss highlights from a symposium held at AMCP 2022 featuring the latest data on the impact of menopause and evolving treatments options. They provide guidance, context, and recommendations for the medical management of VMS beyond estrogen. The nonhormonal treatment options that are currently being studied represent a new horizon for both patients and payers.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Trevor Cabrera, MD
What’s it like becoming a locum tenens physician right out of residency? Dr. Charles Turck joins Dr. Trevor Cabrera, a Board-Certified pediatrician who trained in Houston, Texas, to share his firsthand experience and offer advice for residents.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Yannis Paulus, MD, FACS
Early diagnosis of retinal diseases can make quite a difference when it comes to preserving our patients’ vision. But what are the symptoms we should be looking out for, and how can we optimize screening opportunities with our patients? Find out with Dr. Charles Turck as he explores effective strategies for detecting and treating retinal diseases early with Dr. Yannis Paulus from the University of Michigan Kellogg Eye Center.
Guest: Alessandro Didonna, PhD
Join us as examine the involvement of B cells in MS pathogenesis and the mechanisms that lead to B cell overactivation with Dr. Alessandro Didonna, Associate Professor of Neurology at UCSF Weill Institute for Neurosciences.
Host: Jennifer Caudle, DO
Guest: Maurice G. Sholas, MD, PhD
After years of serving the New Orleans community, one physician decided to pursue locum tenens work. Dr. Jennifer Caudle joins Dr. Maurice Sholas, a pediatric physical rehabilitation physician, to share his experiences with locum tenens and in New Orleans.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Samantha Conroy, MD
Locum tenens can improve quality of care around the globe—especially in remote and underserved communities. To share how, Dr. Paul Doghramji joins Dr. Samantha Conroy, a family practice obstetrician to share her experiences working as a locum tenens obstetrician in underserved communities.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Trevor Cabrera, MD
What’s it like becoming a locum tenens physician right out of residency? Dr. Charles Turck joins Dr. Trevor Cabrera, a Board-Certified pediatrician who trained in Houston, Texas, to share his firsthand experience and offer advice for residents.
Host: Jennifer Caudle, DO
Guest: April W. Armstrong, MD, MPH
Guest: Allan Gibofsky, MD, JD, MACR, FACP, FCLM
There's good news for patients and clinicians dealing with the challenges of psoriasis or psoriatic arthritis (PsA). Novel and emerging therapies exist that can help improve symptoms, and slow or prevent disease progression. In this fast-paced, clinical discussion, you'll hear from two leading experts who will share recent evidence and highlights from the American Academy of Dermatology (AAD) Annual Meeting that support using novel biologic and targeted synthetic agents for psoriasis and PsA. As part of the discussion, they also examine a patient case illustrating how you can optimize treatment plans, integrate the latest guideline recommendations in your practice, and encourage shared decision making with your patients.
Host: Richard Elion, MD
Sexual histories are a vital part of ensuring a patient’s well-being. Nonetheless, many providers are uncomfortable taking a sexual history for an individual who may be at increased risk for acquiring HIV. The ability to offer a preventative medication for HIV acquisition is a cornerstone for informed consent for sexual health. Join Dr. Richard Elion as he takes us through a patient-clinician dialogue demonstrating how to take a sexual history that is complete, respectful, and nonjudgmental.
Host: Jerome Lisk, MD
Guest: Peter Whitehouse, MD, PhD
Guest: Daniel George, MSc, PhD
Although there’s still no cure for Alzheimer’s disease, we’ve made great strides in understanding the tragic disease that affects more than 50 million people worldwide. So what are the latest updates in treating and alleviating this disease? To learn more about what’s new in Alzheimer’s disease research, Dr. Jerome Lisk speaks with Dr. Peter Whitehouse and Dr. Daniel George, co-authors of American Dementia: Brain Health in an Unhealthy Society.
Host: Sagar Lonial, MD
Guest: Noopur Raje, MD
Two newly approved BCMA-directed CAR T cell therapies, idecabtagene vicleucel and ciltacabtagene autoleucel, are providing patients with the prospect of deep and durable remissions. Maximizing the potential of CAR T cell therapy can provide improved length and quality of life for patients with multiply relapsed multiple myeloma. Join us as Dr. Sagar Lonial and Dr. Noopur Raje discuss the available treatment options, current applications of the clinical data, and strategies to improve care for your patients with multiple myeloma who may be candidates for CAR T cell therapy.
Host: Neilanjan Nandi, MD
Guest: Peter D. Higgins, MDm PhD
What's on the horizon for the management of inflammatory bowel disease? To share some of the latest clinical trial updates, Dr. Neil Nandi is joined by Dr. Peter Higgins from the University of Michigan to explore some of the latest developments in early detection tools and treatment strategies for patients with IBD.
Host: John Buse, MD, PhD
Guest: Anastasia-Stefania Alexopoulos, MBBS, MHS
Dr. John Buse joins Dr. Anastasia-Stefania Alexopoulos, an endocrinologist, researcher, and Assistant Professor of Medicine in the Department of Medicine at Duke University School of Medicine to share her research on the deintensification of hypoglycemia-inducing medications in diabetic adults.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Peter D. Higgins, MDm PhD
What were some of the key takeaways from the 2022 Crohn's & Colitis Congress, and what's in store for next year’s conference? Hear from the incoming 2023 Congress Chair Dr. Peter D. Higgins.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Rashid N. Lui, MD
Immune checkpoint inhibitors have evolved the treatment landscape for cancer, but we need to consider the GI side effects. To do so, Dr. Peter Buch is joined by Dr. Rashid N. Lui to assess the GI impacts of ICIs and how to manage them.
Host: Jerome Lisk, MD
Guest: Peter Whitehouse, MD, PhD
The FDA’s recent approval of aducanumab for the treatment of Alzheimer’s disease has been met with a controversial response. So what do we need to know about this new drug and its potential to treat this progressive neurological disorder? Dr. Jerome Lisk is joined by Dr. Peter Whitehouse from Case Western Reserve University to break down the approval of this new drug and what it could mean for patients.
Host: Christie M. Ballantyne, MD
Guest: Gregory Pokrywka MD, FACP, FNLA, FASPC, NCMP
Guest: Joseph Saseen, PharmD, BCPS, BCACP, CLS
Guest: Karol Watson, MD, PhD
Managing patients with established CVD presents challenges in our practice every day. These patients may have had a prior stroke or MI and are at a very high risk of future life-threatening CV events. Join our expert faculty to hear the latest data on new and emerging statin adjuncts presented in a highly relevant and clinically applicable format. Barriers to the optimal management of ASCVD risk in many patient types (ethnicity/race/sex) will be addressed, and solutions to effectively manage such challenges in your everyday clinical practice will be provided.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Michael L. Weinstein, MD
As clinicians, providing the best quality of care is paramount. But when it comes to procedure-intensive specialties, medical malpractice is a notable concern. So what do we need to know about the common malpractice claims in the GI field, and how can we mitigate the risk of those claims? To find out, Dr. Peter Buch is joined by Dr. Michael Weinstein, President and CEO of Capital Digestive Care.
Host: Lyudmila Bazhenova, MD
Guest: Benjamin Levy, MD
HER2-targeted therapies have demonstrated substantial survival benefits for patients with HER2-positive breast cancer. So can we use those agents for HER2-positive NSCLC? Join Dr. Lyudmila Bazhenova and Dr. Benjamin Levy as they discuss the latest data around emerging agents for HER2-positive NSCLC and the best way to identify these mutations in clinical practice.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Heather Moday, MD
When we say the words behavior, diet, habits, and environment, chances are you don't think of the body's immune system. But based on recent research, all of those factors play a role in influencing immune function. So how can we keep them in mind and boost our immunity in the face of prevalent diseases, including COVID-19? Find out with Dr. Charles Turck as he speaks with Dr. Heather Moday, author of The Immunotype Breakthrough: Your Personalized Plan to Balance Your Immune System, Optimize Health, and Build Lifelong Resilience.
Host: Anthony Mato, MD, MSCE
During the past 10 years, BTK inhibitors are increasingly replacing chemotherapy-based regimens, especially in patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Current clinical practice is continuous long-term administration of covalent, irreversible BTK inhibitors, which can be complicated by side effects or the development of drug resistance. Resistance mutations and intolerance contribute to therapy interruption or discontinuation and abrogate clinical benefits associated with continued covalent BTK inhibitor therapy, leading to subsequent care that is suboptimal due to a dearth of effective treatment options (as reflected in lower progression-free survival, overall survival, or response duration). Non-covalent, reversible BTK inhibitors do not bind to C481, therefore providing a potentially effective option to patients with B cell malignancies that have developed resistance to covalent BTK inhibitors. Preliminary clinical studies have suggested that non-covalent BTK inhibitors are effective and well-tolerated.
This educational activity will assist hematology-oncology professionals develop management plans designed to overcome these challenges and offer patients the full benefit of BTK inhibitor therapy. We will discuss the clinical implications of BTK inhibitor selectivity profiles and safety differences; the integration of BTK inhibitors into the management of different B-cell cancer patient populations; and the proactive adaptation of treatment plans to …
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Alexander Perelman, D.O.
Proton pump inhibitors (PPIs) are among the most frequently prescribed medications in the world, but in many instances, they may be unnecessary. So how might this impact our patients’ health, and how can we identify those patients who should be prescribed PPIs? Dr. Peter Buch is joined by Dr. Alexander Perelman to talk about the overuse of PPIs.
Host: Javed Butler, MD, MBA, MPH
Guest: John Cleland, MD
Guest: Fraser Graham, MD
Iron deficiency is one of the most frequent comorbidities in patients with heart failure and is estimated to present in up to 50 percent of patients. So what’s the criteria for iron deficiency, and how is it currently defined in cardiology? To discuss this, Dr. Javed Butler is joined by Drs. John Cleland and Fraser Graham from the Institute of Health and Wellbeing at the University of Glasgow.
Host: Pavani Chalasani MD, MPH
Guest: Aditya Bardia, MD, MPH
For patients with hormone receptor-positive HER 2-negative metastatic breast, treatment can be challenging. But what treatment options are available? Lead investigator from the EMERALD trial Dr. Aditya Bardia joins Dr. Pavani Chalasani to share his insights.
Host: Pavani Chalasani MD, MPH
Guest: Aditya Bardia, MD, MPH
Triple-negative breast cancer can be a challenging battle for patients, especially when it comes to treatment. And that's why the ASCENT trial dove into the treatment landscape for these patients. Lead investigator of this trial, Dr. Aditya Bardia, sits down with Dr. Pavani Chalasani for an inside look at this trial and what it means for patients with triple-negative breast cancer.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Stephanie Martin, DO
How ready are you to go beyond simply ordering CBCs and recognizing anemia? Join Drs. Martin and Shulman as they discuss the latest developments in oral and IV iron therapies. Learn how you may take a more active role in managing iron deficiency anemia, focusing on abnormal uterine bleeding.
Participating in this activity will ensure that you are prepared to address the goals with your patients by improving access and adherence to efficacious and convenient therapies.
Host: Richard S. Isaacson, MD
Guest: Michael Weiner, MD
Are you familiar with available and developing tools for assessing Alzheimer’s disease (AD)? Correctly using these tools can lead to a vital earlier diagnosis which can improve outcomes for our patients. Tune in to hear Dr. Richard Isaacson and Dr. Michael Weiner take us through some of these assessment tools and they ways in which they can help us reach a true diagnosis of AD.
Host: Amer Zeidan, MBBS
Guest: Amy E. DeZern, MD, MHS
MDS is a very heterogenous clonal bone marrow disorder with a high risk for anemia and progression into acute myeloid leukemia. Dr. Amer Zeidan and Dr. Amy DeZern discuss how to appropriately monitor and treat patients with higher-risk MDS.
Host: Ahmad Masri, MD, MS
Guest: Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
—Breaking News—Commentary on HCM-related Late-Breaking Abstracts presented at ACC.22 in April has been added to the start of the program. The rest of the program will cover the following topics: Why do we need new therapies in hypertrophic cardiomyopathy (HCM), and will newer and emerging cardiac myosin inhibitors improve the standard of care for patients with HCM? What differences can we expect regarding patient outcomes and quality of life with these new therapies? Join Dr. Ahmad Masri and Dr. Deepak Bhatt as they explore how newer cardiac myosin inhibitors go beyond traditional medical management (that only addresses the macro-pathophysiology and disease symptoms) to actually treat HCM at the cellular level.
Host: Hector O. Chapa, MD, FACOG
Guest: Naomi Whittaker, MD
The challenges that come with conception can be strenuous and emotionally draining. But with emerging tools and technology, there are many ways we can help our patients conceive naturally. Dr. Naomi Whittaker, an OB/GYN physician, joins Host Dr. Hector Chapa to share these strategies.
Guest: Kenneth J. Moise Jr., MD
Host: Charles Turck, PharmD, BCPS, BCCCP
Hemolytic disease of the fetus/newborn (HDFN) may be rare, but it is important to recognize and diagnose the disease and ensure appropriate patient management since the consequences in cases that go undiagnosed or are poorly managed can be devastating. To help us gain a better understanding of maternal alloimmunization and the risk for HDFN in pregnancy, Dr. Charles Turck speaks with Dr. Kenneth Moise, Director of the Comprehensive Fetal Care Center in Texas.
© Janssen Pharmaceuticals, Inc. 2022 12/21 cp-272563v1
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Hetal A. Karsan, MD, FACG, FAASLD, FASGE, FACP
Primary biliary cholangitis, which was formerly known as primary biliary cirrhosis, is a chronic disease that progresses over time. Fortunately, much progress has been made in that many patients are being diagnosed and treated much earlier than before. But what exactly has changed when it comes to our detection and treatment of this disease? Dr. Peter Buch is joined by Dr. Hetal Karsan, Adjunct Professor of Medicine in the Division of Digestive Diseases at Emory University School of Medicine, to discuss key updates in primary biliary cholangitis care.
Host: Carol Wysham, MD
Guest: Jane J. Kim, M.D.
Since 2020, pediatricians have seen a rapid rise in new-onset type 1 diabetes in children. Is this due to the COVID-19 pandemic or an indirect consequence of it? To answer this question, Dr. Jane Kim, a pediatric endocrinologist at Rady Children's Hospital in San Diego, shares what kind of correlation she's seeing.
Host: Carol Wysham, MD
Guest: Jane J. Kim, M.D.
Emerging research details a rapid rise in type 1 diabetes in children amid the COVID-19 pandemic. But what's causing this to happen? To dive into why, Dr. Carol Wysham is joined by Dr. Jane Kim from the Rady Children's Hospital in San Diego.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Lea Ann Chen, MD
As clinicians, we know that adherence to treatment regimens is associated with improved outcomes in our patients with inflammatory bowel disease (IBD). However, many factors can contribute to a patient's nonadherence, and understanding what those factors are, especially in underserved patient populations, is an important category of care that we need to keep in mind. Tune in to hear Dr. Peter Buch speak with Dr. Lea Ann Chen about how we can manage IBD in underserved patient populations.
Host: Andrew M. Brunner, MD
Guest: Amy E. DeZern, MD, MHS
New and novel therapeutics for the treatment myelodysplastic syndrome (MDS) are in development. What are these agents, and how do they work? Listen in as Dr. Andrew Brunner and Dr. Amy DeZern discuss ongoing clinical trials, current data from those trials, and the future potential for tailoring treatment plans.
Since the completion of this activity, the U.S. Food and Drug Administration has lifted the partial clinical hold placed on studies evaluating the investigational agent magrolimab in combination with azacytidine for the treatment of MDS and AML.
https://clinicaltrials.gov/ct2/results?cond=&term=Magrolimab+&cntry=&state=&city=&dist=
Host: Jennifer Caudle, DO
Guest: Ashish S. Patel, MD
Treating IBD in our pediatric patients can be challenging, which is why creating a strong partnership between care teams and patients’ families is key. Fortunately, that was a central focus of the 2022 Crohn's & Colitis Congress, so to catch the latest updates and strategies for improving IBD care for pediatric patients, tune in to hear Dr. Jennifer Caudle speak with Dr. Ashish Patel.
Host: Michael Greenberg, MD
Guest: Brook Brouha, MD, PhD
How might genomics help us provide better care for our patients? Joining Dr. Michael Greenberg to share how he’s utilizing genomics in practice is Dr. Brook Brouha, a dermatologist and dermatopathologist at West Dermatology in San Diego, California.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Anjay Rastogi, MD, PhD
Defined as high potassium levels in the blood, hyperkalemia can be a life-threatening condition.1 Hyperkalemia is often associated with chronic kidney disease and can be silent or present itself with non-specific symptoms.1,2 However, there are challenges in managing hyperkalemia as a recurrent event.1,3 To help address these challenges, Dr Charles Turck discusses with Dr Anjay Rastogi, nephrologist and head of the CORE Kidney Program at UCLA, the burden of hyperkalemia and how potassium binders can help manage it.3,4 ©2022 AstraZeneca. All rights reserved. US-57356 Last Updated 2/22
Host: Matthew S. Keller MD
Guest: Michael Greenberg, MD
Are you looking to increase business at your dermatology practice? One simple solution is practicing goodness—in other words, being good and kind to your patients and their families. Joining Dr. Matthew Keller to explain why goodness is the best practice builder is fellow ReachMD Host Dr. Michael Greenberg.
Host: Javed Butler, MD, MBA, MPH
Guest: Mikhail Kosiborod, MD
With the prevalence of heart failure continuing to rise worldwide, recent trials have shown that sodium glucose co-transporter 2 (SGLT2) inhibitors may improve impairments and decrease the risk of hospitalizations. So based on these recent findings, what exactly is their role in the management of patients with heart failure? Find out with Dr. Javed Butler as he speaks with Dr. Mikhail Kosiborod, Professor of Medicine at the University of Missouri-Kansas City and Vice-President of Research at Saint Luke's Health System.
Guest: Samira Farouk, MD
The #NephMadness bracket will follow along with this year's National Kidney Foundation Spring Clinical Meeting, and Dr. Samira Farouk from the Icahn School of Medicine at Mount Sinai shares what you can do to get involved and what sessions she's looking forward to attending at this year's meeting.
Guest: Samira Farouk, MD
What can we expect to see at the upcoming Nation Kidney Foundation Spring Clinical Meeting? Dr. Samira Farouk from the Icahn School of Medicine at Mount Sinai shares what sessions she's looking forward to seeing on dialysis access, care coordination, and equitable patient care.
Guest: Vandana Niyyar, MD
What can we expect to see at the 2022 National Kidney Foundation Spring Clinical Meeting? Dr. Vandana Niyyar shares what sessions she plans on attending at this year's meeting, and what she's looking forward to seeing.
Host: Jacqueline Nicholas, MD, MPH
Ever had a multiple sclerosis (MS) patient who needed to start a DMT? Listen to Dr. Jacqueline Nicholas, System Chief of Neuroimmunology and Director of MS Research at Ohio Health, and Kim, a patient who has been living with MS for seven years, share their experiences with the treatment decision process, including benefit-risk considerations, treatment goals, and patient preferences. They talk about the process for starting and continuing treatment with TYSABRI® (natalizumab) and how Biogen Support Services can help.
Please see Important Safety Information, including Boxed Warning for PML, below.
Host: Jennifer Caudle, DO
Guest: Alan C. Moss, MD
When patients with moderate ulcerative colitis fail first-line therapy, it's important to know what to do next. And speaking with your patients about their risks and preferences is key. Join us as Dr. Alan Moss shares highlights from his presentation at the 2022 Crohn's & Colitis Congress on treatment considerations for patients with moderate ulcerative colitis.
Host: Caroline Baumal, MD
Guest: Carl Regillo, MD
Multiple new and novel strategies are now available to treat patients with neovascular age-related macular degeneration and diabetic macular edema. What are these strategies, and how should they be used in everyday practice? Hear Dr. Caroline Baumal and Dr. Carl Regillo discuss the latest data and how they are adopting these new approaches into their retina patient care.
Host: Hector O. Chapa, MD, FACOG
Guest: Ahmed Zayed Obeidat, MD, PhD
Unfortunately, not all of our patients with multiple sclerosis (MS) respond well to treatment. That’s why it’s critical to constantly assess their response to treatment and notice the signs that someone might be an efficacy-challenged patient. But what exactly are those signs, and how can you go about switching therapies? Joining Dr. Hector Chapa to share key strategies for managing efficacy-challenged patients with MS is Dr. Ahmed Obeidat.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Eugene E. Wright, Jr., MD
Guest: Marina Basina, MD
What are some ways we can detect chronic kidney disease in patients with type 2 diabetes early? Joining Dr. Charles Turck to share collaborative strategies for early detection are Dr. Marina Basina from Stanford University Medical Center and Dr. Eugene Wright from the Charlotte Area Health Education Center.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Carlos Jesus Acuña-Villaorduña, MD
What are some of the immunologic mechanisms that alter our ability to fight off a mycobacterium tuberculosis infection—and how does this affect our immunocompromised patients? To answer this question, Dr. Charles Turck meets with Dr. Carlos Acuña-Villaorduña from the Boston University School of Medicine to discuss new insights on TB infection and immunosuppression.
Host: J. Fernando Arevalo, MD, PhD
Guest: W. Lloyd Clark, MD
New technology has arrived that provides prolonged delivery of anti-VEGF therapy and with it comes new techniques for vitreoretinal surgeons. Find out what steps you need to take to ensure both successful implantation and refill-exchange of the port delivery system. Dr. Fernando Arevalo discusses these critical details with Dr. W. Lloyd Clark, one of the leading pioneers of this technology.
Host: Larry Anderson, MD, PhD
Guest: Thomas G. Martin, MD
Patients with multiple myeloma (MM) whose disease has relapsed multiple times have historically poor outcomes. CAR T cell therapy is a novel therapeutic option for those patients and can provide prolonged responses and improved outcomes. However, the treatment is complex, and careful planning is needed to effectively incorporate these treatments into practice. Drs. Thomas Martin and Larry Anderson discuss CAR T cell therapies for MM with a focus on patient selection, accessibility of treatment, and management of patients after administration.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Janos L. Tanyi, MD, PhD
Recently the FDA approved a “Glowing Tumor” imaging drug to help oncologists better identify ovarian cancer cells using an approach pioneered by surgeons at Penn Medicine. Joining Dr. Charles Turck to discuss this recent approval and fluorescence-guided, intraoperative imaging is Dr. Janos Tanyi, Associate Professor of Obstetrics and Gynecology at the Hospital of the University of Pennsylvania.
Host: Neilanjan Nandi, MD
Guest: Jean-Frederic Colombel, MD
There are over a half dozen newer and emerging classes of agents for ulcerative colitis. This abundance is great news for our patients, but it also increases the complexity of treatment. Listen in as Dr. Neil Nandi and Dr. Jean-Frederic Colombel explore the roles that these agents will play in the evolving treatment landscape.
Since the completion of this activity, results from the ELEVATE UC 52 study, a yearlong phase 3 trial of etrasimod in moderate to severe ulcerative colitis, were announced. Etrasimod is an investigational, oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator that showed positive 12- and 52-week results compared to placebo. Patients achieved statistically significant improvements in the co-primary endpoint of clinical remission at weeks 12 and 52 when compared to placebo. Statistically significant improvements were also attained in all key secondary endpoints at both 12 and 52 weeks. We will provide more data as the full results are published and presented in the future.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jonathan D. Rich, MD
Guest: Paul Doghramji, MD
According to recent data, more than 50 percent of patients with heart failure with preserved ejection fraction (HFpEF) are hospitalized. Given that troubling statistic, how can we as clinicians work together to reduce the risk of hospitalization among patients with HFpEF? Joining Dr. Charles Turck to share their multidisciplinary perspectives on this important topic are cardiologist Dr. Jonathan Rich and primary care provider Dr. Paul Doghramji.
Host: Michael Greenberg, MD
Guest: Dustin Portela, DO
The prevalence of social media has grown significantly over the past few decades, and within the field of medicine, we’ve seen a rise in dermatologists using these platforms to grow their professional network, improve patient care, and provide essential education. But what ethical challenges arise from a widespread social media presence, and how can we navigate those challenges? To find out, Dr. Michael Greenberg speaks with Dr. Dustin Portela about his online presence as 208SkinDoc.
Host: Heather Wakelee, MD, FASCO
Standard of care treatment for resectable early-stage NSCLC usually includes surgery in combination with neoadjuvant or adjuvant platinum-based chemotherapy; however, metastatic disease often develops. To lower the risk for recurrence, an area of active research is the use of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy for early-stage NSCLC. Several immune checkpoint inhibitors are now being investigated in early-stage NSCLC, with promising results reported, suggesting a role for the use of neoadjuvant and adjuvant therapy with immune checkpoint inhibitors in early-stage NSCLC.
This educational activity will review the role of immunotherapy in early-stage NSCLC as adjuvant treatment, recent clinical data and the latest advances for immune checkpoint inhibitors as adjuvant treatment, and recent and ongoing clinical trials for adjuvant and neoadjuvant immunotherapy for the treatment of early-stage NSCLC so that clinicians are better able to integrate emerging data and new treatment options into clinical practice and inform, educate, and refer patients to clinical trials when appropriate.
Host: Fuad El Rassi, MD
A common complication of sickle cell disease (SCD), vaso-occlusive crisis (VOC), is characterized by the sudden onset of severe pain and is the most common reason for hospital visits in patients with SCD. Vaso-occlusion is caused by the adhesion of sickled erythrocytes and leukocytes to the endothelium, resulting in vascular obstruction and tissue ischemia. In addition to severe pain, long-term complications of vaso-occlusion may include damage to muscle and/or bone, in addition to vital organs such as the liver, spleen, kidneys, and brain. Vaso-occlusion and VOCs are associated with decreased organ function and can result in life-threatening complications such as acute chest syndrome, pulmonary hypertension, renal failure, and stroke. SCD can also have a profound effect on the quality of life for children and adults.
With increased understanding of the pathophysiology of VOCs, novel therapies that target the pathologic process of vaso-occlusion may reduce cell adhesion and inflammation, leading to decreased incidence of VOCs and prevention of end-organ damage. This educational activity will review the burden of SCD, including VOCs, acute chest syndrome, and end-organ damage in adults and pediatric sickle cell patients, as well as efficacy and safety data of established and novel therapies that target SCD-related complications for …
Host: Jennifer Caudle, DO
Guest: Richard S. Lemons, MD, PHD
Guest: Robert Klamroth, MD, PhD
Factor replacement therapy is commonly used to treat hemophilia B, but could gene therapy be a useful alternative? Dr. Jennifer Caudle joins Dr. Robert Klamroth from the Vivantes Friedrichshain Hospital in Berlin, Germany, and Dr. Richard S. Lemons from the University of Utah Huntsman Cancer Institute to share their clinical trial experience with gene therapy in patients with hemophilia B.
Host: Jacqueline Garcia, MD
Guest: David A. Sallman, MD
In order to effectively treat the MDS patient in front of us, we first need to classify their disease and understand its risk stratification category. Hear what Dr. David Sallman and Dr. Jacqueline Garcia have to say about MDS prognosis and risk stratification to better understand each patient’s disease progression.
Host: Diana Do, MD
Guest: John A. Wells, III, MD
Second-generation intravitreal agents that incorporate new pathogenic targets have emerged for the treatment of retinal diseases. What are these targets, and how should these new medicines be used in clinical practice? Join Dr. Diana Do and Dr. John Wells as they discuss novel mechanisms for therapeutic control of neovascular age-related macular degeneration and diabetic macular edema and how to incorporate these new agents into clinical practice.
Guest: Peter Howarth BSc, (Hons), MBBS, DM, FRCP
Guest: Ian Pavord, MA, DM, FRCP, FERS, FMedSci
Guest: Geoffrey Chupp, MD
Type 2 inflammation can be challenging to identify. What should we be looking for in our patients with severe asthma and COPD? Joining Dr. Peter Howarth to discuss identifying this type of inflammation are Dr. Geoffrey Chupp from the Yale School of Medicine and Dr. Ian Pavord from the University of Oxford.
This is a nonpromotional, non-CME disease state educational podcast brought to you by the American College of CHEST Physicians in collaboration with and paid for by GSK.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Francesca Gilli, MS, PhD
What B-cell therapies are available for multiple sclerosis, and how do they fit into our treatment approach—in the context of the COVID-19 pandemic and beyond? Tune in to hear Dr. Charles Turck speak with Dr. Francesca Gilli about B-cell therapies.
Host: Javed Butler, MD, MBA, MPH
Guest: Nancy M. Albert, PhD, CCNS, CHFN, CCRN, NE-BC, FAHA, FCCM, FHFSA, FAAN
Based on the 2021 American College of Cardiology Expert Consensus Decision Pathway recommendations, it might be time to rethink our approach to heart failure. But what exactly do the latest recommendations say regarding the role of angiotensin receptor-neprilysin inhibitors (ARNis) in the treatment of heart failure with reduced ejection fraction? Joining Dr. Javed Butler to answer that key question is Dr. Nancy Albert.
Host: Hector O. Chapa, MD, FACOG
Guest: Ahmed Zayed Obeidat, MD, PhD
From therapeutic limitations to routes of administration, there’s a lot we need to keep in mind when selecting a treatment option for our patients with multiple sclerosis (MS). But it’s also just as important to consider patient-specific elements too, like their preferences and the socioeconomic factors affecting them. That’s why Dr. Ahmed Obeidat joins Dr. Hector Chapa to share these and other key treatment considerations in MS care.
Host: David A. Wohl, MD
Guest: Lisa Hightow-Weidman, MD, MPH
The CDC’s 2021 update to their PrEP guidelines recommend that PrEP should be offered to all individuals who want or need it. Although PrEP is both safe and extremely effective, persistence to PrEP in the long-term is low, at about 40% at 2 years. Join Drs. Wohl and Hightow-Weidman as they discuss the challenges associated with increasing PrEP uptake and how the emergence of a long-acting injectable PrEP formulation could result in improved long-term persistence.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Javier Morales, MD, FACP, FACE
There are several factors to consider when determining if insulin is the right treatment option for a patient with type 2 diabetes. And once a patient is prescribed insulin therapy, it’s just as important to consider the factors that might lead to nonadherence. That’s why Dr. Charles Turck speaks with Dr. Javier Morales about those factors and how we can improve our patients’ adherence to their insulin regimens.
Host: Mikhail Kosiborod, MD
Guest: Austin G. Stack, MBBCh, MD, MSc, FASN, FRCPI
RAASi therapy is a critical component of heart failure management; however, concern about patients developing hyperkalemia often leads to clinical delay and suboptimal dosing. This is especially evident in our patients with chronic kidney disease. So how can we simultaneously maintain optimal therapy and manage hyperkalemia? Join Dr. Mikhail Kosiborod and Dr. Austin Stack as they discuss a patient case and make sure you’re staying up to date with the evolving data, guidelines, and practices.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Alexis McKee, MD
What communication strategies can we use to create personalized treatment plans and improve adherence among our patients with type 2 diabetes? That’s the exact question Dr. Charles Turck discusses with Dr. Alexis McKee, an Assistant Professor of Medicine in the Division of Endocrinology, Metabolism, and Lipid Research at the Washington University School of Medicine in St. Louis.
Host: Jerome Lisk, MD
Guest: Ashok K. Shetty, PhD
Gulf War Illness is a chronic condition characterized by physiological and psychological symptoms, including cognitive dysfunction, memory problems, and depression. But what’s currently known about this debilitating condition that affects nearly 30 percent of Gulf War veterans? And how can we treat them? Find out with Dr. Jerome Lisk as he speaks with Dr. Ashok Shetty from Texas A&M University College of Medicine.
Host: Esteban Figueroa, MD
Exploring the ACE Index in Acute Ulcerative Colitis
Rebecca K Grant, Gareth-Rhys Jones, Nikolas Plevris, Ruairi W Lynch, Philip W Jenkinson, Charlie W Lees, Thomas A Manship, Fiona A M Jagger, William M Brindle, Mrithula Shivakumar, Jack Satsangi, Ian D R Arnott
Background: Intravenous (IV) steroids remain the first-line treatment for patients with acute ulcerative colitis (UC). However, 30% of patients do not respond to steroids, requiring second-line therapy and/or surgery. There are no existing indices that allow physicians to predict steroid nonresponse at admission. We aimed to determine if admission biochemical and endoscopic values could predict response to IV steroids.
Methods: All admissions for acute UC (ICD-10 K51) between November 1, 2011, and October 31, 2016 were identified. Case note review confirmed diagnosis; clinical, endoscopic, and laboratory data were collected. Steroid response was defined as discharge home with no further therapy for active UC. Nonresponse was defined as requirement for second-line therapy or surgery. Univariate and binary logistic regression analyses were employed to identify factors associated with steroid nonresponse.
Results: Two hundred and thirty-five acute UC admissions were identified, comprising both acute severe and acute nonsevere UC; 155 of the 235 patients (66.0%) …
Host: Ahmad Masri, MD, MS
Guest: Steve R. Ommen, MD
What if a patient has fatigue, dyspnea, chest pain, palpitations, presyncope, left ventricular afterload, and diastolic dysfunction? Is it heart failure? Is it left ventricular hypertrophy due to arterial hypertension? Is it aortic stenosis? Did you even consider hypertrophic cardiomyopathy? Join Dr. Ahmad Masri and Dr. Steve Ommen as they discuss the challenges of HCM diagnosis and why you should get to know HCM!
Host: Matthew Sorrentino, MD
Guest: William W. Li, MD
Some patients who recover from COVID-19 may continue to experience long-term cardiovascular complications. So what symptoms should we be looking out for? Joining Dr. Matthew Sorrentino to discuss the long-term cardiovascular impacts of COVID-19 is Dr. William Li.
Host: Neilanjan Nandi, MD
Guest: David T. Rubin, MD
The proliferation of new classes of therapies for ulcerative colitis is affecting how we decide which treatments are most appropriate for our patients who are first- or second-line non-responders. This creates not only new challenges, but also new opportunities for all community gastroenterologists. Dr. Neil Nandi and Dr. David Rubin walk us through a case to highlight some of these challenges.
Since the completion of this activity, results from the ELEVATE UC 52 study, a yearlong phase 3 trial of etrasimod in moderate to severe ulcerative colitis, were announced. Etrasimod is an investigational, oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator that showed positive 12- and 52-week results compared to placebo. Patients achieved statistically significant improvements in the co-primary endpoint of clinical remission at weeks 12 and 52 when compared to placebo. Statistically significant improvements were also attained in all key secondary endpoints at both 12 and 52 weeks. We will provide more data as the full results are published and presented in the future.
Host: Patty Cason, RN, MS, FNP-BC
Guest: Joely Pritzker, RN, MS, FNP-C
Are you ready to apply the latest counseling techniques to address the contraceptive revolution?
Join nurse practitioners Patty Cason and Joely Pritzker as they briefly review the history of contraceptive counseling and then use case vignettes to illustrate how shared decision-making techniques will support the appropriate use of nonhormonal contraceptive options, such as the vaginal pH modulator (VPM).
Participating in this activity will ensure that you are ready to effectively counsel patients on their many options so that each patient’s reproductive and sexual health goals can be met.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Amy McGorry PT, DPT, MTC
Guest: Catherine C. Crowley, PhD, CCC-SLP
COVID-19 has led to several unexpected challenges, impacting several parts of the body, including our patients' voices. What do we need to know about these impacts to better care for our patients? To answer this question, Drs. Amy McGorry and Catherine Crowley of Long Island University in New York join Dr. Charles Turck to share their clinical experience with vocal fatigue and dysphonia related to COVID-19.
Host: Jacob Sands, MD
Guest: Manish A. Shah, MD FASCO
For patients with unresectable liver-limited hepatocellular carcinoma, treatment can be challenging. Clinicians typically care for these patients with local-regional therapies, but is that the best option for all of them? To answer this question, Dr. Jacob Sands joins Dr. Manish Shah from Weill Cornell Medicine to take a look at current and emerging strategies for managing and treating unresectable liver-limited hepatocellular carcinoma.
Host: Hector O. Chapa, MD, FACOG
Guest: Erin D. Michos, MD, MHS, FACC, FAHA, FASE
Guest: Anum Minhas, MD, MHS
Cardiovascular disease is currently the leading cause of death for pregnant and postpartum women in the United States, and from a global perspective, hypertensive complications during pregnancy result in 50,000 maternal deaths each and every year. This, along with the increasing rates of peripartum cardiomyopathy diagnoses, is why a new subspeciality of cardiology is needed. So what exactly is cardio-obstetrics? To learn more about how this emerging subspecialty is helping to provide better care for our pregnant and postpartum patients, Dr. Hector Chapa speaks with Drs. Erin Michos and Anum Minhas.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Vikram V. Bhise, MD
Guest: Patty Bobryk, MHS, PT, MSCS, ATP
When it comes to managing multiple sclerosis (MS), it’s important to keep the patient at the center of care by learning about their unique goals as well as the sociodemographic and socioeconomic factors affecting them. So how can we learn more about our patients, and once we do, what evidence-based management strategies are available to us? Joining Dr. Charles Turck to share how we can tailor treatment plans for our patients with MS are Dr. Vikram Bhise and certified assistive technology practitioner Ms. Patty Bobryk.
Host: Carol Wysham, MD
Guest: Rodica Pop-Busui, MD, PhD
Type 2 diabetes can be reflected in a patient's oral health, but can we say the same for patients with type 1 diabetes? Here to dive into that question and to share her latest findings in oral health in patients with type 1 diabetes is Dr. Rodica Pop-Busui, a Larry D. Soderquist Professor of Diabetes and Vice-chair for Clinical Research in the Department of Internal Medicine and also the Director of Clinical Research, Mentoring and Development of M-Diabetes at the University of Michigan.
Host: Paul Doghramji, MD
Guest: Vikram V. Bhise, MD
Shared decision-making is essential when it comes to caring for patients with multiple sclerosis. But what does its utilization actually look like in practice? To find out, Dr. Paul Doghramji speaks with Dr. Vikram Bhise, who shares a patient case in multiple sclerosis care that demonstrates how we can incorporate shared decision-making in practice.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Erick Argueta, MD
Since only 70 percent of initial eradication attempts of Helicobacter pylori are successful, it’s important for us to understand the factors that might be contributing to this startling statistic. That’s why Dr. Peter Buch speaks with Dr. Erick Argueta about why Helicobacter pylori can be difficult to eradicate and how we can best treat this infection.
Host: Jacob Sands, MD
Guest: Edith Mitchell, MD, MACP, FCPP, FRCP
Appointed member to the President's Cancer Panel and Clinical Professor of Medicine at Thomas Jefferson University, Dr. Edith Mitchell, shares what the panel recommends to close gaps in cancer screening in the U.S.—with a focus on colorectal cancer—to improve access for all patients.
Host: Neal Bhatia, MD
Guest: Jeffrey Sugarman, MD, PhD
Drs. Neal Bhatia and Jeff Sugarman discuss how the new formulation of benzoyl peroxide can change our treatment armamentarium for rosacea. Find out how microencapsulation technology stabilizes BPO and improves outcomes for patients.
Host: Linda Stein Gold, MD
Guest: Hilary Baldwin, MD
Microencapsulation technology is allowing us to combine agents that were previously incompatible. One new formulation is preserving the advantages of BPO while minimizing limitations and improving adherence for patients with acne. Join Dr. Linda Stein Gold and Dr. Hilary Baldwin as they walk through a case scenario to demonstrate how the new formulation of BPO and tretinoin fits into clinical practice.
Host: Linda Stein Gold, MD
Guest: Neal Bhatia, MD
Guest: Julie C. Harper, MD
Do you ever wish you could mix the unmixable when it comes to treatment selection? Microencapsulation is the answer! This new technology preserves the advantages of BPO while minimizing limitations for patients with acne and rosacea. Tune in to our chapterized panel discussion with Drs. Linda Stein Gold, Julie Harper, and Neal Bhatia and view 3D animation revealing how microencapsulation works.
Host: Matthew S. Keller MD
Guest: Shawn Kwatra, MD
As the most common type of eczema, atopic dermatitis is a chronic, inflammatory skin disorder that affects millions of people worldwide. And although it’s a complex disease with no cure, the FDA recently approved two oral JAK-1 inhibitors for patients with mild-to-severe-symptoms. So what do we need to know about these new treatment options? Joining Dr. Matthew Keller to review the role of JAK inhibitors in atopic dermatitis is Dr. Shawn Kwatra, Associate Professor of Dermatology at Johns Hopkins University School of Medicine and Director of the Johns Hopkins Itch Center.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Benjamin L. Cohen, MD
Inflammatory bowel disease (IBD) among the elderly is common, and when compared to IBD in younger patients, it’s characterized by a different disease course and has an increased risk of mortality. So how can we achieve better outcomes for our elderly patients? Dr. Peter Buch is joined by Dr. Benjamin Cohen, Co-Section Head and Clinical Director for Inflammatory Bowel Disease at the Cleveland Clinic, to discuss evaluation and treatment strategies for our elderly patients with IBD.
Host: Jacob Sands, MD
Guest: Edith Mitchell, MD, MACP, FCPP, FRCP
Widespread health disparities have led to challenges in colorectal cancer screening. What's causing these disparities—and what are some ways we can overcome these obstacles? To dive into this topic, Dr. Jacob Sands is joined by Dr. Edith Mitchell from Thomas Jefferson University to discuss these disparities and how they may be impacting clinical outcomes.
Host: Jennifer Caudle, DO
Guest: Leonard A Valentino, MD
Unfortunately, recognizing and diagnosing patients with bleeding disorders is only the first of many challenges. Once a diagnosis is reached, patients may face a variety of chronic health challenges and even altered family dynamics. Fortunately, recent treatments and developments—and even those on the horizon—can help alleviate the burden of bleeding disorders on patients and their loved ones. Join Dr. Jennifer Caudle as she uncovers those important efforts with Dr. Leonard Valentino, President and Chief Executive Officer at the National Hemophilia Foundation.
Host: Adrienne W. Scott, MD
Guest: Rajendra Apte, MD, PhD
Guest: Jennifer I. Lim, MD, FARVO
A main goal in the treatment of diabetic retinopathy is to intervene early enough to prevent vision loss. New data are giving us new tools for our armamentarium and helping us define what constitutes “early”—and if there’s such a thing as “too early.” Join us to take a closer look at the data surrounding the management of NPDR and CI-DME with good vision and hear our panelist of experts explain how the data translate into clinical care.
Guest: Claresa Levetan, MD
How can we better communicate lifestyle changes and glucose monitoring levels with our diabetic patients? Dr. Claresa Levetan, an endocrinologist at Grand View Health in Lansdale, Pennsylvania, shares key communication strategies she uses with her patients.
Guest: Claresa Levetan, MD
Diabetes impacts around 40 million Americans and 25% of them don't even know they have it. Luckily, Diabetes Alert Day was created to spread awareness of this widespread disease. To help us understand this campaign, Dr. Claresa Levetan, an endocrinologist at Grand View Health in Lansdale, Pennsylvania, shares insights on the importance of Diabetes Alert Day.
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Guest: Cheryl Carcel, MD, PhD
Although research suggests that women have a similar stroke risk as men, a new analysis has found that a very small percentage of participants in clinical trials investigating stroke treatments are female. So why are women underrepresented in these clinical trials, and what can be done to reverse this troubling trend? Joining Dr. Andrew Wilner to discuss strategies to improve the representation of women in stroke trials is Dr. Cheryl Carcel, neurologist and senior research fellow at the George Institute of Global Health.
Host: Matthew Sorrentino, MD
Guest: Javed Butler, MD, MBA, MPH
In a groundbreaking procedure, a 57-year-old man with life-threatening heart disease received a heart from a genetically altered pig. Surgeons at the University of Maryland Medical Center performed the 8-hour operation, making it the first successful transplant of a pig's heart into a human being. And while much is still uncertain, what could this achievement mean for the future of organ transplantation? That’s what ReachMD hosts Dr. Matthew Sorrentino and Dr. Javed Butler explore together.
Please note: Since the date of publication, David Bennet, the patient who received a heart transplant from a pig, died at the age of 57 at the University of Maryland Medical Center on March 8, 2022.
Host: Rachel Caskey, MD, MAPP
Guest: Gwendolyn Ramirez
Vaccine hesitancy is a very challenging, and often tiring topic, for clinicians to address. Join Dr. Rachel Caskey in an engaging clinician-patient dialogue as she uses a dynamic and presumptive approach to overcome common vaccination challenges. What communication pearl will you use with your patients?
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Sean Lau, RN, VA-BC
What are some ways we can reduce the prevalence of difficult venous access? Dr. Charles Turck is joined by Sean Lau, a vascular access specialist at Stanford Health Care, to share strategies to help reduce DIVA rates and improve vascular access care.
Host: Neilanjan Nandi, MD
Guest: Monica Schwartzman, MD, MS
It's estimated that 50 percent of patients with IBD experience arthralgia, with the most common form being peripheral arthritis. What screening strategies are available to help us identify those patients with peripheral discomforts? Tune in to hear multidisciplinary perspectives on peripheral arthritis in IBD from gastroenterologist Dr. Neil Nandi and rheumatologist Dr. Monica Schwartzman.
Host: Neilanjan Nandi, MD
Guest: Samir Shah, MD
From new guideline recommendations to a concert featuring the American College of Gastroenterology’s official band, a lot is being done to help raise awareness of the importance of screening for colorectal cancer. So how can you help increase screening rates in your own community? Get inspired with these creative initiatives shared by Dr. Neil Nandi and Dr. Samir Shah, President of the American College of Gastroenterology.
Host: George I. Papakostas, MD
Host: Larry Culpepper, MD, MPH
This Expert Exchange webcast is designed to help clinicians achieve better outcomes in patients with MDD who have an inadequate initial treatment response.
Host: John E. Anderson, MD
Guest: Scott Pilla, MD, MHS
One of the most serious side effects of diabetes, hypoglycemia can lead to severe consequences, and keeping up with the latest in care can help us prevent this complication. To share the latest updates, Dr. John Anderson is joined by Lead Researcher Dr. Scott Pilla to share insights from his recent studies on hospital utilization and primary care communication for patients with diabetes.
Host: John J. Russell, MD
Guest: Drew Weissman, MD, PhD
Guest: Katalin Karikó, PhD
As mRNA technology continues to emerge and evolve, Penn Researchers Dr. Drew Weissman and Dr. Katalin Karikó join Dr. John Russell to take a deep dive into the future of mRNA technology.
Host: Jane Mast, PA-C, MPAS, DMSc
Guest: Douglas DiRuggiero, DMSc, PA-C
Join podcast guest Doug DiRuggiero, PA, a certified physician assistant and the founding president of Georgia Dermatology Physician Assistant Society, and host Jane Mast, a Novartis Medical Director and certified physician assistant in a discussion focusing on the diagnosis and management of psoriasis in pediatric and adolescent patients.
During their discussion, they address the following topics:
- Important clinical features of psoriasis in children and adolescents and how they may differ from those in adult patients
- Communication strategies to use when talking to parents about their child’s psoriasis
- Psychosocial impact of psoriasis
- Approaches to management
This podcast is sponsored by Novartis Pharmaceuticals Corporation and the podcast guest is being compensated for his time.
© 2021 Novartis Pharmaceuticals Corporation
Host: Michael Greenberg, MD
Guest: Arash Mostaghimi, MD, MPA, MPH
Acne vulgaris is a common dermatologic condition with a variety of treatment options available. But due to its multifactorial pathogenesis and the limitations of current therapies, evolving treatments and management guidelines are needed. Fortunately, several therapies have emerged in recent years, so to learn more about what’s new in the treatment landscape, Dr. Michael Greenberg speaks with Dr. Arash Mostaghimi, Director of Dermatology Inpatient Service at Brigham and Women’s Hospital.
Host: Jacob Sands, MD
Guest: Daniel Sessler, MD
Our choice of anesthesia, whether it's regional or general, can have an effect on the outcome of our patients. But can this decision also contribute to cancer recurrence? To understand this, Dr. Jacob Sands sits down with renowned researcher in the anesthesia community, Dr. Dan Sessler, to learn more about his research on the impacts of general anesthesia.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Gates B. Colbert, MD, FASN
Guest: Robin Dore, MD
When managing patients with lupus nephritis, it’s imperative that rheumatologists and nephrologists work together to coordinate care. Unfortunately, several challenges can keep us from putting care coordination strategies into practice, so how can we overcome those challenges and incorporate shared decision-making into our clinical approach to lupus nephritis? Joining Dr. Charles Turck to share their perspectives are rheumatologist Dr. Robin Dore and nephrologist Dr. Gates Colbert.
Host: Jacob Sands, MD
Guest: Daniel G. Arkfeld, MD
The focus of lupus treatment has evolved from controlling symptoms to taking a treat-to-target approach to help patients feel more comfortable and to prevent organ damage. So what role do biologics play in all of this? Find out with Dr. Jacob Sands as he speaks with Dr. Daniel Arkfeld, who shares key insights on this approach to treating lupus.
Host: Jennifer Caudle, DO
Guest: David S. Batt, MD
Many factors can lead to diagnostic delays when it comes to systemic lupus erythematosus (SLE), such as the wide range of clinical manifestations and the variable age of onset. So given those factors, how can we get better at recognizing SLE early on to help close the diagnostic gap? And then once we do diagnose patients, what strategies can we use to tighten the therapeutic window? Joining Dr. Jennifer Caudle to answer those and other key questions regarding early intervention strategies for SLE is Dr. David Batt.
Host: Eugene E. Wright, Jr., MD
Guest: Jolanta Małyszko, MD, PhD
Guest: María José Soler, MD, PhD
Achieving optimal outcomes when treating patients with chronic kidney disease (CKD) in type 2 diabetes (T2D) remains a challenge due to the multidisciplinary response needed to prevent progressive renal dysfunction. Low screening rates and underdiagnosis impede early interventions. On the other hand, early diagnosis and regular screening of CKD in T2D set the stage for clinicians to optimize drug therapy to prevent progression to end-stage renal disease while aggressively managing comorbid T2D and other CKD risk factors.
Host: Scott Kopetz, MD, PhD
Guest: Elena Elez, MD, PhD
Guest: Elizabeth Smyth, MD
Even with the recent advances in therapeutic options for patients with BRAF V600E-mutated metastatic colorectal cancer (mCRC), they still have an uphill climb ahead of them.
How will the new standard of care in the second-line setting address global challenges and unmet needs regarding molecular profiling and treatment sequencing options?
Join us as 3 experts, Dr. Scott Kopetz, Dr. Elizabeth Smyth, and Dr. Elena Elez, untangle these new advances in treatment and offer their insights on how diagnostic testing can improve patient outcomes.
Host: Rahul N. Khurana, MD
Guest: Jennifer K. Sun, MD, MPH
The results from the Protocol W and PANORAMA clinical trials have sparked a lot of talk in the retina community about what the data really mean. So how should physicians interpret these data, and what is changing for their patients with diabetic retinopathy?
Find out in this activity as Dr. Rahul Khurana and Dr. Jennifer Sun review the findings from both trials and discuss if treatment with anti-VEGF really improves outcomes for patients with moderate to severe NPDR.
Host: Ruth S. Weinstock, MD, PhD
Guest: Susan B. Bressler, MD
Guest: Mark Dunbar, OD, FAAO
With the increasing prevalence of diabetes in the United States, more individuals are at risk of losing their vision due to diabetic retinopathy every day. Fortunately, research is improving our understanding of this disease. But what does the latest information mean for our patients?
Hear Dr. Susan Bressler, Dr. Mark Dunbar, and Dr. Ruth Weinstock share their perspectives as multidisciplinary specialists treating these patients. Find out what the evidence shows and how timely referral, early diagnosis, and appropriate treatment can prevent the vision-threatening complications of diabetes.
Guest: Eser Adiguzel, PhD (Novartis)
Guest: Randy Wong, MD (Novartis)
A common complication of diabetes is diabetic macular edema (DME). Of the 463 million people worldwide aged 29 to 79 years old living with diabetes, many will develop diabetic retinopathy at about a rate of 27 percent. And of those 27 percent, a smaller subset will develop DME.1,2 Given its high prevalence, it’s important to understand its pathophysiology, clinical features, challenges, and management approaches, which is why Drs. Eser Adiguzel and Randy Wong are here to share their insights on DME.
- International Diabetes Federation. Diabetes Atlas 9th Edition. 2019.
- Thomas RL, et al. Diabetes Res Clin Pract. 2019 Nov; 157:107840.
181534 2/22
Guest: Pranay Sinha, MD
Where are we on the path to eliminating tuberculosis? To understand this, Dr. Pranay Sinha, a postdoctoral researcher at Boston Medical Center, discusses what we need to know and shares what’s on the horizon for TB elimination.
Host: John J. Russell, MD
Guest: Joseph E. Bavaria, MD
Featuring a wide range of disciplines and a new approach to comprehensive care, what do we need to know about the Aorta Center at Penn Medicine? Dr. John Russell is joined by Dr. Joseph E. Bavaria to dive into this aortic program and discuss a new approach to comprehensive care.
Host: William Mencia, MD, FACEHP, CHCP
Guest: Andrew F. Alexis, MD, MPH
There is often a delay in the diagnosis of psoriasis and/or psoriatic arthritis for people with skin of color. Among the multiple factors that cause this disparity are a low index of suspicion for such a diagnosis in skin of color and a lack of familiarity with the morphology of these conditions in richly pigmented skin. Join Drs. William Mencia and Andrew Alexis as they address pathways to overcoming these systemic and experiential healthcare barriers.
Host: Sergio Schwartzman, MD
Guest: April W. Armstrong, MD, MPH
Guest: Philip J. Mease, MD, MACR
Integrating routine assessments of psoriatic arthritis (PsA)-related structural progression has proven challenging in clinical practice. Join Drs. Sergio Schwartzman, Philip Mease, and April Armstrong as they discuss evidence that frequent monitoring of PsA structural progression permits earlier intervention with effective therapies as well as provides indications for when to switch to another class of agent. They also address which therapeutic agents have been shown to impact PsA structural progression in clinical trials and provide insight into how best to incorporate collaborative treatment strategies across disciplines. These practices are likely to improve outcomes for patients with PsA, so be sure to stay informed.
Host: Muhammad Adrish MD, MBA, FCCP, FCCM
Guest: Navitha Ramesh, MD, FCCP
Inhalers are one of the most common methods of delivery for the treatment of COPD, but is it the best option for all of our patients? Associate Professor of Pulmonary Critical Care at Baylor College of Medicine, Dr. Muhammad Adrish, reviews LAMA use for COPD patients with Dr. Navitha Ramesh, Assistant Professor at Drexel University College of Medicine.
This episode is produced in partnership with the American College of CHEST Physicians and is sponsored by Viatris Inc.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Michelle Hughes, MD
Over the past two decades, there has been an increasing need for GI hospitalists to help provide rapid access to care. Since then, GI hospitalists have become an important part to many healthcare systems and their approach to patient care. Joining Dr. Peter Buch to discuss the benefits and challenges that come along with the GI hospitalist role is Dr. Michelle Hughes, Assistant Professor of Medicine and Medical Chief of Quality and Safety for Digestive Health at Yale New Haven Health.
Host: Javed Butler, MD, MBA, MPH
Guest: Stefan D. Anker, MD, PhD
The DIAMOND trial recently released topline results, adding to the growing clinical evidence for the use of potassium binders in the management of hyperkalemia in patients with heart failure. So what do the data mean for our patients? Join Dr. Stefan Anker and Dr. Javed Butler as they discuss the value of these results and make sure you’re staying up to date with the evolving data, guidelines, and practices.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Margaret Chisolm, MD
The Diagnostic and Statistical Manual of Mental Disorders (DSM) is the handbook traditionally used by healthcare professionals to guide the diagnosis of psychiatric conditions, but a number of psychiatrists advocate for the perspectives approach, which extends beyond the DSM model. So how exactly do these two models differ? And how might this newer approach impact our patients? Joining Dr. Charles Turck to answer those and other key questions on the perspectives approach to diagnosing and treating patients with mental illness is Dr. Margaret Chisolm, author of From Survive to Thrive: Living Your Best Life with Mental Illness.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Amir E. Masoud, MD
Gastroparesis affects approximately five million people in the United States alone, and there are more than 50 recognized causes. In recent years, however, it's been shown that simply accelerating gastric emptying may not improve symptoms, and the overlap of functional dyspepsia and gastroparesis has further clouded our understanding of this condition. So to help clear up some of that confusion, Dr. Peter Buch speaks with Dr. Amir Masoud about treatment strategies for gastroparesis.
Host: Hector O. Chapa, MD, FACOG
Guest: Dani Dumitriu, MD, PhD
The COVID-19 pandemic has taken a toll on all patients, especially pregnant women. Here to walk us through her research on the pandemic's impact on the psychosocial health of mothers and the neurodevelopment of their fetuses is Dr. Dani Dumitriu, a pediatrician, neuroscientist, and pediatric environmental health scientist at Columbia University in New York.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Maryam Lustberg, MD, MPH
Amid the evolving treatment landscape for HER2-low breast cancer, many therapeutic challenges and limitations remain, resulting in unmet needs for our patients. Fortunately, developments in the therapeutic landscape can help address those unmet needs, and joining Dr. Charles Turck to share what’s on the horizon is Dr. Maryam Lustberg.
Host: Neilanjan Nandi, MD
Guest: Karen Krok, MD, FAASLD
While hepatologists can help gastroenterologists manage the pulmonary manifestations that may occur in our patients with chronic liver disease, it’s still important for gastroenterologists to know what they should be on the lookout for so that patients can receive timely and appropriate treatment. Additionally, gastroenterologists need to consider the potential impacts of those pulmonary manifestations on transplant outcomes. Joining Dr. Neil Nandi to discuss those and other key considerations gastroenterologists need to know is Dr. Karen Krok from Penn State Health Milton S. Hershey Medical Center.
Host: Neilanjan Nandi, MD
Guest: Nitin K. Ahuja, MD
The symptoms of early satiety, chronic nausea, and even vomiting can be physically and emotionally challenging for the gastroparesis patient. Adding to the challenge is the fact that the journey from diagnosis to treatment is often daunting and frustrating. So to help us combat these challenges, Dr. Neil Nandi speaks with Dr. Nitin Ahuja, who walks us through the ins and outs of diagnosing and managing gastroparesis.
Host: David J. Portman, MD
Guest: Patty Cason, RN, MS, FNP-BC
Guest: David L. Eisenberg, MD, MPH, FACOG
Are you ready for the contraceptive revolution? Are you applying the latest information on contraceptive efficacy, recent clinical trial data, and sexual satisfaction when counseling your patients on contraceptive options? Join Dr. David Portman, Dr. David Eisenberg, and Ms. Patty Cason as they discuss the novel mechanisms of action of cutting-edge, non-hormonal contraceptive options, such as the vaginal pH modulator (VPM). Participating in this activity will ensure that you are prepared to discuss sexual and reproductive goals with your patients and confirm that your patients’ goals are being met.
Host: Carol Wysham, MD
Guest: Deepak Vashishth, PhD
Guest: Bowen Wang
Can we predict when a patient with COVID-19 requires hospitalization? To answer this question, Dr. Carol Wysham is joined by Dr. Deepak Vashishth and Mr. Bowen Wang from the Rensselaer Polytechnic Institute to share data from their study on the impact of glycemic levels and common medications on COVID-19 severity in patients with type 2 diabetes.
Host: Neilanjan Nandi, MD
Guest: Nicholas Shaheen, MD, MPH
How do we determine which of our patients with Barrett's esophagus with dysplasia are good candidates for ablation therapy, and what’s the role of the gastroenterologist in serving patients who've already received post-ablative therapy? Joining Dr. Neil Nandi to answer those and other key questions is Dr. Nicholas Shaheen, who was the primary investigator of one of the largest multicenter studies of radiofrequency ablation.
Host: John J. Russell, MD
Guest: Benjamin Abramoff, MD, MS
Once a patient is discharged from the hospital after battling COVID-19, the war they face with this disease may not be over. In fact, many patients continue to experience long-term effects, which is why some institutions have formed clinics that are solely dedicated to caring for these patients. To learn more about how one such clinic is helping patients manage these devastating effects, Dr. John Russell speaks to physiatrist Dr. Benjamin Abramoff from the Post-COVID Assessment and Recovery Clinic at Penn Medicine in Philadelphia.
Host: Javed Butler, MD, MBA, MPH
Guest: Shelley Zieroth, MD
Have you started using newly approved therapies when caring for your patients with heart failure with reduced ejection fraction (HFrEF)? Tune in to hear Drs. Javed Butler and Shelley Zieroth discuss strategies you can use to determine the best treatment approaches for your most challenging patients. A 3D mechanism of action animation is included to help you understand the workings of novel classes of agents in heart failure. Make sure you get with the guidelines, because guideline-directed medical therapy really does work.
Host: Hector O. Chapa, MD, FACOG
Guest: Kellie Moore, ND
We've all heard the phrase "you are what you eat." But are we now at a point where science is backing up that old saying? To find out how our diet can impact our cognitive function and mood, Dr. Hector Chapa speaks with naturopathic physician Dr. Kellie Moore. Together, they’ll review the foods that we should eat versus avoid and the resources we can use to help our patients have a healthy mind and body.
Host: Matthew S. Keller MD
Guest: Linda Stein Gold, MD
For many years, acne scarring was considered to be a result of severe acne, but recent research shows that scarring can affect any patient regardless of the severity. Additionally, acne scarring can significantly reduce a patient's quality of life, which is why it's important that treatment is started early to achieve better outcomes. So to help us gain a better understanding of the assessment and treatment strategies currently available, Dr. Matthew Keller speaks with Dr. Linda Stein Gold, Director of Dermatology Clinical Research at Henry Ford Health System in Detroit.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: William Schaffner, MD
From widespread variants to the threat of a twindemic -- what has the COVID-19 pandemic taught us? And can we learn to coexist with this virus? Dr. Charles Turck is joined by Dr. William Schaffner from the National Foundation for Infectious Diseases to discuss what's on the horizon for the pandemic.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Donna Cipolla, MD
Microscopic colitis can have a variety of symptoms ranging from very mild to debilitating. Fortunately, there are several treatment options and strategies available that can help you alleviate your patient’s symptoms. Joining Dr. Peter Buch to share those options and strategies is Dr. Donna Cipolla.
Host: Jacob Sands, MD
Guest: Kathleen Fenn, MD
Guest: Oudai Hassan, MD
How do the 2018 ASCO/CAP guidelines redefine our approach to caring for patients with HER2-mutated breast cancer? Find out as Dr. Jacob Sands speaks with Dr. Kathleen Fenn and Dr. Oudai Hassan about HER2 scoring criteria and how the data drives collaborative care between the medical oncology and pathology teams.
Host: Megan Conroy, MD, MA(Ed)
Guest: Farrukh Abbas, MD
On average, more than two-thirds of patients with chronic obstructive pulmonary disease (COPD) make at least one error in using an inhaler device. Fortunately, nebulized long-acting muscarinic antagonists (LAMAs) can help our patients overcome this common challenge in COPD care. That’s why Drs. Megan Conroy and Farrukh Abbas come together to talk about the GOLD treatment guidelines, strategies for reducing patient hesitancy regarding nebulized LAMAs, and more.
This episode is produced in partnership with the American College of CHEST Physicians and is sponsored by Viatris Inc.
Guest: Alexander Spira, MD, PhD, FACP
When it comes to HER2 mutations in non-small cell lung cancer (NSCLC), there’s a lot to consider, like CNS metastases, current therapies, patient characteristics, and more. That’s why Dr. Alexander Spira from Johns Hopkins is here to give us an essential overview of HER2 mutations in NSCLC.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Ayman Al-Hendy, MD
Surgery has long been the default choice when managing uterine fibroids and endometriosis. However, over the past few years, reliable and durable medical interventions have emerged, notably GnRH antagonist therapy. Clinical trial data for GnRH antagonists highlight both their safety and efficacy for a broad demographic of patients. Join Drs. Lee Shulman and Ayman Al-Hendy as they discuss the “how” and the “why” of a paradigm shift that is occurring, changing our focus from surgery to first-line medical intervention for uterine fibroids and endometriosis.
Host: Jennifer Caudle, DO
Guest: Michiel Coppens, MD, PhD
While there are several treatment options available for patients with hemophilia B, do they have any limitations? Dr. Jennifer Caudle speaks with Dr. Michiel Coppens, a medical specialist in vascular medicine with a focus on hemophilia at the Amsterdam University Medical Centers, about the current treatment challenges and unmet needs for patients with hemophilia B.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Diane M. Harper, M.D., M.P.H., M.S.
While HPV 16 causes nearly 60 percent of the cervical cancers, it’s only associated with about 20 percent of the NILM, ASCUS, and LSIL cytology diagnoses. This means that 80 percent of early screening abnormalities associated with types other than 16 are missed. So how can we better detect types beyond HPV types 16 and 18? Joining Dr. Charles Turck to discuss same-genotype persistence for high-risk HPV is Dr. Diane Harper.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Donald Middleton, MD
Influenza causes considerable morbidity and mortality in children. In fact, the CDC estimates that from the 2010-2011 season to the 2019-2020 season, seasonal flu-related hospitalizations among children younger than 5 years old have ranged from 7,000 to as high as 26,000 every year.1 This is a sobering reminder of the pivotal role vaccination plays in preventing influenza disease, and now, recent safety and immunogenicity data has led to the expanded age indication for the cell-based vaccine FLUCELVAX QUADRIVALENT. Explore that data and what this approval means for patients 6 months of age and older with Drs. Charles Turck and Donald Middleton.
- Centers for Disease Control and Prevention. Flu and young children. https://www.cdc.gov/flu/highrisk/children.htm. Accessed December 22, 2021
USA-QIVc-21-0169 December 2021
Host: Matt Birnholz, MD
Guest: Andrew Wang, MD
Although hypertrophic cardiomyopathy is the most common inherited heart disease, it is estimated that many patients remain undiagnosed. But why is that, what are the steps to help close the diagnostic gap, and what are the current management approaches for HCM? Joining Dr. Matt Birnholz to answer these questions and more is Dr. Andrew Wang, Vice Chief for Clinical Affairs for Duke University's Division of Cardiology and Director of the Duke Hypertrophic Cardiomyopathy Clinic.
Guest: Pavani Chalasani MD, MPH
What were the key findings from the EMERALD, Destiny-03, and PADA 1 trials that were featured at the 2021 San Antonio Breast Cancer Symposium? Explore the data on emerging breast cancer therapies with Dr. Pavani Chalasani, Associate Professor of Medicine and Program Director of the Hematology and Oncology Fellowship at the University of Arizona Cancer Center.
Host: John J. Russell, MD
Guest: Leana S. Wen, MD, MSc
From immigrant child to public health leader, emergency physician and medical expert Dr. Leana Wen sits down with Dr. John Russell to share her journey. Together, they’ll discuss the personal experiences that have framed her career.
Host: Hector O. Chapa, MD, FACOG
Guest: Linda Bradley, MD
Medical commentators have stated that medicine as a profession is sick. So what can medicine do to change and better impact the community? That’s the exact question Dr. Hector Chapa explores with Dr. Linda Bradley from Case Western Reserve University. Together, they’ll discuss why social determinants of health exist, the impact they have on communities, and even more importantly, how we can combat them.
Host: Hector O. Chapa, MD, FACOG
Guest: Linda Bradley, MD
While many people across the country have access to COVID-19 vaccines, there are certain communities where access is not as easy. So what can we do to address the vaccination gaps and barriers to care during the COVID-19 pandemic and beyond? Find out with Dr. Hector Chapa as he speaks with Dr. Linda Bradley from Case Western Reserve University, who shares a brief history of the presence of social determinants of health and racial disparities across our nation and how they impact our current vaccination efforts.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Eric D. Donnenfeld, MD
Dry eye disease is one of the most common ophthalmic complaints; it results from the activity of various pathways and is considered a multifactorial disease. An important factor that contributes to the onset of dry eye disease is meibomian gland dysfunction. Meibomian gland dysfunction causes a disruption in the tear film lipid layer, which affects the rate of tear evaporation. This evaporation leads to tear hyperosmolarity, eventually triggering the onset of dry eye disease. Dry eye disease and meibomian gland dysfunction are strongly associated with each other, such that many of their risk factors, signs, and symptoms overlap. In this educational podcast, our expert faculty will review the association between dry eye disease and meibomian gland dysfunction, and highlight best practices for assessment, diagnosis, and management.
Host: Neilanjan Nandi, MD
Guest: Monica Schwartzman, MD, MS
It's currently estimated that 50 percent of IBD patients experience some form of joint stiffness, otherwise known as arthralgia. With so many patients being affected, how can you determine if it’s inflammatory or noninflammatory arthralgia and treat it appropriately? To find out, Dr. Neil Nandi speaks with Dr. Monica Schwartzman, assistant attending physician at the Hospital for Special Surgery and Clinical Instructor of Medicine at Weill Cornell Medical College. Together, they’ll discuss the screening tools gastroenterologists can use to differentiate the types of arthralgia in their patients as well as key management approaches.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Joshua Richter, MD
Here to share his perspective on the use of triplet therapy for the treatment of multiple myeloma is Dr. Joshua Richter. Dr. Richter shares a patient case and speaks with Dr. Charles Turck about why this treatment may be an option for some patients.
Host: Kristen Whitaker, MD, MS
Guest: Ricki Fairley, BA, MBA
Guest: Sara M. Tolaney, MD, MPH
For patients with recurrent unresectable or metastatic triple negative breast cancer (TNBC), standard systemic therapy has largely consisted of chemotherapy, though the outlook has improved recently following FDA approval of several targeted therapies and immunotherapeutic options. The management of TNBC remains quite challenging for clinicians, particularly in light of persistent disparities in TNBC care that disproportionately impact specific patient populations (eg, women of minoritized populations). Racial disparities specific to TNBC include a higher incidence, more advanced stage at diagnosis, and increased mortality among black women versus white women in the United States.
This web-based, on-demand, activity will review health disparities and inequities in TNBC and how they impact care, along with the latest evidence for current and emerging antibody-drug conjugates and immunotherapeutic agents, to assist oncology professionals in delivering impartial care to all patients.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Chris Beyrer, MD, MPH
Amid the ongoing COVID-19 pandemic, countries in Sub-Saharan Africa are also facing high rates of HIV and AIDS prevalence. But after the success of the mRNA COVID-19 vaccines, could an mRNA vaccine for HIV/AIDS be on the horizon? Here to explore emerging research and the potential role that mRNA technology might have in battling this global epidemic is Dr. Chris Beyrer, a Professor of Epidemiology at the Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland.
Guest: S. Michelle Shiller, DO, AP/CP, MGP
Guest: John V. Heymach, MD, PhD
Exon 20 insertion mutations account for up to 10 percent of EGFR mutations and approximately 2 percent of all non-small cell lung cancer mutations. Although less common, EGFR mutations at exon 20 have an important impact on therapy selection. That’s why Dr. John Heymach speaks with Dr. Michelle Shiller about what those impacts are as well as the available therapies for patients with these mutations.
All trademarks are the property of their respective owners.
Host: John E. Anderson, MD
Guest: Elizabeth A. Beverly, PhD
Current treatment strategies for diabetic patients focus on behavioral and clinical targets alone, but can shared experiences and peer support improve care? To learn more about this, Dr. John Anderson talks to Dr. Elizabeth Beverly from the Ohio University Heritage College of Osteopathic Medicine to discuss her recent study on positive experiences for patients living with type 1 or type 2 diabetes.
Host: Miguel A. Escobar, MD
Guest: Cindy Leissinger, MD
Guest: Guy Young, MD
Hemophilia A is an X-linked genetic disorder characterized by a deficiency in normal factor VIII resulting in an increased risk of bleeding. Repeated bleeds, notably in the joints, lead to chronic pain and loss of function. Joint damage can be prevented, at least in part, with prophylactic factor VIII replacement. Although factor VIII can be replaced, its intravenous administration is burdensome, which may impair adherence. Furthermore, about 30% of patients treated with factor VIII will develop inhibitors—neutralizing alloantibodies to factor VIII—making factor VIII replacement ineffective. Although patients with inhibitors can be treated with bypassing agents, these agents are expensive and less predictable than factor VIII.
However, there is now another option for both patients with and without inhibitors: bispecific antibody non–factor replacement prophylaxis. It is important for the interprofessional care team to be aware of how this treatment compares with traditional prophylactic agents, its safety and efficacy data, and how to appropriately incorporate prophylaxis therapy based on the latest real-world clinical data.
In this educational activity, an expert faculty will review and provide their interprofessional perspectives on currently approved prophylaxis therapy in hemophilia A, including the benefits of prophylaxis and adherence, real-world experience, and patient quality of life factors.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Jonathan Leighton, MD
If you suspect your patient might have small bowel bleeding despite a massive workup, what evaluation tools are at your disposal to help you find out for sure? Tune in to hear Dr. Peter Buch explore the available tools—and their inherent challenges to be aware of—with Dr. Jonathan Leighton, one of the nation’s leading experts on small bowel bleeding.
Host: Jacob Sands, MD
Guest: Yasmin Jayasinghe, FRANZCOG, PhD
Cancer treatment can impact fertility outcomes for individuals throughout the U.S. as well as around the globe, which is why the emerging field of oncofertility is here to help male and female patients navigate their fertility options before and after their cancer treatments. So what can we learn from oncofertility services and efforts from other countries around the world? Joining Dr. Jacob Sands to share her global viewpoints on the field of oncofertility is Dr. Yasmin Jayasinghe, Director of the Oncofertility Program at the Royal Children’s Hospital.
Host: Jacob Sands, MD
Guest: Yasmin Jayasinghe, FRANZCOG, PhD
Pediatric and adolescent oncofertility patients are cared for differently than adult patients. That’s why Dr. Yasmin Jayasinghe, Director of the Oncofertility Program at the Royal Children’s Hospital, is here to give us an overview of the available procedures for pediatric patients and the key considerations that go along with them.
Guest: Jeniffer Hernandez, PhD
Over 1.5 million viruses could potentially cause a future pandemic. Could antibodies be the key to neutralizing those viruses? Here to share how future vaccination efforts might incorporate neutralizing antibodies and her research on preventing future pandemics is Dr. Jeniffer Hernandez, Associate Professor of Biopharmaceutical Sciences at the Keck Graduate Institute.
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Guest: Jose Rubio, MD
Schizophrenia is rarely a single-episode illness. In fact, 8 out of 10 patients will experience a relapse of symptoms after initial treatment. So how can we help reduce the frequency of relapse—and even non-adherence—among our patients with schizophrenia? To find out, Dr. Andrew Wilner is joined by Dr. Jose Rubio, psychiatrist at Long Island Jewish Medical Center and Assistant Professor at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, to talk about the use of long-acting injectable (LAI) antipsychotics for schizophrenia treatment.
Host: Matthew S. Davids, MMSc, MD
Many CLL treatments cause a high risk for tumor lysis syndrome (TLS), an oncologic emergency due to the release of intracellular contents of tumor cells characterized by hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia. These electrolyte imbalances may be severe enough to cause acute renal failure, cardiac arrhythmias, seizures, loss of muscle control, and even death. In addition, neutropenia is a common side effect associated with CLL therapies, which increases the risk for infection and can disrupt or delay treatment, ultimately affecting patient outcomes.
A greater understanding of assessment and management of TLS and neutropenia is critical for reducing the likelihood of life-threatening complications in patients with CLL, which allows patients to continue to receive treatment.
AXIS routinely collects and analyzes data gathered from participants in our live activities. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment and management of patients with cancer to verify where clinical practice gaps exist. This activity will provide expert answers to questions asked during a recent educational series on preventing and managing tumor lysis syndrome and neutropenia in CLL.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Joseph Marek, MD
Sudden cardiac death is rare in younger patients, but it remains one of the leading causes of death in young athletes. To learn more about this, Dr. Alan Brown is joined by Dr. Joseph Marek, Clinical Cardiologist and Senior Medical Director of Cardiopulmonary Service at Advocate Medical Group, to share how his foundation, Young Hearts 4 Life, is working to increase awareness for sudden cardiac arrest and provide young athletes resources.
Host: Peter Rossing, DMSc, MD
Guest: Gerasimos S. Filippatos, MD, FESC, FHFA, FHFSA(h)
Guest: Matthew R. Weir, MD
Achieving optimal outcomes in the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) remains a challenge, and treating physicians need to embrace multidisciplinary components when managing progression to CKD.
In this discussion, Drs. Gerasimos Filippatos, Peter Rossing, and Matthew Weir review the unmet needs of patients with CKD and T2D. They also explore the role of mineralocorticoid receptor antagonists (MRAs) in the treatment spectrum and review recent findings from clinical trials. Tune in to ensure you’re doing all you can for each of your patients.
Host: John J. Russell, MD
Guest: R. Scott Turner, MD, PhD
Alzheimer’s disease (AD) is an irreversible, age-related, neurodegenerative disorder characterized by gradual decline in understanding, memory, and ability to perform activities of daily living. It is the most common cause of dementia worldwide and its’ prevalence continues to grow in part because of the aging world population. AD is characterized classically by two hallmark pathologies: β-amyloid plaque deposition and neurofibrillary tangles of hyperphosphorylated tau. Diagnosis is based upon clinical presentation fulfilling several criteria including fluid and imaging biomarkers. Until recently, current therapies were limited to delaying cognitive decline in some patients, but not treating the underlying causes of the disease nor halting the progression of the disease. This program discusses recent advances in our understanding of the clinical evaluation for early and accurate diagnosis, newly approved and emerging disease-modifying therapies, as well as non-pharmacological strategies for the management of patients with AD.
Host: Jennifer Caudle, DO
Guest: Maryam Lustberg, MD, MPH
Developing a coordinated survivorship care plan between oncologists and primary care physicians is a top priority for cancer patients. To better understand what goes into this, Dr. Jennifer Caudle is joined by Dr. Maryam Lustberg, Director of The Breast Cancer Center at the Smilow Cancer Hospital and Chief of Breast Medical Oncology at Yale Cancer Center, to discuss the role of the primary care physician in survivorship care for breast cancer patients.
Host: Javed Butler, MD, MBA, MPH
Guest: Faiez Zannad, MD, PhD
What do we need to know about the relationship between heart failure and ejection fraction? Dr. Javed Butler is joined by Dr. Faiez Zannad, Emeritus Professor of Cardiology at Université of Lorraine, to discuss current updates in ejection fraction and share what we need to know.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Naga Chalasani, MD
Drug-induced liver injury (DILI) continues to be one of the leading causes of acute liver failure, and its prevalence is only increasing. That’s why Dr. Peter Buch speaks with leading expert Dr. Naga Chalasani, who talks about everything we need to know about DILI—from its phenotypes to common symptoms to look for in patients.
Host: John J. Russell, MD
Guest: Jessica Malaty Rivera, MS
Social media and the ability to quickly spread information across the internet has allowed misinformation surrounding COVID-19 vaccines and the disease itself to spread like wildfire. But the good news is that when armed with effective counseling strategies and data from initiatives like the COVID-19 Tracking Project, we as clinicians can help stop the spread of harmful conspiracies and myths. Joining Dr. John Russell to talk about those essential strategies and the COVID-19 Tracking Project is infectious disease epidemiologist Ms. Jessica Rivera.
Host: Jayanth Sridhar, MD
Guest: Avni P. Finn, MD, MBA
Are you aware of the latest data that adds to our understanding of the management of diabetic retinopathy (DR)? Listen in as Dr. Avni Finn and Dr. Jay Sridhar discuss what those data are and the impact they have on the early referral and timely treatment of patients with DR. Make sure you’re properly using all of the resources in your armamentarium to save your patients’ sight.
Guest: Pavani Chalasani MD, MPH
Has our understanding of HER2 status changed? Dr. Pavanai Chalsani from the University of Arizona Cancer Center dives into the reclassification of HER2 status and shares emerging clinical trial data.
Guest: Timothy Yap, MBBS, PhD, FRCP
As DNA damage response therapies move beyond PARP inhibitors, what do we need to know? Dr. Timothy Yap from the University of Texas MD Anderson Cancer Center shares insights and takeaways from his presentation at the 2021 San Antonio Breast Cancer Symposium.
Host: Mark Socinski, MD
Guest: Sandip Patel, MD
Medical innovation in the treatment of lung cancer is at an all-time high. However, the gap between recent developments and their adoption into clinical practice continues to expand for community oncologists as the plethora of scientific and clinical data for the treatment of NSCLC rapidly emerges. Dr. Mark Socinski and Dr. Sandip Patel go through the selection and management of immune checkpoint inhibitors for patients with advanced NSCLC who do not have an actionable mutation.
Guest: George L. Bakris, MD
From diagnostic criteria to risk stratification, what do we need to know about recognizing early-stage diabetic kidney disease? Dr. George Bakris from the University of Chicago Medicine discusses detection strategies for diabetic kidney disease.
Host: Lisa K Moores, MD, FCCP, MACP
Guest: David Jiménez MD, PhD, FERS
Guest: Geert-Jan Geersing MD, PhD
Physicians are challenged in adopting the latest clinical guidelines and integrating new and existing treatment advances into practice when managing patients with VTE.
Guest: Timothy Yap, MBBS, PhD, FRCP
With a lack of clear standards of care in the post CDK4/6 inhibitor setting, a new study aims to address this unmet need. Dr. Timothy Yap from the University of Texas MD Anderson Cancer Center shares clinical trial data and its impact on cancer patients.
Host: Linda Stein Gold, MD
Guest: Jonathan S. Weiss, MD
Our understanding of the pathogenesis and pathophysiology of psoriasis continues to evolve, with one of the more recent pathways identified being the aryl hydrocarbon receptor. Here to share what we currently know about the role of the aryl hydrocarbon receptor in psoriasis are Dr. Linda Stein Gold and Jonathan Weiss.
Host: Linda Stein Gold, MD
Guest: Jonathan S. Weiss, MD
When assessing the burden of psoriasis, are you looking beyond the skin? Here to share their perspectives on the burden of psoriasis are Dr. Linda Stein Gold and Jonathan Weiss. Together, they’ll discuss the psychological impacts of psoriasis, how we can talk to patients, and more.
Guest: Terry P. Mamounas, MD
What do we need to know about the management of the axilla for patients with early-stage breast cancer? Dr. Terry Mamounas shares highlights from his presentation at the 2021 San Antonio Breast Cancer Symposium titled, “Refining Axillary Management After Neoadjuvant Chemotherapy - What Does the Evidence Support?”
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Kathryn Gallagher, MS, RN, BSN
Guest: Kate Newcomb-DeSanto, MSN, RN, MSW
What does Penn Medicine’s newly-opened patient room facility have to offer? Dr. Charles Turck is joined by Penn Medicine Clinical Advisors Kathy Gallagher and Kate Newcomb-DeSanto to discuss the new pavilion and how it's revolutionizing patient care.
Guest: Jared Nathan Silver, MD, PhD
Guest: Praveen Akuthota, MD
Eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndromes are often mistaken for each other. How can we better distinguish these diseases? Dr. Jared Silver discusses how to diagnose these diseases with Dr. Praveen Akuthota, a pulmonologist from U.C. San Diego Medical Center in California.
This is a non-promotional, non-CME disease state disease education podcast series brought to you by American College of CHEST Physicians in collaboration with and paid for by GSK.
Host: Tom Corbridge, MD, FCCP
Guest: Michael E. Wechsler, MD, MMSc
Severe asthma is an uncontrolled disease that can be difficult to diagnose. To help us overcome this obstacle, Dr. Tom Corbridge joins Dr. Michael Wechsler from National Jewish Health in Denver to discuss the challenges we face while trying to diagnose severe asthma.
This is a non-promotional, non-CME disease state disease education podcast series brought to you by American College of CHEST Physicians in collaboration with and paid for by GSK.
Guest: Steven J. Chmura, MD, PhD
What do we need to know about the ablation of oligometastatic disease? Dr. Steven J. Chmura shares his vantage point on this topic and others from the 2021 San Antonio Breast Cancer Symposium.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Diana Do, MD
Guest: Nathan Steinle, MD
From comorbidities to adverse events, there’s a lot to consider when treating retinal diseases. But are you prioritizing your patient’s preferences? Dr. Diana Do and Dr. Nathan Steinle join Dr. Charles Turck to share strategies to better incorporate your patients’ needs into their treatment plan.
Host: Hyunseok “Hyu” Kang, MD, MPH
Guest: Jochen Lorch, MD
Although multi-kinase inhibitors (MKIs) have been the standard of care for the treatment of thyroid cancer, they produce excessive “off-target” clinical adverse effects and toxicity that limit their use in some patients, leading to drug discontinuation or dose reduction. The introduction of RET inhibitors into the thyroid cancer treatment landscape offers novel, efficacious therapies for patients who previously had limited treatment options.
This online, on-demand educational activity will review RET alterations in thyroid cancer, molecular diagnostic testing, and recent and emerging clinical data on novel therapies targeting RET-altered or RET-driven thyroid cancer. A Virtual Case Clinic Video Exercise will highlight and demonstrate the translation of these RET-targeted therapies into real-world clinical practice for the treatment of patients with thyroid cancer.
Guest: Charles Wykoff, MD, PhD
Learn more about wet or dry retinal diseases and some of their most common challenges from Dr. Charles Wykoff, a board-certified medical and surgical retina specialist and ophthalmologist at Retina Consultants of Texas in Houston.
Host: Jacob Sands, MD
Guest: Millie Das, MD
Getting a better understanding of your patient’s challenges might help you improve their care and streamline the path from diagnosis to treatment. To better understand this, Dr. Jacob Sands sits down with Dr. Millie Das from the Stanford School of Medicine to share strategies to choose the best course of care.
Host: Jennifer Caudle, DO
Guest: Christina Y. Weng, MD, MBA
What treatment options are currently available for retinal diseases—and do we need to reevaluate our standard of care? Dr. Jennifer Caudle is joined by Dr. Christina Weng to take a look at current approaches to management for diabetic retinopathy, diabetic macular edema, wet age-related macular degeneration, and macular edema following retinal vein occlusion.
Host: Mark Socinski, MD
Guest: Vivek Subbiah, MD
RET rearrangements occur in about 1 to 2% of non-small cell lung cancers. Comprehensive genomic testing is critical for identifying these patients and selecting the appropriate treatment option. Find out the exciting progress that has been made with precision oncology in RET+ NSCLC.
Host: Mark Socinski, MD
Guest: Benjamin Levy, MD
With the availability of more immunotherapies for the management of first-line metastatic NSCLC, PD-L1 status takes on greater importance in determining which approach is best for each patient. Follow along as Dr. Mark Socinski and Dr. Benjamin Levy discuss the factors they use when considering either an immuno-monotherapy or immunotherapy plus chemotherapy approach, and how they monitor for and manage immunotherapy-related adverse events.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jeffrey D. Cirillo, PhD
How prevalent is tuberculosis in long-term care facilities? To better understand this, Dr. Charles Turck meets with Dr. Jeffrey Cirillo to examine screening and testing strategies to better monitor TB risk, specifically for high-risk patient populations.
Host: Linda Stein Gold, MD
Guest: Keri Holyoak, PA-C, MPH
When it comes to psoriasis, it’s important to not just treat the skin, but also the patient as a whole. That’s why Dr. Linda Stein Gold and Keri Holyoak are here to discuss the often-overlooked psychosocial burden of psoriasis and how we can talk to our patients about their mental health.
Host: Murray Epstein, MD
Guest: Gates B. Colbert, MD, FASN
Determining the optimal strategies for treating patients with chronic kidney disease (CKD) can be challenging. After decades of waiting, exciting and rapid progress in renin-angiotensin-aldosterone system (RAAS) inhibition is being made, but these therapies can lead to hyperkalemia. The trick is to sustain optimal therapy in the patient without interruption or reduction. Are you familiar with novel potassium binders and recent changes in guideline-directed medical therapy surrounding their use? Tune in because these resources are offering new therapeutic opportunities for your patients with CKD.
Join Drs. Murray Epstein and Gates Colbert to ensure you’re up to date on the latest treatment options for your patients with CKD.
Host: Peter van der Meer, MD, PhD
Guest: Pieter Martens, MD, PhD
Iron deficiency (ID), independent of anemia status, is common in heart failure with reduced ejection fraction (HFrEF). In normal cardiac physiology, contractility increases disproportionally to heart rate; however, in HFrEF and concomitant ID, this response is impaired. Additionally, HFrEF patients with ID who receive cardiac resynchronization therapy (CRT) exhibit diminished cardiac reverse remodeling after CRT implant.
In this discussion, Drs. Martens and van der Meer discuss how physicians can work to improve reverse cardiac remodeling, the force-frequency relationship, and quality of life in patients with HFrEF and ID receiving CRT.
Host: Mark Socinski, MD
Guest: Edward B. Garon, MD, MS
The therapeutic landscape for the first-line treatment of non-driver metastatic NSCLC has become complex and, in some cases, controversial. Based on PD-L1 status, do you know which patients should receive immune checkpoint inhibitor (ICI) monotherapy and when ICI should be combined with chemotherapy? Join Drs. Mark Socinski and Edward Garon as they focus on the intricacies associated with making these therapeutic choices, while also looking at future immunotherapeutic opportunities in the neoadjuvant and adjuvant settings.
Host: David H. Ilson, MD, PhD
This Clinical Case Challenge is designed to assess a learner’s ability to implement appropriate treatment HER2 strategies for patients with gastric cancer.
Host: Jonathan C. Routh, MD, MPH, FAAP
Guest: Benjamin M. Whittam, MD, MS, FAAP, FACS
This Expert Exchange webcast is designed to enhance clinicians’ awareness of advances in the pharmacotherapeutic armamentarium for treating NDO in the pediatric population.
View the Advances in the Treatment of Neurogenic Detrusor Overactivity Clinical Compendium here: https://cdn.reachmd.com/uploads/clinicalcompendium_ndo_v2_final.pdf
Host: Diana Shechtman, OD, FAAO
Guest: Carolyn E. Majcher, OD, FAAO
When it comes to diabetic retinopathy, studies and new data are constantly being published. Are you up to date with the progress being made? Join Dr. Diana Shechtman and Dr. Carolyn Majcher for a discussion on the latest data around the treatment of nonproliferative diabetic retinopathy and how these advances affect the management of your patients.
Guest: Richard Channick, MD
Guest: Vallerie V. Mclaughlin, MD
It can be very challenging to differentiate between WHO Class 1 Pulmonary Arterial Hypertension and WHO Class 3 Pulmonary Hypertension due to Lung Disease or Chronic Hypoxia. Despite similar clinical manifestations, these two conditions are characterized by different hemodynamic definitions and etiologies. Through the use of 2 case studies, clinicians can learn about the diagnosis and management of PAH versus PH due to lung disease or chronic hypoxia.
Host: Michael E. Thase, MD
Guest: Sagar V. Parikh, MD
Depression can cause a multitude of symptoms, many of which are associated with impairment that, if not treated appropriately, can go on for months or even years. With traditional antidepressants having a longer time to onset, the role of rapid-acting agents can greatly improve the quality of life for patients with major depressive disorder (MDD). Dr. Michael Thase and Dr. Sagar Parikh discuss the clinical diagnosis of MDD and the role of emerging neuroactive steroids. Tune in and fasten your seat belt for faster results!
Host: George L. Bakris, MD
Guest: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
Hyperkalemia is common in chronic heart failure and is associated with an increased risk of hospitalization and death. The incidence is further elevated in those with chronic kidney disease, and the presence of hyperkalemia can often lead to clinical delay and suboptimal dosing of RAAS inhibitors in these patients.
Join the discussion as Drs. George Bakris and Giuseppe Rosano examine the management of hyperkalemia in patients with HF and provide individualized approaches for optimizing RAASi therapy. Collaboration between nephrologists and cardiologists is key, and these experts make sure to stress the strong connection between the heart and kidneys when managing these patients.
Host: Joël Guigay, MD, PhD
Guest: Kevin J. Harrington, MD
Formulating individualized treatment plans for patients with recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN) is increasingly essential and increasingly complex. Newer regimens have become the standard of care because of their efficacy in overall survival and reduced toxicities. So how do we deploy them now that they’re in our treatment armamentarium?
Join Drs. Joël Guigay and Kevin Harrington as they explore the role of IO as the standard of care in SCCHN and discuss the potential of taxanes to reduce dependence on fluorouracil-based chemotherapeutic regimens. Tune in to make sure you’re meeting the needs of your patients’ with SCCHN.
Host: Jennifer Caudle, DO
Guest: Jennifer B. Green, MD
What are some ways we can close the gaps in care for patients with diabetic kidney disease? Dr. Jennifer Caudle is joined by Dr. Jennifer Green from the Duke University School of Medicine to explore management challenges and share strategies to optimize care.
Host: Hector O. Chapa, MD, FACOG
Guest: Linda Ahn, MD, FACOG
Amid growing evidence that infection with high-risk HPV can increase the risk of cervical cancer, the American College of Obstetricians and Gynecologists, the American Society for Colposcopy and Cervical Pathology, and the American Cancer Society have all updated their guidelines to help identify patients at risk while reducing unnecessary invasive procedures and over-testing. Joining Dr. Hector Chapa to walk us through these guidelines is board-certified obstetrician/gynecologist Dr. Linda Ahn.
Host: Lisa Baumann Kreuziger, MD, MS
Guest: Marc Carrier MD, FRCPC
Guest: Rachel P. Rosovsky, MD, MPH
Although evidence corroborates the safety and efficacy of managing low-risk patients with VTE in outpatient settings through prophylactic extension, the majority of this subtype is still being treated in hospital settings.
Host: William Mencia, MD, FACEHP, CHCP
Guest: Eliza B. Geer, MD
The primary goals in the medical management of Cushing’s disease are to normalize cortisol levels and reduce or eliminate the associated comorbidities, physical features, and symptoms for our patients. With recently approved therapies and more in development, it really is an exciting time in this treatment space! Tune in to hear Dr. Eliza Geer discuss novel medical options and how we should remember the importance of looking at patient outcomes to make sure we’re addressing Cushing’s disease holistically.
Guest: David H. Ilson, MD, PhD
Guest: Jaffer Ajani, MD
This Expert Exchange webcast is designed to help improve clinicians’ ability to implement appropriate treatment HER2 strategies for patients with gastric cancer.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Laila Woc-Colburn, MD, DTM&H, FACP, FIDSA
What are some ways we can better care for our patients prior to starting biologic therapy? Dr. Charles Turck joins Dr. Laila Woc-Colburn from the Emory University School of Medicine to discuss ways to improve safety for patients with tuberculosis.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Steven W. Pipe, MD
Guest: Giancarlo Castaman, MD
As we continue to explore the role gene therapy may play in treating patients with hemophilia, what do we need to consider? Joining Dr. Charles Turck to share key lessons learned from implementing gene therapy in the clinical trial setting are Drs. Steven Pipe and Giancarlo Castaman.
Host: Sara A. Hurvitz, MD, FACP
Guest: William J. Gradishar MD, FASCO, FACP
Guest: Nancy U. Lin, MD
HER2 is overexpressed and/or amplified in about 20% of breast cancers and signifies aggressive tumor behavior. New anti-HER2 therapies are improving the outlook for advanced or metastatic disease with targeted therapeutics, but while physicians now have a multitude of therapies to choose from, patient-specific characteristics and sequencing still present a challenge.
Tune in to enhance your knowledge and skills with this lively panel discussion examining 2 different patient cases with metastatic breast cancer (mBC). Explore optimal treatment selection based on patient-specific characteristics and ensure that you’re keeping up with the rapidly evolving landscape of HER2+ mBC. Find out what changes can make in your practice today to improve the lives of your patients.
Note that this program follows a previous case-based simulation activity titled “Improving the Standard of Care in Community-Based HER2-Positive Metastatic Breast Cancer.” This panel discussion analyzes choices made in that simulation and expands on optimal recommendations. If you haven’t participated in the simulation and would like to put yourself to the test, you can find the link to the activity in the related section.
Since the recording of this interview, additional data have been released specific to efficacy in certain patient subgroups. To learn more about …
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Sandy Marks
Guest: Kim Horvath, JD
Guest: Kyle Thomson, JD
With telehealth services expanding during the COVID-19 pandemic, has our access to them changed? To better understand this, Dr. Charles Turck meets with Sandy Marks, Kim Horvath, and Kyle Thomson from the AMA to explore what’s been done to provide Medicare coverage during a public health emergency and what’s on the horizon for telehealth access.
Host: Jennifer Caudle, DO
Guest: Vikram V. Bhise, MD
Pediatric multiple sclerosis (MS) occurs in more than 8,000 children in the United States alone, but there’s little data regarding these patients’ quality of life. That’s why Dr. Vikram Bhise recently conducted research to gain a better understanding of pediatric MS patients’ quality of life as they transition into adulthood. And now, Dr. Bhise joins Dr. Jennifer Caudle to share the results that were presented at the 2021 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting.
Host: Stavros Konstantinides, MD, FRCP (Glasg)
Guest: Riyaz Bashir MD, FACC
Guest: Akhilesh Sista, MD, FSIR, FAHA
High risk patients and those with identifiable symptoms are not routinely receiving prophylaxis treatment that could prevent the development of VTE.
Host: Ilene Weitz, MD
Guest: Jamile Shammo, MD, FASCP, FACP
In a “how I do it” clinical commentary, Dr. Jamile Shammo and Dr. Ilene Weitz share their real-world experience in the diagnosis and management of PNH in special patient populations. This case-based activity includes clinical scenarios and treatment strategies to improve patient outcomes.
Guest: Norman E. Lepor, MD
Tune in to hear Dr. Norman Lepor from the UCLA Geffen School of Medicine discuss the role of LDL-C and comorbidities in atherosclerotic cardiovascular disease (ASCVD) risk assessment as well as the limitations of statin treatment.
10/21 121913
Guest: Sara A. Hurvitz, MD, FACP
Are you involved in treating patients with triple negative breast cancer (TNBC)? The emergence of TROP2-directed antibody drug conjugate (ADC) technology has paved the way for exciting new targeted treatment approaches for patients with TNBC.
What are the latest data with these ADCs? Why is TROP2 an effective target in TNBC? How do we best incorporate these TROP2-targeted ADCs into TNBC care? This expert-led recording from a series of national visiting lecture series updates clinicians on how recently approved and investigational ADCs overcome current challenges in TNBC treatment. This activity also reviews patient cases that incorporate the latest clinical evidence and recommendations. The activity includes excerpts from the live question and answer session as well as downloadable resources to improve care for your patients with TNBC.
Host: Jennifer Caudle, DO
Guest: Kevin Black, MD
Hallucinations and delusions cause a significant number of hospitalizations and nursing home admissions for our patients with Parkinson’s Disease. Listen to Dr Kevin Black share his approach to timely diagnosis and evidence-based management that can improve the daily lives of these patients and their caregivers.
Kevin Black, MDProfessor of Psychiatry, Neurology, Radiology, and Neurobiology
Washington University in St Louis School of Medicine
St Louis, Missouri
Host: Mimi Secor, DNP, FNP-BC, FAANP
Guest: Maria Trent, MD, MPH, FAAP, FSAHM
There are gaps in resources available to care for patients with mycoplasma genitalium (MGen). Since access to testing and to resistance testing are critical to be able to properly care for women suspected of having MGen, Dr. Mimi Secor talks with Dr. Maria Trent from Johns Hopkins School of Medicine about how clinicians can overcome common diagnostic and treatment challenges and shares guidelines updates from the CDC.
Host: Mimi Secor, DNP, FNP-BC, FAANP
Guest: Maria Trent, MD, MPH, FAAP, FSAHM
Dr. Mimi Secor is joined by Dr. Maria Trent to discuss mycoplasma genitalium (MGen), how we can better understand this infection and help reduce our patients' risk of it.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Emily Carroll, JD, MSW
The No Surprises Act aims to protect consumers from surprise medical bills. But how exactly does it go about doing that, and what’s the current status of its implementation? Joining Dr. Charles Turck to share progress and challenges associated with the No Surprises Act is Ms. Emily Carroll, a senior legislative attorney for the American Medical Association's Advocacy Resource Center.
Host: Peter Libby, MD
Guest: Lawrence A. Leiter, MD
Guest: Prof. Kausik Ray, MBChB, MD, MPhil
This CME Roundtable highlights key takeaways and late-breaking data shared at a symposium held at the AHA annual meeting. Hear updated management strategies, new data, and guidelines to help you manage patients with established ASCVD who are at an increased risk of myocardial infarction, stroke, and death.
Guest: Adam M. Brufsky, MD, PhD
Guest: Nina Thomas, MD
Interstitial lung disease (ILD) is a heterogeneous group of diseases that produce inflammation and fibrosis of the parenchyma, affecting the alveolar, interstitial, and vascular spaces. Drug-induced (DI) ILD is associated with a range of novel targeted therapies for the treatment of multiple cancer types, including immune checkpoint inhibitors, CDK 4/6 inhibitors, EGFR tyrosine kinase inhibitors, HER2 targeted therapies, and mechanistic target of rapamycin inhibitors.
Although management of low-grade or asymptomatic ILD with corticosteroid treatment and/or treatment interruption may slow or reverse ILD progression, higher-grade/symptomatic ILD requires permanent discontinuation of therapy. Therefore, it is critical that the interprofessional care team is prepared to monitor for and detect anti-cancer therapy–induced ILD. This educational activity will review the latest evidence and strategies for the early detection of medication-induced ILD and pneumonitis and appropriate management strategies to overcome these treatment challenges in patients who receive select anti-cancer therapies. Expert thought leaders will present relevant information about cancer therapy–induced ILD and pneumonitis and how to integrate the latest advances into real-world clinical practice regarding differential diagnosis, hallmark signs/symptoms, recommended management strategies, implications of patient/caregiver education, and the essentials of team-based management to optimize patient outcomes.
Host: Clete A. Kushida, MD, PhD
Guest: Lois E. Krahn, MD
Tune in to hear about new treatments for patients with narcolepsy. Data were recently presented at the American College of Chest Physicians Annual Meeting, and Drs. Clete Kushida and Lois Krahn are breaking it down for you: they examine the evolving treatment landscape and dive into the latest research on currently available and emerging pharmacologic options including the expanding range of oxybate therapies. Join us and find out why it’s such an exciting time to be caring for patients with narcolepsy.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Andrea S. Lukes, MD, MHSc, FACOG
By 50 years of age, 70% to 80% of women are affected by uterine fibroids, and nearly 10% of women are affected by endometriosis. Clinical trial data demonstrate that GnRH antagonist therapy can dramatically impact pain and bleeding and improve results across all EHP-30 domains. Join Drs. Lee Shulman and Andrea Lukes as they dive into these data and offer strategies to help you better incorporate patient-centric medical management for uterine fibroids and endometriosis into your clinical practice.
Host: Jacob Sands, MD
Guest: Suneeta Senapati, MD, MSCE
Guest: Mindy Christianson, MD
Patients undergoing treatments such as chemotherapy may be at significant risk of impairment or inability to have children later in life. This risk impacts both men and women equally, but fortunately, the field of oncofertility can help guide patients as they navigate their fertility options prior to cancer treatment. Here to share their insights on this emerging field with Dr. Jacob Sands are Dr. Mindy Christianson and Dr. Suneeta Senapati.
Host: Daniel P. Petrylak, MD
Guest: Arlene O. Siefker-Radtke, MD
It's critical that we select and sequence appropriate therapeutics to provide our patients with the best possible outcomes. Dr. Petrylak and Dr. Siefker-Radtke provide a rundown of multiple disease factors to consider, evolving clinical trial data, and the various therapeutic options available in the second and subsequent lines of therapy for patients with locally advanced or metastatic urothelial carcinoma. With so many new treatment options now available and a cure becoming a real possibility, we invite you to tune in to find out if your treatment strategies are on target.
Host: Jennifer Caudle, DO
Guest: Sarah Ali, MD
From working in a big city to taking on an assignment in a small mountain village, Dr. Sarah Ali from the Ventura County Medical Center joins Dr. Jennifer Caudle to talk about her adventures abroad with locum tenens and share key lessons she learned along the way.
Host: Mark Socinski, MD
Guest: Justin Gainor, MD
With an expanding arena of available selective RET inhibitors and more data being released on emerging therapies, the landscape for patients with RET-positive metastatic NSCLC is evolving rapidly. Join Drs. Mark Socinski and Justin Gainor as they review the importance of molecular testing in every patient, as well as when to initiate the use of selective RET-inhibitors across multiple lines of therapy. Did we mention you should be testing every patient? Tune in to make sure you’re identifying everyone who can benefit from these newer therapies.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Maryam Lustberg, MD, MPH
Can cardiac rehabilitation programs play a role in the management of breast cancer survivors? Dr. Maryam Lustberg, Chief of Breast Medical Oncology and the Director of The Breast Cancer Center at Smilow Yale Cancer Center, shares the common risk factors between cardiovascular disease and cancer and why these types of programs are beneficial to patient care.
Guest: Daniel O. Persky, MD
From updates in combination therapy to developments in novel agents, Dr. Daniel Persky shares what he expects to see for chronic lymphocytic leukemia and mantle cell lymphoma from the American Society of Hematology’s 63rd Annual Meeting and Exposition.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Andrew H. Lipsky, MD
Dr. Charles Turck is joined by Dr. Andrew Lipsky to examine the mechanisms contributing to acquired resistance in CLL and MCL targeted therapies and outline strategies to prevent this resistance.
Guest: Michael Wang, MD
What can we look forward to seeing at the 63rd American Society of Hematology Annual Meeting and Exposition? Dr. Michael Wang shares anticipated updates in mantle cell lymphoma, or MCL.
Guest: Ashley Moncrief, RN, BSN
Guest: Natasha Johnson, MSN, APRN, AOCNP
Tune in to hear nurse practitioners Ms. Natasha Johnson and Ms. Ashley Moncrief discuss myelodysplastic syndromes (MDS), a rare type of blood cancer, and how it is classified and identified. Together, they share personal experiences from their practices and tips for conversations with MDS patients about their care.
© TAIHO ONCOLOGY 11/2021 INQ-PM-US-0390
Guest: Patty Bobryk, MHS, PT, MSCS, ATP
A multidisciplinary approach to multiple sclerosis (MS) is becoming more and more integral in practice as research continues to emerge on its significance. That’s why physical therapist Ms. Patty Bobryk is here to debrief us on some highlights from the rehabilitation track at the 2021 Consortium of Multiple Sclerosis Centers (CMSC) that focused on collaborative care.
Guest: Rami Komrokji, MD
Guest: Natasha Johnson, MSN, APRN, AOCNP
Myelodysplastic syndromes (MDS) can require lifelong treatment.1 Learn how hematologist-oncologist Dr. Rami Komrokji and nurse practitioner Ms. Natasha Johnson approach their MDS protocol–from characterization, to diagnosis, to treatment. Together, they explain their process for scoring, transplants, and choosing a treatment regimen. They also share their experiences with INQOVI® (decitabine and cedazuridine), the only oral hypomethylating agent in the treatment of MDS, including chronic myelomonocytic leukemia.2
References: 1. Platzbecker U. Treatment of MDS. Blood. 2019;133(10):1096-1107. 2. INQOVI [package insert]. Princeton, NJ: Taiho Oncology, Inc.; 2022.
Host: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Javed Butler, MD, MBA, MPH
Guest: Marco Metra, MD
Guest: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
In the management of patients with heart failure, foundational therapy is critical to improving patient outcomes. Are you up to date on the latest recommendations concerning MRAs, ACEI/ARBs/ARNI, beta-blockers, and SGLT2 inhibitors? Recent updates to the ESC/HFA guidelines, heart failure clinical trials, and the COVID-19 pandemic have impacted the way we manage our patients, so tune in to keep up with the latest developments.
Our experts, Drs. Ileana Piña, Javed Butler, Marco Metra, and Giuseppe Rosano, discuss the ESC/HFA guideline updates and how these changes impact the clinical considerations for managing recurrent hyperkalemia and the recommended foundational therapy for patients with heart failure.
Guest: Vivian Shi, MD, FAAD
Atopic dermatitis is one of the most common chronic inflammatory skin diseases in America, especially among African American and Asian American patients. However, several factors contribute to the misdiagnosis and underdiagnosis of atopic dermatitis among these patients, which is why Dr. Vivian Shi is here to shed light on those factors as well as the key signs and symptoms of atopic dermatitis in patients with skin of color.
VERSION 1.0 | NOVEMBER 2021 | ABBV-US-00686-MC
Guest: Patty Bobryk, MHS, PT, MSCS, ATP
The rehabilitation track at the 2021 Consortium of Multiple Sclerosis Centers (CMSC) was filled with key updates regarding collaboration, nonpharmaceutical symptom management strategies, and more. And Ms. Patty Bobryk, a physical therapist at Yampa Valley Medical Center, is here to review those updates with us.
Host: Jennifer Caudle, DO
Guest: Mark Socinski, MD
Dr. Mark Socinski from the AdventHealth Cancer Institute in Florida joins Dr. Jennifer Caudle to discuss a patient profile in the treatment of relapsed small cell lung cancer to help us better understand the burden of this disease and how to approach treating patients in the second-line setting with treatment options like ZEPZELCA.
Guest: Vivian Shi, MD, FAAD
Atopic dermatitis affects patients’ lives in a way that goes beyond just visible symptoms. In fact, many patients with atopic dermatitis also suffer from anxiety, depression, and attention deficit hyperactivity disorder. That’s why Dr. Vivian Shi is here to review available tools that can help us assess the severity of the visible and invisible impacts of atopic dermatitis.
VERSION 2.0 | DECEMBER 2021 | ABBV-US-00687-MC
Guest: Azra Raza, MD
Guest: Rami Komrokji, MD
Listen to hematologist-oncologists Drs. Rami Komrokji and Azra Raza discuss myelodysplastic syndromes (MDS). Together, they explain the classification system for diagnosing this rare blood disorder and touch upon current events in the space and the impact on patients living with MDS.
© TAIHO ONCOLOGY 11/2021 INQ-PM-US-0384
Host: Mikhail Kosiborod, MD
Guest: Javed Butler, MD, MBA, MPH
Guest: Matthew R. Weir, MD
Renin-angiotensin-aldosterone system inhibition (RAASi) is the foundation of guideline-directed medical therapy (GDMT) for heart failure patients. However, due to practice gaps, a significant proportion of the population requiring its use do not experience the benefits of RAASi therapy, which is especially true for patients with comorbid conditions. Hyperkalemia is a common adverse effect of RAASi therapy that needs to be anticipated and mediated so that the optimal dosing of necessary medications can occur. Maximizing GDMT in the face of hyperkalemia remains a key clinical challenge that, if not handled properly, can result in increased morbidity and mortality.
In this activity, Drs. Javed Butler, Mikhail Kosiborod, and Matthew Weir review a patient case and discuss different treatment approaches to optimize GDMT while managing hyperkalemia. Tune in to make sure you’re doing all you can to improve outcomes for your patients with heart failure and comorbid conditions.
Host: Jennifer Caudle, DO
Guest: Cheryl Campos, DNP, RN-BC, CEN, CPHQ
Difficult IV access (DIVA) is a term used to describe patients who require multiple attempts to cannulate a vein. And since the prevalence of DIVA can be as high as 59 percent, Dr. Jennifer Caudle speaks with Dr. Cheryl Campos about how we can better identify high-risk patients, how we can manage DIVA patients, and more.
Host: Lauren Ritterhouse, MD ,PhD
Guest: Pasi Antero Jänne, MD, PhD
Guest: Kanwal Raghav, MD
HER3 is the new marker on the block, but is it diagnostic, predictive, or prognostic? Hear from the experts, Drs. Lauren Ritterhouse, Pasi Jänne, and Kanwal Raghav, as they explore the role of HER3 in oncogenesis and resistance to EGFR TKIs. Find out how we can now target HER3 signaling in metastatic solid tumors through the use of emerging HER3-targeted therapies along with novel and exciting antibody-drug conjugate studies and strategies.
*Since the recording of this activity, clinical trial NCT04479436, patritumab deruxtecan in colorectal cancer, has been terminated early. To learn more about this trial, search for NCT04479436 on ClinicalTrials.gov.
Host: Jacob Sands, MD
Guest: Tejas Patil, MD
What kind of role does next-generation sequencing play in HER2-mutated non-small cell lung cancer? Dr. Jacob Sands is joined by Dr. Tejas Patil from the University of Colorado Medicine to explore the clinical utility of NGS and highlight opportunities to expand molecular testing into clinical practice.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Manish Thapar, MD, AGAF, FAASLD, FACG
Acute hepatic porphyria (AHP) is a rare genetic condition characterized by severe, diffuse abdominal pain and a broad range of seemingly unrelated symptoms. AHP presents differently in each patient, with symptoms that mirror those of more common conditions, making it difficult to diagnose. Although AHP can be misleading, it can be easy to detect once you know what to look for. Joining Dr. Charles Turck to discuss AHP signs and symptoms and when a doctor should consider AHP in a patient is porphyria expert Dr. Manish Thapar, gastroenterologist and associate professor of medicine in Philadelphia.
©2021 Alnylam Pharmaceuticals, Inc. All Rights Reserved. AS1-USA-01069
Host: Javed Butler, MD, MBA, MPH
Guest: Ileana L. Piña, MD, MPH, FAHA, FACC
Not all patient subgroups respond to medication the same way, making equal representation in clinical trials essential. Dr. Javed Butler is joined by Dr. Ileana Piña, a Heart Failure Cardiologist and Clinical Professor of Medicine at Central Michigan University, to talk about how we can improve diversity in cardiovascular clinical trials.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Caren Heller, MD, MBA
For patients living with IBD, paying special attention to their nutrition is paramount. So which is more effective for IBD patients with mild-to-moderate symptoms: a Mediterranean style diet or the Special Carbohydrate diet? That’s what the Diets to Induce Remission in Crohn's Disease (DINE-CD) study sought to find out, and now the results are in. Join Dr. Peter Buch as he explores the study's key findings with Dr. Caren Heller, Chief Scientific Officer at the Crohn's and Colitis Foundation.
Guest: Peter Goadsby, MD, PhD, DSc
Guest: Kathleen B. Mullin, MD
Women with migraine have unique needs that often remain undermanaged. Have you taken a critical look at the standard of care and how current treatment strategies have recently shifted? Groundbreaking research on the calcitonin gene-related peptide (CGRP) pathway has led to the development of new medications that act on the specific cascade of inflammatory response associated with migraine. Also called gepants, the CGRP receptor antagonists confer clinical benefit to patients who seek better control of their migraines.
Tune in to this Women’s Health 2021 program to hear our experts, Drs. Peter Goadsby and Kathleen Mullin, discuss the diagnosis of migraine with a focus on the recent evolution of acute and preventive treatment strategies and the role of gepants. Are you doing all you can to ensure that your patients’ needs are optimally addressed?
Host: Neilanjan Nandi, MD, FACP
Guest: Sergio Schwartzman, MD
Inflammatory bowel disease (IBD) has long been associated with the development of arthritis, which can be detected in up to 30 percent of IBD patients. So how can gastroenterologists and rheumatologists work together to detect and manage IBD-associated arthritis? To find out, Dr. Neil Nandi speaks with rheumatologist Dr. Sergio Schwartzman about IBD-associated arthritis.
Host: Jerome Lisk, MD
Guest: Tissa Wijeratne MD PhD FRACP FRCP FAAN
Since the onset of the COVID-19 pandemic, researchers and clinicians alike have strived to address the mysteries surrounding the virus, including its long-term side effects on patients. So what we do need to know about the emerging syndrome pointing to COVID-19’s neurological and cognitive impacts? To find out, Dr. Jerome Lisk is joined by Dr. Tissa Wijeratne, the Director of the Department of Neurology and Stroke Services at the University of Melbourne, to talk about post-COVID-19 neurological syndrome.
Guest: Maureen Brogan, MD
From emerging treatment options to finding new ways to combat healthcare disparities, a lot was covered at the 2021 American Society of Nephrology (ASN) Annual Meeting. And here to talk about some of the latest updates is Dr. Maureen Brogan, an Associate Professor of Medicine at Albert Einstein College of Medicine and the Clinical Director in the Division of Nephrology at Montefiore Medical Center.
Guest: Maureen Brogan, MD
The COVID-19 pandemic has impacted care across all specialties, and the 2021 American Society of Nephrology (ASN) Annual Meeting offered a platform for nephrologists to share their experiences. Tune in to hear how Dr. Maureen Brogan adapted her practice to overcome supply and staffing shortages.
Guest: Maureen Brogan, MD
By focusing on patient-driven kidney care, innovation can emerge. Here to review this topic that was featured at the 2021 American Society of Nephrology (ASN) Annual Meeting is Dr. Maureen Brogan, an Associate Professor of Medicine at Albert Einstein College of Medicine and the Clinical Director in the Division of Nephrology at Montefiore Medical Center.
Host: Misako Nagasaka, MD, PhD
One area of recent progress in the treatment of non–small cell lung cancer (NSCLC) is the development of HER2 targeted therapies for the rare, emerging genetic variant, ERBB2 (HER2) mutations. In fact, the NCCN lists ERBB2 (HER2) mutations as an emerging biomarker to identify novel therapies for patients with metastatic NSCLC. The HER2-directed antibody-drug conjugates (ADC) ado-trastuzumab emtansine (T-DM1) and fam-trastuzumab deruxtecan-nxki are now listed as available targeted agents with activity against HER2 mutations. ADCs with other targets such as Trop-2 and HER3 are now also under investigation and showing promise in NSCLC. ADCs have the potential to increase treatment choices for patients with mNSCLC.
For practicing clinicians, this evolution of HER2-directed therapy and ADCs will add to the complexity of NSCLC treatment. This activity will review the emerging role and potential application of ADCs in mNSCLC, including HER2 as a target in NSCLC, biomarker testing, HER2-, HER3-, and TROP2-targeted ADCs, available clinical data on safety and efficacy, evidence-based guideline recommendations, and how newer targeted agents may fit into the treatment paradigm for patients with mNSCLC.
Host: Mark Socinski, MD
Guest: John V. Heymach, MD, PhD
FLAURA and RELAY have changed the landscape of treatment in EGFR-mutant advanced non-small cell lung cancer (NSCLC). But how do know which patients will benefit from these important advances in our knowledge of treating these cancers in the first and subsequent lines of therapy? Join Drs. Mark Socinski and John Heymach as they examine a patient case and discuss the “art” of treatment selection and sequencing of therapy. They also dive into recent advances in the dual blockade of antiangiogenics and TKIs in the frontline setting. Tune in to keep up!
Host: Anita H. Clayton, MD
Guest: Nancy Byatt, DO
Guest: Jennifer L. Payne, MD
In this panel discussion, Drs. Anita Clayton, Jennifer Payne, and Nancy Byatt walk us through two clinical cases of postpartum depression. Listen in as they discuss optimal strategies to screen, diagnosis, and treat patients, as well as go over the newer class of medications specifically targeted at treating PPD.
Guest: John Friedewald, MD
The 2021 American Society of Nephrology Annual Meeting covered everything from inequities in organ allocation to policy updates. Here to share those and other key takeaways from the conference is Dr. John Friedewald, Professor of Medicine and Surgery at the Northwestern University Feinberg School of Medicine.
Guest: Howard (Jack) West, M.D.
For patients with advanced non-small cell lung cancer, broad molecular testing can be both a solution and a challenge. Here to share key challenges for next-generation sequencing is Dr. Jack West, Associate Clinical Professor at the City of Hope Comprehensive Cancer Center in California.
Host: Hector O. Chapa, MD, FACOG
Guest: Sandra Misale, MD
As the treatment landscape continues to evolve, what do we need to know about current treatment challenges and novel therapeutic options? Dr. Hector Chapa is joined by Dr. Sandra Misale to explore emerging therapies in HER2-mutated non-small cell lung cancer.
Guest: Nicolas Girard, MD
Guest: Alex Spira, MD, PhD, FACP
While the management and treatment of HER2-mutated non-small cell lung cancer continues to evolve, patients still face many unmet needs. Dr. Nicolas Girard, a pneumologist and Professor of Respiratory Medicine at Versailles Saint Quentin University, explores these unmet needs and how we can solve them.
Guest: Banu Arun, MD
Here to give highlights from the “Finetuning Risk Assessment and Risk Reduction” session at the 2021 San Antonio Breast Cancer Symposium (SABCS) is Dr. Banu Arun, Professor of Breast Medical Oncology at the University of Texas MD Anderson Cancer Center and Executive Director of Cancer Genetics for the MD Anderson Cancer Networks.
Host: Jacob Sands, MD
Guest: Nicole Lamanna, MD
When determining a patient’s therapy regimen, what disease-related factors do we need to keep in mind? Dr. Nicole Lamanna, a Hematologist/Oncologist at Columbia University Medical Center, share strategies for tailoring chronic lymphocytic leukemia treatment and how that can impact patient outcomes.
Guest: John C. Byrd, MD
For patients with chronic lymphocytic leukemia, molecular analysis can provide critical information. Dr. John C. Byrd discusses the importance of IGHV and TP53 sequencing and the clinical value they provide.
Host: Hector O. Chapa, MD, FACOG
Guest: Alexander W. Pastuszak, MD, PhD
Despite the fact that there’s no evidence showing any correlation between COVID-19 vaccines and fertility risks, many patients are still concerned. So how did this myth become so prominent, and how can we talk to our patients about it? Join Dr. Hector Chapa and Dr. Alex Pastuszak as they dive deep into this myth.
Host: Anita L. Nelson, MD
How confident are you in determining which of your patients with endometriosis are suitable candidates for medical intervention? Do you ask about each patient’s goals and preferences? Have you heard about the paradigm shift occurring in the medical management of endometriosis?
While medical management of endometriosis is often a secondary consideration to surgery, it should often be the first line of treatment. Join Dr. Anita Nelson as she discusses long-standing and novel medical strategies for managing endometriosis. Find out how you can use shared decision-making strategies to help you provide more options to your patients. Join us and take an important first step that can improve outcomes and quality of life for your patients while enabling them to make educated decisions about their immediate and long-term treatment.
Host: Javed Butler, MD, MBA, MPH
Guest: Piotr Ponikowski, MD, PHD, FESC, FHFA
In this video, Drs. Javed Butler and Piotr Ponikowski discuss the clinical significance of iron deficiency in patients suffering from heart failure with reduced ejection fraction. They also take a close look at the key updates to the 2021 ESC/HFA guidelines. Tune in to stay up to date with the latest recommendations.
Host: Anita L. Nelson, MD
In this Women’s Health 2021 lecture, Dr. Anita Nelson discusses why uterine fibroids are such a high priority for both women and their clinicians. Listen in as she shares strategies to engage patients in discussions about their fibroid symptoms and their preferences for treatment. Dr. Nelson also evaluates the latest evidence on the mechanisms of action, safety, and efficacy of the newer class of therapies that are now available and can improve the quality of life for women with fibroids.
Host: John J. Russell, MD
Guest: Randy C. Miles, MD, MPH
Are enlarged lymph nodes caught on CT scans following mRNA vaccination cause for concern? Or is it just a case of incidentaloma? Joining Dr. John Russell to answer those and other key questions regarding the link between COVID-19 vaccines and abnormal mammogram findings is Dr. Randy C. Miles.
Host: Jennifer Caudle, DO
Guest: Erik Munson, Ph.D
Mycoplasma genitalium (M. gen) is an STI that shares similar health consequences to chlamydia and gonorrhea. Further complicating this health threat is the fact that there’s been little guidance on how to manage this new pathogen until recently when the 2021 STI Treatment Guidelines were released. Joining Dr. Jennifer Caudle to talk about M. gen and why the guidelines recommend the use of nucleic acid amplification tests for the diagnosis of this pathogen is Dr. Erik Munson, an Assistant Professor of Clinical Laboratory Science at Marquette University.
Host: Jennifer Caudle, DO
Guest: Drew Weissman, MD, PhD
mRNA vaccines are one of the latest developments in medicine, but researchers have been evaluating mRNA technology for years. One of those researchers, Dr. Dr. Drew Weissman, Professor of Medicine at the Perelman School of Medicine at the University of Pennsylvania, joins Dr. Jennifer Caudle to talk about his role in the research and development of mRNA vaccines as well as what’s on the horizon for them.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Erica E. Marsh MD, MSCI, FACOG
Hear from Dr. Erica Marsh and Dr. Lee Shulman as they discuss the burden, prevalence, and treatment of uterine fibroids and endometriosis and the disproportionate impact these conditions have on vulnerable populations. Learn how to prioritize early diagnosis and treatment to improve outcomes for your patients; as well as evaluating barriers to proper diagnosis and treatment
Our experts offer strategies to guide discussions beyond surgical treatment approaches to include pharmacotherapeutic options such as GnRH agonists and new oral GnRH antagonists. Open communication with patients allows them to carefully consider symptom severity, risks, and fertility preferences to optimize treatment outcomes and patient satisfaction. Tune in to make sure that you’re really doing all you can for your patients.
Host: Mark Socinski, MD
Guest: Edward B. Garon, MD, MS
In the treatment of EGFR-mutated advanced non-small cell lung cancer (NSCLC), when is an EGFR TKI not enough? Answer: When you don’t have all of the information. Digging deeper into the specific EGFR mutations has led to advances in the dual blockade of VEGF and EGFR in the frontline setting. Join Drs. Mark Socinski and Edward Garon as they discuss the evolving role of EGFR and VEGF blockade based on clinical trial data. Find out how you can have an immediate impact on your patients by making targeted treatment decisions based on specific oncogenic driver mutations in NSCLC. Be sure to keep up with our experts because making the right choice is more critical than ever.
Host: Anita H. Clayton, MD
Listen in as Dr. Anita Clayton takes us through the importance of screening for postpartum depression (PPD) and reaching an early diagnosis in the perinatal and postnatal stages of pregnancy. This Women’s Health 2021 lecture also covers the exciting new agents that are targeted specifically for PPD. Find out how they compare to the traditional antidepressants and how they can improve the quality of life for your patients with PPD.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Thomas Kipps, MD, PhD
What do the NCCN guidelines recommend for the management of patients with chronic lymphocytic leukemia, or CLL, and mantle cell lymphoma, or MCL? Dr. Charles Turck is joined by Dr. Thomas Kipps to talk about prognostic risk indicators, current therapeutic agents, and adverse events for patients with CLL and MCL.
Guest: Lindsey Roeker, MD
As the field of chronic lymphocytic leukemia continues to evolve, what we can look forward to seeing at the 63rd American Society of Hematology Annual Meeting and Exposition? Dr. Lindsey Roeker shares what she expects to see at this year’s ASH meeting.
Guest: Thomas Kipps, MD, PhD
Has the COVID-19 pandemic limited our treatment options for patients with mantle cell lymphoma? To answer this, Dr. Thomas Kipps reviews key treatment challenges and considerations for these patients amid the ongoing pandemic.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Rachael Consoli, MD, MPH, FACOG
With years of missionary work under her belt, one OB-GYN is fighting to reduce maternal mortality in underserved communities around the world. Dr. Charles Turck is joined by Dr. Rachel Consoli, an OB-GYN surgeon and Hospitalist based at North Shore Medical Center, to share stories from her time serving medical missions around the globe.
Host: Hector O. Chapa, MD, FACOG
Guest: Sandra Misale, MD
Did you know that HER2 mutations can be found in about 4 percent of patients with non-small cell lung cancer (NSCLC)? Although it’s not a very common genetic event, it’s still important to know how these mutations drive disease progression and how you can treat these NSCLC patients. That’s why Dr. Sandra Misale joins Dr. Hector Chapa to explore the clinical features and characteristics of HER2 mutations along with the available therapeutic options.
Host: Nabil F. Saba, MD
Couldn’t attend the 2021 European Society of Medical Oncology (ESMO) Conference? No worries—ReachMD host Dr. Nabil Saba is here to share the latest updates in head and neck cancer from the 2021 ESMO Conference.
Guest: Cynthia Leifer, PhD
In the midst of a global pandemic, where do vaccine ethics come into play? Dr. Cynthia Leifer, a Professor of Immunology at Cornell University, reviews diversity in clinical trial, the impact of vaccine mandates, and more.
Guest: Cynthia Leifer, PhD
With variants continuing to emerge, how are the COVID-19 vaccines faring. Here to share how these vaccines are holding up—and what that means for future variants—is Dr. Cynthia Leifer, Professor of Immunology at Cornell University.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Onyema Ogbuagu MBBCh, FACP, FIDSA
With so many questions and confusion points surrounding booster shots, what do we need to know? Dr. Charles Turck is joined by Dr. Onyema Ogbuagu, Associate Professor in the section of Infectious Diseases at Yale University School of Medicine, to answer common questions regarding the COVID-19 vaccine booster shots.
Guest: Jeniffer Hernandez, PhD
mRNA vaccines are far from the only emerging technology out there. Dr. Jeniffer Hernandez, Associate Professor of Biopharmaceutical Sciences at the Keck Graduate Institute, reflects on where vaccine technology is headed.
Guest: John Friedewald, MD
Could novel technologies like noninvasive biomarkers help us achieve the goal of “one kidney for life”? Find out with Dr. John Friedewald, Professor of Medicine and Surgery at the Northwestern University Feinberg School of Medicine, as he shares the latest developments that can help monitor patients with kidney transplants.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Leslie Cooper, Jr., MD
Can COVID-19—along with its vaccines—impact the heart? Dr. Charles Turck is joined by Dr. Leslie Cooper, a myocarditis expert and chair of the Department of Cardiovascular Diseases at Mayo Clinic in Florida, to investigate the cardiac impacts of COVID-19 and the COVID-19 vaccines. For more information about referring a patient to Mayo Clinic, please visit mayoclinic.org.
Host: Matt Birnholz, MD
Guest: Ripal Patel, MD, MPH
Locum tenens can take you on an exciting journey, but you may encounter a few horror stories along the way. Joining Dr. Matt Birnholz to share his own challenging experiences—and how we can avoid them—is Dr. Rip Patel, founder and lead for Mercision Emergency Medicine, and Assistant Professor at the Baylor College of Medicine in Houston, Texas.
Host: Roger S. McIntyre, MD, FRCPC
Guest: Charles L. Raison, MD
This patient-provider role play webcast is designed to provide clinicians with effective communication strategies for discussing long-acting injectable antipsychotics with patients in a variety of scenarios.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Mark Blatter, MD
Despite their crucial role in preventing seasonal influenza, traditional influenza vaccines may not be providing as much protection as we thought, leading researchers to take a look at different methods of vaccine production, specifically cell-based flu vaccine production. Here with Dr. Charles Turck to discuss influenza prevention and the latest evidence supporting a cell-based vaccine option is Dr. Mark Blatter.
USA-QIVc-21-0146 November 2021
Host: Roger S. McIntyre, MD, FRCPC
Guest: Martha Sajatovic, MD
This Expert Exchange webcast is designed to help clinicians determine the appropriate time to initiate LAI therapy in patients with bipolar disorder, and how to discuss that treatment decision with patients.
Host: Jacob Sands, MD
Guest: Joseph Tuscano, MD
While lymphoma can sometimes be difficult to treat, emerging therapies and clinical developments are on the horizon. But could they help improve patient outcomes? Dr. Jacob Sands is joined by Dr. Joseph Tuscano, Physician and Professor of Hematology and Oncology at UC Davis Comprehensive Cancer Center to talk about updates in Lymphoma treatment.
Host: Gregg C. Fonarow, MD
Guest: Andrew J. S. Coats, MD
Rapid initiation and up-titration of renin-angiotensin-aldosterone system inhibitor (RAASi) therapy is critical in the management of heart failure, especially given the prevalence of comorbid conditions, such as recurrent hyperkalemia, in these patients. To improve patient outcomes, it is crucial that physicians avoid any unnecessary halting or dose reductions to these medications.
In this discussion, Drs. Coats and Fonarow review updates to the ESC/HFA guidelines and explain how these changes affect patient care. Find out how to maintain optimal RAASi therapy for your patients with heart failure in the face of their challenging comorbidities.
Host: Jacob Sands, MD
Guest: Howard (Jack) West, MD
Guest: Nicolas Girard, MD
How can we better diagnose and treat patients with HER2-mutated non-small cell lung cancer? Dr. Jacob Sands is joined by Dr. Nicolas Girard and Dr. Jack West to explore diagnostic and therapeutic challenges and share collaborative patient management strategies for these patients.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Hassan Bencheqroun, MD
Evaluating the need for therapy escalation can be challenging. So joining Dr. Charles Turck to help us understand how to escalate treatment for patients with chronic obstructive pulmonary disease is Dr. Hassan Bencheqroun, Assistant Professor of Medicine at the University of California Riverside School of Medicine.
This is a non-promotional, non-CME disease state disease education podcast series brought to you by American College of CHEST Physicians in collaboration with and paid for by GSK.
Host: Jeffrey S. Weber, MD, PhD
Approximately half of metastatic cutaneous melanomas carry mutations in BRAF, leading to more aggressive disease. For patients with BRAF V600–activating mutations, treatment options now include the use of combination targeted therapy with BRAF and MEK inhibitors, and combination targeted therapy and immunotherapy. However, even with guideline recommendations, the optimal treatment selection and sequencing is unclear, and additional combination strategies continue to be studied in clinical trials.
In this activity, expert faculty will review and evaluate combination strategies for the treatment of BRAF V600–activating mutation–positive metastatic melanoma, including considerations for treatment selection, sequencing, and management of associated toxicities.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Animesh Ray, PhD
Getting ahead of the next pandemic may be possible thanks to deep machine learning’s ability to predict the structure of antibodies. And while that may sound like science fiction, this technology is currently being studied, which is why Dr. Animesh Ray from the Keck Graduate Institute joins Dr. Charles Turck to provide insight on where the research currently lies and what we have to look forward to.
Host: Michael Greenberg, MD
Host: Matthew S. Keller MD
As clinicians, we often need to address our patients’ emotional health just as much as their physical health, and bedside manner plays a big part in that. So to help ensure our patients are getting the most out of their visits, Drs. Matthew Keller and Michael Greenberg come together in this two-part discussion to share their tips for improving bedside manner.
Host: Jennifer Caudle, DO
Guest: Melodie Young, MSN
Plaque psoriasis is canonically characterized by red, scaly, well demarcated plaques; however, the impact of this chronic systemic disease cannot be fully understood by the extent of skin involvement alone. Moderate psoriasis can have a large impact on patients due to factors such as involvement of special areas (such as the scalp) and persistent itching. Reaching a better understanding of these patients requires looking beyond skin involvement, assessing all aspects of disease, and considering patient perspectives.
Ms. Melodie Young, a Nurse Practitioner specialist of dermatology, joins Dr. Jennifer Caudle to give us deeper insight into this systemic disease, the potential impact on patients with moderate disease, and important aspects of psoriasis to consider in disease assessment.
USA-407-81472
Host: Michael Greenberg, MD
Host: Matthew S. Keller MD
How do you respond when your patient’s frustrations—and even perhaps your own—creep into a visit? And how can you incorporate professional intimacy into your practice? Find out in part 2 of Dr. Matthew Keller and Dr. Michael Greenberg’s discussion on how we can improve our bedside manner.
Guest: Phil Lieberman, MD
Host: Jennifer Caudle, DO
Are you familiar with the role of serum tryptase testing in diagnosing idiopathic anaphylaxis and mastocytosis? What role does serum tryptase play in the ongoing management of patients who have anaphylactic reactions to insect venom, and are there different considerations when a patient has a known trigger? Expert faculty Dr. Phil Lieberman shares his insights on serum tryptase testing in clinical practice and its importance in assessing mast cell disorders and anaphylaxis. This moderated discussion is enhanced with animation, key takeaways, and support slides to provide an engaging learning experience.
Serum tryptase plays an important diagnostic role in the setting of mast cell activation resulting from a variety of causes, including mastocytosis and anaphylaxis. Emergency medicine specialists, allergists, and primary care providers serve as the first-line responders to patients experiencing the effects of mast cell activation. The measurement of tryptase levels helps confirm diagnoses and inform management decisions for these life-threatening disorders. To help physicians provide optimal evaluation and management, it is essential that they be knowledgeable regarding the appropriate use of tryptase testing in these clinical settings. This education enables multidisciplinary clinicians to identify patients at risk of mast cell activation due to a variety of causes and employ …
Host: Keith C. Ferdinand, MD
Guest: Marco Metra, MD
There is a substantial gap between the guideline recommendations for treatment and the real-world prescribing patterns of RAASi therapy. This disconnect results in worse cardiorenal outcomes and higher mortality in patients receiving suboptimal dosing. This is particularly true in patients with CKD who develop hyperkalemia, which constitutes the major barrier to optimal therapy.
In this activity, Drs. Ferdinand and Metra discuss how best to manage comorbidities, optimize RAASi therapy, and improve the long-term care for our patients with heart failure.
Host: Jennifer Caudle, DO
Guest: Lindsey Roeker, MD
From causes to counseling strategies, Dr. Lindsey Roeker joins Dr. Jennifer Caudle to dive into chronic lymphocytic leukemia fatigue and how we can help our patients who are experiencing this kind of fatigue.
Host: Mimi Secor, DNP, FNP-BC, FAANP
Guest: Maria Trent, MD, MPH, FAAP, FSAHM
Dr. Mimi Secor is joined by Dr. Maria Trent, Chief of the Division of Adolescent and Young Adult Medicine at Johns Hopkins School of Medicine, to discuss diagnosing and treating antibiotic resistant MGen.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Deborah Levine, MD, FCCP
To better understand whether or not corticosteroids should be incorporated in treatment for our patients with COPD, Dr. Charles Turck is joined by Dr. Deborah Jo Levine, a Professor of Medicine and Director of the Pulmonary Hypertension Center at the University of Texas Health.
This is a non-promotional, non-CME disease state disease education podcast series brought to you by American College of CHEST Physicians in collaboration with and paid for by GSK.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Sheng Xu, PhD
Sheng Xu, Professor of Nanoengineering, Bioengineering, Computer and Electrical Engineering at the UC San Diego Jacobs School of Engineering, meets with Dr. Alan Brown to discuss his innovative technology to change the way we predict cardiovascular risks.
Guest: John Friedewald, MD
Kidney Week 2021 tackled everything from kidney transplants to systemic inequities. Here to share his insight on the latest updates is Dr. John Friedewald, Professor of Medicine and Surgery at the Northwestern University Feinberg School of Medicine.
Guest: John Friedewald, MD
What did the first day of the American Society of Nephrology’s Kidney Week 2021 showcase? From COVID-19 to developments in kidney disease, Dr. John Friedewald, Professor of Medicine and Surgery at the Northwestern University Feinberg School of Medicine, shares highlights from Day 1.
Guest: Randy Cron, MD, PhD
Dr. Randy Cron, Professor of Pediatrics and Medicine at the University of Alabama at Birmingham and the Director of the Division of Pediatric Rheumatology at Children’s of Alabama, shares highlights from his session on “Rheumatology Complications of Emerging Viral Infections and SARS-CoV-2” from the 2021 American College of Rheumatology Convergence.
Host: Michael E. Wechsler, MD, MMSc
Guest: Eileen Wang, MD, MPH
In this session, National Jewish Health faculty experts will discuss a new paradigm of severe asthma pathophysiology and potential treatment targets that may impact patients with non-allergic and non-eosinophilic as well as eosinophilic severe asthma. This session will explore new understanding of the immunology of severe asthma, new potential targets for treatment, and emerging data on novel therapies that may improve outcomes for your patients with severe asthma.
Guest: Garth W. Garrison, MD
The diagnosis and management of chronic cough can be challenging. Only an estimated 50% of patients with chronic cough are accurately diagnosed. Recent advances in the understanding and management of refractory chronic cough, have led to the development of novel therapies and ongoing clinical studies. In this two-part educational curriculum, pulmonary experts will discuss the prevalence, unmet clinical needs, and impact of chronic cough in patients who do not find relief from recommended management strategies. They will also review the clinical trial data and mechanisms of action of emerging therapies for patients with refractory chronic cough; and finally, summarize the current guidelines and emerging treatment strategies for the management of patients with chronic cough.
Guest: Ann D. Bass, MD
Guest: Barry A. Singer, MD
Multiple sclerosis is a chronic inflammatory and neurodegenerative disease with a highly variable clinical course.1,2 Most patients who have relapsing-remitting multiple sclerosis (RRMS) will eventually transition to a secondary progressive course (SPMS).3 Patients with SPMS may live with significant impairment in physical and cognitive functions.4 Early identification of disease progression is important.2
Join Dr. Barry Singer from the MS Center for Innovations in Care at the Missouri Baptist Medical Center in St Louis, Missouri as well as Dr. Ann Bass from the Neurology Center of San Antonio in San Antonio, Texas as they share their real-world clinical perspectives on the management of patients with more progressed RMS, including those with aSPMS, and MAYZENT as a treatment option. Together, they will explore the following decision points:
- How to actively identify first signs of RMS progression
- A therapy for progressing RMS, including active SPMS
- What to consider when getting patients started on MAYZENT, a disease-modifying treatment
Host: Neilanjan Nandi, MD
Guest: Susan Kais, MD
Many IBD clinicians and patients talk about diet, but not many conversations happen about fitness. Based on the latest research, exercise may be one therapeutic tool in our kit that remains unexploited. That’s why IBD specialist Dr. Susan Kais joins Dr. Neil Nandi to walk us through key findings and how we can prescribe fitness for our IBD patients.
Host: Jinoos Yazdany, MD, MPH
Which of our patients with rheumatic diseases are at higher risk for severe outcomes from COVID-19? That’s the exact question Dr. Jinoos Yazdany, Chief of the Division of Rheumatology at Zuckerberg San Francisco General Hospital, addresses in her presentation at the 2021 American College of Rheumatology (ACR) Convergence.
Host: Laura Cappelli, MD, MHS,MS
What does the future of rheumatology look like around the globe? Here to give a quick overview of her presentation at the 2021 American College of Rheumatology (ACR) Convergence is Dr. Laura Cappelli, Assistant Professor of Medicine at the Johns Hopkins University School of Medicine Division of Rheumatology and a faculty member of the Johns Hopkins Arthritis Center.
Host: Scott Kopetz, MD, PhD
Guest: Rona Yaeger, MD
Advances in the diagnosis and treatment of mCRC enable personalized care based on the molecular profile of the tumor to achieve improved outcomes. About 5% to 15% of mCRC patients have a mutation in the proto-oncogene BRAF. BRAF is part of an essential cell signaling pathway, mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK). The BRAF V600E mutation induces constitutive activation of BRAF, leading to increased cell growth and proliferation downstream. Patients with the V600E mutation have a 2-fold increased risk for mortality compared to patients with wild-type BRAF, suggesting this gene mutation may act not only as a prognostic biomarker but also as a predictive biomarker. Understanding the current research regarding the consequences of the V600E mutation and testing for it can help guide treatment decision-making in patients with BRAF V600E–mutated mCRC.
This web-based, on-demand activity will feature an expert panel discussion on the latest trends and emerging research in the treatment of BRAF-mutated mCRC. Expert faculty will review and provide their interprofessional perspectives on testing patients for BRAF mutations, recent and emerging data for combination therapies, appropriate treatment selection, and side effect management.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Chitra Lal, MD
Dr. Charles Turck is joined by Dr. Chitra Lal, a Professor of Medicine at the Medical University of South Carolina in Charleston, to share strategies for adherence to treatment and discuss multiple versus single inhaler triple therapy for COPD.
This is a non-promotional, non-CME disease state disease education podcast series brought to you by American College of CHEST Physicians in collaboration with and paid for by GSK.
Host: Johann de Bono, MD, PhD
Guest: Alicia K. Morgans, MD, MPH
Prostate cancer is the second most common cancer in incidence and the fifth most frequent cause of cancer-related mortality in men worldwide. With the broader availability of PSA screenings, the incidence of disease is only rising.
This lively discussion focused on prostate cancer is designed to help you keep pace in GU cancers. You will enhance your knowledge and skills related to targeted therapy in patients with metastatic castrate-resistant prostate cancer, discover relevant biomarkers in prostate cancer, follow a patient case example, and hear about the latest clinical trial data presented at ASCO and ESMO 2021.
The prostate cancer landscape is rapidly evolving, so tune in to find out what changes you can make in your daily practice today.
Host: Andrea Singer, MD, FACP, CCD
Guest: Paul A. Anderson, MD
Guest: Susan V. Bukata, MD, FAOA, FAAOS
While there’s growing awareness among orthopedic surgeons that osteoporosis is the underlying cause of fractures, there is often a disconnect between this recognition and action in the form of treatment to prevent subsequent fractures. In this discussion, Drs. Andrea Singer, Paul Anderson, and Susan Bukata address the pathophysiology of osteoporosis and the need to identify patients at risk for additional fractures. Osteoporosis treatment (including pharmacotherapy) can play a critical role in preventing future fractures, but physicians must first recognize that fracture is a sentinel event and treat it as a call to action.
Guest: Alexander Spira, MD, PhD, FACP
The 2021 ESMO Congress featured a lot of new advancements in non-small cell lung cancer (NSCLC) treatment. Here to provide a recap of one of those treatments for NSCLC patients with HER2 mutations is Dr. Alexander Spira, Co-Director of the VCS Research Institute, Director of the Thoracic and Phase I Program, and Clinical Assistant Professor at Johns Hopkins.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Aasma Shaukat, MD, MPH
Screening for colorectal cancer is unique because there are several screening options available. So how can we balance the latest ACG Clinical Guidelines with patient preferences, cultural context, and insurance coverage to find the best screening option for our patients? Joining Dr. Peter Buch to discuss the updated recommendations is Dr. Aasma Shaukat, lead author of the 2021 ACG Clinical Guidelines for colorectal cancer screening.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Joshua Ofman, MD, MSHS
Despite significant advancements in therapeutics, the oncology community has not yet been able to declare victory in the “war on cancer.” In fact, about 40 percent of Americans receive a cancer diagnosis in their lifetime, amounting to over 600,000 American deaths on average every year or nearly 1,700 loved ones a day. But could hope be on the horizon thanks to technological developments like multi-cancer early detection (MCED)? Find out with Dr. Paul Doghramji and Dr. Joshua Ofman, a public health services researcher as well as the Chief Medical Officer and Head of External Affairs at GRAIL.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Elizabeth A. Brem, MD
Guest: Ehab L. Atallah, MD
Dr. Elizabeth Brém, an Assistant Professor in the Division of Hematology/Oncology at the University of California Irvine School of Medicine and Dr. Ehab Atallah, a Professor of Medicine and Section Head of Hematological Malignancies in the Medical College of Wisconsin’s Division of Hematology and Oncology join Dr. Charles Turck to explore collaborative approaches and share best practices in the management of chronic lymphocytic leukemia.
Host: John J. Russell, MD
The global pandemic incited the expedited development of COVID-19 vaccines. But how did that change the development process? ReachMD host and Family Medicine Physician, Dr. John Russell, tells us how the rollout of the COVID-19 vaccine differs from other vaccines and what it could mean for the medical field.
Host: Jennifer Caudle, DO
Guest: Charles P. Vega, MD
The development of mRNA vaccines marked a turning point in the battle against the COVID-19 pandemic, but what do we need to know about this emerging vaccine technology? Dr. Jennifer Caudle and Dr. Charles Vega, a Clinical Professor in the Department of Family Medicine at the University of California Irvine, discuss some of the benefits and common concerns.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: René F. Najera, DrPH
Misinformation regarding the COVID-19 vaccines have prevented patients from getting vaccinated. How should we talk to our patients about these misconceptions? Dr. Charles Turck joins epidemiologist, Dr. René Najera, to review leading myths surrounding the COVID-19 vaccines and how we can counsel our patients.
Guest: James G. Christensen, MD
Catch up on how new research presented at the 2021 ESMO Congress is helping to evolve targeted therapies for colorectal and pancreatic cancer with Dr. James G. Christensen.
Guest: Edward B. Garon, MD
Could a new standard of treatment be on the horizon for patients with HER2 mutated NSCLC? Dr. Edward Garon, a Thoracic Medical Oncologist at UCLA Health, shares key takeaways on non-small cell lung cancer from the ESMO 2021 Congress.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jill Foster, MD
From mRNA vaccines to egg-based vaccines, what do we need to know about the different types of vaccines? Dr. Jill Foster, Director of the Division of Pediatric Infectious Diseases and Immunology at the University of Minnesota, joins Dr. Charles Turck to explore what we need to know about the various types of vaccines available.
Guest: Muthiah Vaduganathan, MD, MPH
What do we currently know about the cardiac consequences of the COVID-19 vaccines? Dr. Muthiah Vaduganathan, cardiologist and investigator at Brigham Women's Hospital at Harvard Medical School, addresses the cardiac concerns surrounding the vaccines and how we can talk to patients about them.
Host: Mikhail Kosiborod, MD
Guest: Ewa A. Jankowska, MD, PhD, FESC
Guest: Phil McEwan, PhD
Assessing iron deficiency is a crucial aspect of heart failure (HF) that warrants close clinical consideration, especially because it remains underdiagnosed and undertreated.
In this expert panel discussion, we examine data from AFFIRM-HF supporting the importance of correcting iron deficiency in patients with HF. Find out how treating iron deficiency can change the natural history of heart disease, lead to cost savings, and improve patients’ lives.
Host: Jason Freeman, MD, MBA
Guest: Scott Zamvil, MD, PhD
Our understanding of immunoglobins’ role in multiple sclerosis (MS) has evolved over the years. Joining Dr. Jason Freeman to share what we currently know about immunoglobins and immunology considerations for MS therapies and patient case scenarios is Dr. Scott Zamvil, Professor of Neurology and Faculty Member in the Program in Immunology at the University of California, San Francisco.
9/21 152858
Guest: Cem Akin, MD, PhD
Host: Jennifer Caudle, DO
What is the risk of anaphylaxis following vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; COVID-19)? Are you familiar with the role of serum tryptase testing in patients with a suspected anaphylactic reaction? Expert faculty, Dr. Cem Akin, discusses serum tryptase testing and its importance in assessing anaphylaxis in response to COVID-19 vaccination. This moderated discussion is enhanced with animation, key takeaways, and support slides to provide an engaging learning experience.
Serum tryptase plays an important diagnostic role in the setting of mast cell activation resulting from a variety of causes, including mastocytosis and SARS-CoV-2 vaccination. Emergency medicine specialists, allergists, and primary care providers serve as the first-line responders to patients experiencing the effects of mast cell activation. The measurement of tryptase levels helps confirm diagnoses and inform management decisions for these life-threatening disorders. This education enables multidisciplinary clinicians to identify patients at risk of mast cell activation due to a variety of causes and employ appropriate use of tryptase testing across acute and follow-up care settings.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Mojgan Saber, MD
Can Locum Tenens be an option for healthcare professionals just completing their residency? Dr. Paul Doghramji is joined by Dr. Mojgan Saber to share her own experience as well as tips and tricks for residents looking at Locum Tenens right after residency.
Host: Jerome Lisk, MD
Guest: Shivashankar Othy, DVM, PhD
Despite the high prevalence of multiple sclerosis (MS), there’s still a lot we don’t know about this disease. One such area of uncertainty is in regard to how MS causes the immune system to become dysfunctional, but this knowledge is key as it could help us develop new treatment options. And now, we might be one step closer to discovering those treatments thanks to a recent study exploring specific T cells, and joining Dr. Jerome Lisk to discuss that study is Dr. Shiva Othy, a Project Scientist in the Department of Physiology and Biophysics at the University of California Irvine School of Medicine.
Guest: Steven Fishbane, MD
Guest: Shayan Shirazian, MD
Host: Jennifer Caudle, DO
At least 25% of patients with chronic kidney disease (CKD), and between 50% to 86% of patients with CKD on dialysis suffer from CKD-associated pruritus (CKD-aP). The itch can substantially interfere with sleep and quality of life and has been linked with depression, fatigue, and isolation. There are at least 4 pathways that have been hypothesized as possible etiologies of CKD-aP, leading to a wide range of potential therapeutic strategies for the itch. Difelikefalin is the first agent FDA-approved specifically for the treatment of moderate-to-severe pruritus in CKD patients undergoing dialysis; it is a peripheral kappa-opioid receptor agonist that targets the opioid dysregulation theory. It is imperative that all clinicians involved in the care of patients with CKD routinely inquire about pruritus and adequately treat their patients for CKD-aP. This case-based program will apply the foundational information presented in the first program of this 2-part series to real-world patients.
Host: Neilanjan Nandi, MD
Guest: Gary Falk, MD
Once we’ve diagnosed a patient with Barrett’s esophagus, strict surveillance is necessary to help prevent the development esophageal cancer. But what do surveillance strategies look like according to the latest guidelines? Joining Dr. Neil Nandi to share how we can best maximize surveillance guidelines for Barrett's esophagus and apply some of the evolving technologies that are helping us do just that is Dr. Gary Falk, Director of the Esophagology and Swallowing Center at the University of Pennsylvania.
Host: Neilanjan Nandi, MD
Guest: Gary Falk, MD
Since patients with chronic GERD may develop Barrett’s esophagus, screening and prevention are both critical. But who should we screen, and how do we screen? Joining Dr. Neil Nandi to answer those and other questions to help us better screen chronic GERD patients for Barrett’s esophagus is Dr. Gary Falk, Director of the Esophagology and Swallowing Center at the University of Pennsylvania.
Have you considered POMALYST® (pomalidomide) containing regimens for your appropriate patients with relapsed/refractory multiple myeloma who have received lenalidomide and a proteasome inhibitor? Tune in to hear key findings from clinical trials, including safety and efficacy data, and other important information regarding these treatment regimens.
Please see full Prescribing Information for POMALYST, including Boxed WARNINGS, and full Prescribing Information for EMPLICITI.
POMALYST and EMPLICITI Indications
POMALYST® (pomalidomide) is a thalidomide analogue indicated, in combination with dexamethasone, for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.
EMPLICITI® (elotuzumab) is indicated in combination with POMALYST and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
POMALYST + dexamethasone + daratumumab Indication
POMALYST + dexamethasone + daratumumab is indicated for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
Information about POMALYST + dexamethasone + …
Host: Jennifer Caudle, DO
Guest: Jennifer Brown, JD
The risks associated with pregnancy are disproportionately higher for some patient populations, but several organizations are taking action to change that. Dr. Jennifer Caudle joins Jennifer Brown, senior legislative and regulatory attorney at the American Medical Association, to discuss the AMA’s efforts to improve maternal health.
Host: Hector O. Chapa, MD, FACOG
Guest: Shay Walters
Mrs. Shay Walters was just 15 years old when she first became involved with substance use, and it wouldn’t be until years later that she would finally overcome her addiction. Her story, however, is far from the only one like it. Millions of Americans currently struggle with addiction, which is why she founded the “From Prison to Purpose” Facebook group that now has half a million followers. And to further help those who are trapped under drug addiction and even the clinicians who care for those patients, Mrs. Walters joins Dr. Hector Chapa to share her inspiring story.
Host: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Javed Butler, MD, MBA, MPH
Guest: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
Rapid initiation and up-titration of guideline-directed medical therapy (GDMT) is critical to achieve optimal patient outcomes in heart failure. This is particularly important in patients with multiple comorbidities and in pivotal situations to avoid stopping or lowering the dose of any of the four critical medicines that these patients must receive.
Drs. Javed Butler, Ileana Piña, and Giuseppe Rosano will recap the data and the views that were presented at a symposium held in conjunction with the Heart Failure Society of America’s 2021 annual scientific meeting.
Host: Robert J. Chilton, DO
Guest: John R. Nelson, MD, FACC, FNLA, FASNC
Join Drs. Chilton and Nelson as they discuss recent omega-3 fatty acid (OM-3) outcomes trial results and how to apply those results along with evidence-based guidelines to reduce ASCVD risk. Tune in to hear about the use of OM-3s including dietary supplement OM-3s that are readily available in pharmacies and online, so you can keep your patients informed!
Host: Mario R. Nacinovich, Jr., MSc
Guest: Randy Young, MD
Amid the surge of the Delta variant, critical care physician Dr. Randy Young is traveling to ICUs across the country to help treat patients. Tune in to hear Dr. Young share how this surge is impacting both patients infected with the variant and the healthcare professionals caring for them.
Host: Neilanjan Nandi, MD
Guest: Jason Schairer, MD
How can we make the differentiation between pouchitis and cuffitis to provide the best possible care? And once we accurately identify and treat pouchitis, how can we manage surgical complications that may arise? Tune in to hear Dr. Jason Schairer from the Henry Ford Health System in the Division of Gastroenterology and Hepatology discuss these FAQs with Dr. Neil Nandi.
Host: Neilanjan Nandi, MD
Guest: Jason Schairer, MD
For a significant portion of our patients, pouchitis can be a frustrating and trying condition plagued with urgent diarrhea, incontinence, and even complications of fistula and stricture. Fortunately, a group of clinicians have gathered together to develop consensus guidelines on the endoscopic evaluation and clinical management of pouchitis and its potential complications. And who better to give us an in-depth review of the new guidelines than Dr. Jason Schairer, one of the authors of the guidelines.
Host: Michael Greenberg, MD
Guest: Howard K. Steinman, MD
We always want patients to leave our office feeling happy, healthy, and pleased with their care, but unfortunately, that isn't always the case. The good news, however, is that the acronym BLAST can help guide our conversations with patients who are less than satisfied with their care. Joining Dr. Michael Greenberg to break down this five-step method for speaking with displeased patients is Dr. Howard Steinman, a board-certified dermatologist and fellow of the American College of Mohs Surgery.
Host: Michael E. Greenberg, MD, MPH
Guest: Randy Young, MD
Despite widespread eligibility, only half of Americans received their flu vaccine last year, and only 55% have been fully vaccinated against COVID-19. Dr. Randy Young joins host Dr. Michael Greenberg to discuss the latest coadministration guidelines and how they could impact vaccination rates.
This episode is produced in partnership with the American College of CHEST Physicians and sponsored by Sanofi Pasteur.
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Guest: Nicola Cascella, MD
Although there’s currently no cure for schizophrenia, it can be managed with therapy and medication—for some patients, that is. In fact, up to one-half of patients with severe symptoms don’t respond to medication. So how are we to care for this large percentage of patients living with treatment-resistant schizophrenia? That’s the question Dr. Andrew Wilner asks Dr. Nicola Cascella, an Assistant Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine who recently conducted a case study exploring the potential use of deep brain stimulation for patients with treatment-resistant schizophrenia.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Michael Kornberg, MD, PhD
What does the patient journey in multiple sclerosis progression look like? Dr. Charles Turck is joined by Dr. Michael Kornberg to discuss the impact of early detection and share strategies to help manage the burden of this disease.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Lauren Gluck, MD
Relapsing forms of multiple sclerosis can progress quickly and aggressively. What should our patients be looking out for? Dr. Charles Turck is joined by Dr. Lauren Gluck to discuss how we can help patients cope with progressing RMS.
Host: David L. Eisenberg, MD, MPH, FACOG
Many women prefer to use a nonhormonal contraceptive. They also want the freedom to self-administer on demand and want assurances that the contraceptive is safe, effective, and has received FDA approval. One such contraceptive is a self-administered, hormone-free gel that functions as a vaginal pH modulator. Join Dr. David Eisenberg as he describes the evolution of this vaginal pH modulator and the clinical trials leading to FDA approval. Even more significant is patient acceptance, which was remarkably high for this contraceptive. In fact, approximately 9 out of 10 women participating in the clinical trials indicated they would continue using the vaginal pH modulator and also recommend this novel method to their friends.
Host: John J. Russell, MD
Guest: Greg Berry, MD
We are at a time when COVID-19, respiratory syncytial virus, and the flu all pose serious risks. Quick and accurate diagnoses are vital to determining the correct patient pathway and minimizing viral spread. But what diagnostic challenges do we face, and how can we overcome them? Joining Dr. John Russell to discuss these respiratory testing challenges and Cepheid’s 4-in-1 respiratory test is Dr. Greg Berry, Associate Director of the Center for Advanced Laboratory Medicine at the Columbia University Irving Medical Center in New York.
Host: Louis Kuritzky, MD
Guest: Karl Doghramji, MD, FAASM, DFAPA
Guest: Julie Flygare, JD
Guest: Phyllis C. Zee, MD, PhD
Excessive sleepiness is a common, highly impactful problem not commonly reported and frequently misdiagnosed by physicians. While prevalence reports of narcolepsy vary, patients often do not seek medical advice for their symptoms or, if they do, they receive inaccurate diagnoses. Because of this, it’s possible that more than 1 in 2000 people are living with narcolepsy. It may even take 10 to 15 years to be diagnosed, during which time these patients are impaired. What signs and symptoms are both clinicians and patients missing?
Tune in to hear a patient, Julie Flygare, JD, recount her bizarre symptoms and receive clinical tips on how to improve your identification of overlooked sleep disorders and narcolepsy. Drs. Zee, Doghramji, and Kuritzky provide their clinical insight and expertise on this serious medical condition that continues to be grossly misdiagnosed, underdiagnosed, and undermanaged. By improving your ability to detect, accurately diagnose, and appropriately manage narcolepsy, you can improve the quality of life and health outcomes for your patients. Find out what subtle signs and red flags you need to be on the lookout for and what exciting therapies are now available for these patients.
Host: Charles P. Vega, MD
Guest: Candice Taylor Lucas, MD, MPH, FAAP
What is cultural humility, and how can it be incorporated into clinical practice? How does your patient's culture impact their health behaviors, and why does your culture matter?
Listen in as two leading experts navigate concerns surrounding cultural humility and emphasize the importance of empathy, awareness, and advocacy. Discover ways to integrate small but important changes into your clinical practice to help bridge communication gaps and enable your patients to thrive.
Host: Brooke M. Faught, DNP, WHNP-BC,NCMP, IF
Our patients express a number of misperceptions about combined hormonal non-LARC contraceptives such as the contraceptive patch, vaginal rings, and oral contraceptive pills. How well do you explain the advantages and disadvantages of these different options to your patients? How often have you prescribed what appeared to be a good contraceptive method for your patients only to have them be dissatisfied and become nonadherent?
Join Dr. Brooke Faught in this Women’s Health 2021 lecture as she tackles these issues and offers insights into how to discuss the full range of combined hormonal non-LARC contraceptive options with your patients using shared decision-making strategies. Remember, each patient’s needs, goals, and cultural background are important factors in a patient-centric approach to the choice of contraception.
Host: Charles P. Vega, MD
Guest: Lionel Phillips, MBA
Learn why diversity in clinical trials is so important to community health. Two experts discuss the key role that trusted messengers play in enrollment, why it is critical to break the cycle of medical mistrust, and the downstream effect of a lack of diversity in clinical trials.
Host: Paul Nyirjesy, MD
The global burden of acute vulvovaginal candidiasis (VVC) and the substantial morbidity and poor quality of life associated with recurrent disease (RVVC) requires improved solutions and quality of care for affected women. Join Dr. Paul Nyirjesy as he dissects the barriers to managing VVC and RVVC in your clinical practice and provides both diagnostic and therapeutic guidance inclusive of newly emerging and novel agents. These agents have unique qualities that may well represent a significant step forward in how you manage this challenging infection.
Guest: Madhukar H. Trivedi, MD
Guest: Steven Shoptaw, PhD
Join Drs. Madhukar Trivedi and Steven Shoptaw as they discuss the evolving landscape of pharmacologic intervention for methamphetamine use disorder. Their focus will be on evidence from the ADAPT-2 clinical trial supporting the combination of extended release naltrexone and high dose bupropion to reduce methamphetamine use for patients with moderate to severe methamphetamine addiction. These important data from ADAPT-2 offer a significant therapeutic advance for methamphetamine use disorder that can be taken into the clinic.
Host: Charles P. Vega, MD
Guest: Robert O. Roswell, MD, FACC, FACP
Diversifying our physician workforce so that it is more racially, ethnically, and geographically balanced can ultimately have a positive impact on community health. Join us as two experts discuss how pipeline programs reaching children as early as elementary school can help ensure workplace diversity. Also find out how clinicians can be advocates for their patients by helping to disentangle them from structural inequities and working towards policy changes. There’s a lot than can be done to provide more balanced care, but we need to look beyond simple fixes to the root causes of the issues. So find your bandwidth – that’s what you can do today – and discover why it’s so important to move upstream to solve the problems manifesting downstream.
Host: Charles P. Vega, MD
Guest: Sateria Venable
Regional healthcare disparities are biases that are based on where people live. Are your patients’ treatment options being impacted and limited by their geographical location? Join us as our two experts discuss how to support broader policy issues and highlight the importance of diagnostic algorithms that have been developed with diverse input. These steps may be of value in your clinical practice to ensure all patients have equal access to care regardless of their epidemiologic, socioeconomic, or insurance circumstances.
Host: Jennifer Caudle, DO
Host: John J. Russell, MD
“What makes the Delta variant different?” “I keep hearing about breakthrough infections, so are the COVID-19 vaccines effective?”
These are just some of the questions patients now have amid the surge of the Delta variant, and many patients are turning to physicians for answers. That’s why ReachMD hosts and primary care physicians Drs. Jennifer Caudle and John Russell sit down to share their approach to answering these FAQs regarding the Delta variant, the COVID-19 vaccines, and more.
Guest: Gregory Pokrywka MD, FACP, FNLA, FASPC, NCMP
Guest: Karol Watson, MD, PhD
Join us to discover optimal ways to identify women at risk or with atherosclerotic cardiovascular disease (ASCVD). In this Women’s Health 2021 lecture, our experts, Dr. Gregory Pokrywka and Dr. Karol Watson, dive deeper into evidence-based approaches to assess and manage ASCVD in women. They discuss topics from lifestyle modifications to recent clinical trial data on the use of omega-3 fatty acids for ASCVD event reduction.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Karen Keough, MD
Guest: Dawn S. Eliashiv, MD
Dr. Dawn Eliashiv of the University of California—Los Angeles and Dr. Karen Keough of the Child Neurology Consultants of Austin, Texas discuss using EPIDIOLEX® to treat patients 1 year of age or older with seizures associated with LGS, Dravet syndrome, or TSC.
Host: Ricardo Franco, MD
Guest: Catherine A. Chappell, MD MSc
With alarming increases in the incidence of maternal HCV, your obstetrics and gynecology (OB/GYN) practice plays a critical role in screening of all pregnant patients and engaging HCV-infected women who otherwise may not seek medical care. This educational activity will provide practical tactics for implementing Centers for Disease Control and Prevention (CDC) screening guidelines at the practice level, insights for destigmatizing behavioral risk inquiries and harm-reduction discussions, current recommendations for postpartum HCV treatment, and evolving perspectives on HCV treatment during pregnancy.
Host: Ricardo Franco, MD
Guest: David L. Wyles, MD
The COVID-19 pandemic has taken a disproportional toll on already vulnerable persons, yet substance use, psychosocial comorbidities, and preexisting disparities in access to care may translate to an even greater adverse impact among persons with chronic HCV. This educational activity offers up-to-date information on the impact of COVID-19 on the normal and HCV-infected liver, practical strategies for optimizing telehealth-delivered HCV care, and other recommendations for engaging vulnerable populations in HCV care during times of reduced service capacity.
Host: Jennifer Caudle, DO
Guest: Iris (Vanessa) V. Marin Collazo, MD
What can we do better to recognize relapsing multiple sclerosis in our patients? Dr. Iris V. Marin Collazo joins Dr. Jennifer Caudle to discuss key signs of progression and critical clinical tools to help measure it.
Host: Matt Birnholz, MD
Guest: Mark H. Stoler, MD
Now that vaccinated women have entered the screening population, we are seeing HPV 16 and 18 decreasing. These changes in HPV genotype prevalence may have a significant impact on the clinical management of cervical cancer, and an HPV test with extended genotyping may change the way we screen for cervical cancer as well. Joining Dr. Matt Birnholz to discuss the role of HPV extended genotyping in cervical cancer screening and the importance of identifying HPV 31 is Dr. Mark Stoler, Professor of Pathology and Clinical Gynecology at the University of Virginia Health System.
Host: John J. Russell, MD
In order for us to better understand how mRNA vaccines were able to move beyond clinical trials amid the COVID-19 pandemic, we must first know how they were originally developed. That’s why ReachMD host and family medicine physician Dr. John Russell reviews the history of mRNA vaccines and how we can use them in the future.
Host: John J. Russell, MD
Guest: Bobby Mukkamala, MD
Chair of the AMA Substance Use and Pain Care Task Force, Dr. Bobby Mukkamala, joins Dr. John Russell to discuss the nation’s worsening drug overdose epidemic and the AMA’s recommendations to help patients.
Guest: Steven Fishbane, MD
Guest: Shayan Shirazian, MD
Host: Jennifer Caudle, DO
At least 25% of patients with chronic kidney disease (CKD) and between 50% to 86% of patients with CKD on dialysis suffer from CKD-associated pruritus (CKD-aP). The itch can substantially interfere with sleep and quality of life, and has been linked with depression, fatigue, and isolation. There are at least 4 pathways that have been hypothesized as possible etiologies of CKD-aP, leading to a wide range of potential therapeutic strategies for the itch. Difelikefalin is the first agent FDA-approved specifically for the treatment of moderate-to-severe pruritus in CKD patients undergoing dialysis; it is a peripheral kappa-opioid receptor agonist that targets the opioid dysregulation theory. It is imperative that all clinicians involved in the care of patients with CKD routinely inquire about pruritus and adequately treat their patients for CKD-aP. This first program will review the epidemiology, consequences, evaluation, pathophysiology and available and emerging treatments for CKD-aP; a second case-based program will apply the information to real-world patients.
Host: Stuart H. Isaacson, MD
Guest: Salima Brillman, MD
Guest: Sean C. Beinart, MD
Join Dr. Stuart Isaacson, a neurologist and movement disorder specialist, as he welcomes fellow neurologist and movement disorder specialist Dr. Salima Brillman and cardiologist Dr. Sean Beinart to discuss neurogenic orthostatic hypotension (nOH) causes, symptomatology, disease burden, and approaches to optimal management involving collaboration between neurology and cardiology specialists.
During their discussion, the following questions will be addressed:
- What is nOH and how is it diagnosed?
- What leads to symptoms of nOH?
- What are some common and less common symptoms of nOH?
- What is the impact of nOH symptoms on the patient and the caregiver?
- How do we approach the management of nOH symptoms?
- How can cardiologists and neurologists collaborate in managing patients with nOH?
For additional reference please review: Cutsforth-Gregory JK, Low PA. Neurogenic Orthostatic Hypotension in Parkinson Disease: A Primer. Neurol Ther. 2019 Dec;8(2):307-324.
© 2021 Lundbeck. All rights reserved. UBR-D-100900
Host: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Javed Butler, MD, MBA, MPH
Guest: Gregg C. Fonarow, MD
Guest: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
Recent guideline updates and publications are leading to changes in care in patients with heart failure with reduced ejection fraction (HFrEF). What clinical evidence is driving recent changes to guideline directed medical therapy (GDMT) in HFrEF, and what real-world data exists that may impact the landscape of care and patient outcomes?
Host: Jennifer Shu, MD, FAAP
Tune in to hear pediatrician Dr. Jennifer Shu share what we currently know about the risks and impacts of the Delta variant on our youngest patients and perhaps even more importantly, how we can help keep them safe.
Published September 23, 2021
Host: Javed Butler, MD, MBA, MPH
Guest: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
Guest: Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
The COVID-19 pandemic has had an unprecedented impact on the entire global population. COVID-19 fears have not only disrupted the regular care of patients with heart failure, but also clinical trials and their participation rates.
These studies are critical for determining the safety and efficacy of new drugs and innovative treatments. When the pandemic started, some clinical trials shut down permanently while others are finally, albeit slowly, resuming. This has created a delay in the research pipeline that may hinder how quickly new heart failure medications come to market in the next few years.
Join us as our experts—Drs. Deepak Bhatt, Javed Butler, and Giuseppe Rosano—discuss the impact of COVID-19 on patient care and the implications for clinical trial data moving forward.
Host: Jennifer Shu, MD, FAAP
School’s back in session, and that means it’s time we take a look at how we can help keep children safe and healthy both inside and outside the classroom with pediatrician Dr. Jennifer Shu.
Published September 21, 2021
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Joseph William Ray, MD
Fabry disease is a progressive, genetic disorder that can cause multisystemic damage and reduce life expectancy when left undiagnosed and unmanaged, making the timely and appropriate management of Fabry disease essential. Recent clinical outcome data and real-world evidence led to the approval of Fabrazyme, a treatment option for Fabry disease. Joining Dr. Charles Turck to share that data is Dr. Joseph William Ray, an Associate Professor of Pediatrics and Director of Medical Genetics at the University of Texas Medical Branch.
For more information, please visit www.fabrazyme.com/hcp.
MAT-US-2107750-v1.0-08/2021
Host: Ricardo Franco, MD
Guest: Charles P. Vega, MD
Armed with Centers for Disease Control and Prevention (CDC) guidelines for HCV universal screening and risk-based testing — and an understanding of the simplicity of prescribing and managing direct-acting antiviral (DAA) therapies — primary care providers (PCPs) will be well equipped to step up and provide comprehensive HCV care and cure. This educational activity offers practical tips and tactics to prepare PCPs for their central role in eliminating HCV.
Host: Jay Raman, MD, FACS
Guest: Oguz Akin, MD
Guest: Robert J. Motzer, MD
Guest: Elizabeth Plimack, MD, MS
Immune checkpoint inhibitor/tyrosine kinase inhibitor combination therapy has forged to the front-line for the management of metastatic RCC and recurrent RCC, but how do clinicians select the ideal treatment regimen for their patients? How does patient risk status influence the decision-making process? This virtual tumor board features a multidisciplinary expert panel presenting a favorable-risk patient case and discussing treatment strategies and evidence-based therapy selection to optimize outcomes in this patient population. Faculty additionally cover the importance of incorporating the patient perspective into treatment decisions.
After viewing the activity, visit the Related tab for supplemental resources.
Host: Jacob Sands, MD
Guest: Shirish Gadgeel, MD
Immunotherapy using checkpoint inhibitors has become a standard of practice in advanced non-small cell lung cancer. But can combination therapy further improve patient outcomes? Dr. Jacob Sands is joined by Dr. Shirish Gadgeel, Chief of the Division of Hematology and Oncology at Henry Ford Cancer Institute, who recently spoke about this topic at the American Society of Clinical Oncology’s annual meeting.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: Emily Louise Johnson, MD
According to recent estimates, between 150,000 and 450,000 transgender patients have epilepsy. And as that number is only expected to grow, Assistant Professor of Neurology at Johns Hopkins School of Medicine Dr. Emily Johnson shares key considerations for treating transgender patients with epilepsy.
Host: Carol Wysham, MD
Guest: Christopher Taylor, PhD, RDN, LD, FAND
Dr. Carol Wysham meets with Dr. Christopher Taylor, Professor of Medical Dietetics at the Ohio State University School of Health and Rehabilitation Sciences, to take a look at low protein intake and its overall impact on diabetic patients.
Host: Jennifer Caudle, DO
Guest: Keith McCrae, MD
In order to reflect the evolving management of immune thrombocytopenia (ITP), the American Society of Hematology updated their clinical practice guidelines. Here to share some of the key recommendations for the management of adult and pediatric ITP is Dr. Keith McCrae, a board-certified hematologist and an author of the 2019 ASH Guidelines.
© 2021 Amgen Inc. All rights reserved. USA-531-80829 08/21
Host: Jennifer Caudle, DO
Guest: Stephen Hanauer, MD
Even though biosimilars serve as a much-needed treatment option for patients in several fields of medicine, gastroenterologists have been reluctant to adopt them. Joining Dr. Jennifer Caudle to explore why this might be and the evolving role of biosimilars in anti-inflammatory care for GI patients is Dr. Stephen Hanauer, Professor of Medicine at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.
USA-CBU-81030
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Pradipta Ghosh, MD
Artificial intelligence (AI) is rapidly changing how we practice medicine in a variety of ways, especially in the midst of the COVID-19 pandemic. In fact, a recently developed AI model can help us predict the disease course of patients infected with COVID-19, and here to share how that model was developed based on pandemics of the past and how it can be used in the current—and even future—pandemics is Dr. Pradipta Ghosh, Professor of Cellular and Molecular Medicine at UC San Diego.
Host: Neilanjan Nandi, MD
Guest: James D. Lewis, MD, MSCE
An ongoing question for clinicians and patients alike is how diet can impact IBD treatment and management. Here to discuss this topic with Dr. Neil Nandi is Dr. James Lewis of the University of Pennsylvania IBD Center. Dr. Lewis recently conducted a clinical randomized trial that compared the impact of two diets on patients with mild-to-moderate Crohn’s disease symptoms, and now, Drs. Nandi and Lewis are diving into this study, the reasoning behind it, and its outcomes.
Host: Jacob Sands, MD
Guest: Benjamin Kann, MD
Artificial intelligence-based models have become a growing area of interest in clinical oncology. What do we need to know about them? Dr. Benjamin Kann, a physician at Dana Farber Cancer Institute, and Assistant Professor of radiation oncology at Harvard Medical School, meets with Dr. Jacob Sands to discuss the use of AI in oncology.
Throughout this 8-chapter program, you’ll hear from cardiologist Dr. Rachel Bond, cardiologist and vascular medicine specialist Dr. Geoff Barnes, and patient advocate Elizabeth about the increasing prevalence of peripheral artery disease (PAD) along with key strategies for diagnosing and managing patients with PAD.
©Janssen Pharmaceuticals, Inc. 2021 08/21 cp-230791v1
Host: Jennifer Caudle, DO
Guest: Lindsey Roeker, MD
Dr. Jennifer Caudle is joined by Dr. Lindsey Roeker, a hematologist and medical oncologist at Memorial Sloan Kettering Cancer Center, to discuss evolving outcome measures and critical diagnostic biomarkers in patients with chronic lymphocytic leukemia.
Host: Jennifer Caudle, DO
Guest: Jennifer A. Woyach, MD
Dr. Jennifer Caudle is joined by Dr. Jennifer A. Woyach, a professor in the Division of Hematology at Ohio State University, to discuss tailoring treatment to unique populations for patients with chronic lymphocytic leukemia.
Host: Jacob Sands, MD
Guest: Elizabeth A. Brem, MD
Dr. Jacob Sands is joined by Dr. Elizabeth Brém, an Assistant Professor in the Division of Hematology/Oncology at the University of California Irvine School of Medicine to explore opportunities and challenges with fixed duration therapy for patients with chronic lymphocytic leukemia.
Host: Jacob Sands, MD
Guest: Bruce D. Cheson, MD, FACP, FAAAS, FASCO
Is frontline treatment for chronic lymphocytic leukemia evolving? Dr. Jacob Sands is joined by Dr. Bruce Cheson, a Scientific Advisor at the Lymphoma Research Foundation, to review the CLL treatment landscape and take a look at emerging data on long-term outcomes.
Guest: Brian Hill, MD, PhD
Dr. Brian T. Hill, a physician in the Department of Hematology and Medical Oncology at Cleveland Clinic, explores some of the most recent—and ongoing—impacts of the COVID-19 pandemic on treatment decision-making for patients with chronic lymphocytic leukemia.
Host: Jennifer Caudle, DO
Guest: Mikkael A. Sekeres, MD, MS
Guest: Sara M. Tinsley, PhD, ARNP, AOCNP
Please note: This activity is no longer available for continuing education credit.
There is a lack of available therapeutic options for the management of patients with myeloid malignancies, including myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML). Novel therapeutic approaches are being evaluated, particularly those that target the NEDD8-activating enzyme (NAE). Evaluating the rationale for NAE inhibition, assessing emerging safety and efficacy data on use of NAE inhibitors in myeloid malignancies, and developing strategies based on the evolving implications of this research will allow for greater understanding of their potential impact on management and health outcomes of patients with MDS, CMML, and AML.
Host: Michael Greenberg, MD
Guest: Robert T. Brodell, MD
As children, stories and fables capture our imaginations and even teach us some important life lessons, and our love of stories isn't necessarily something we grow out of. After all, as adults, we're constantly hearing news stories and catching the latest movies, podcasts, and shows. So might there be a role for storytelling in our visits with patients? To find out, Dr. Michael Greenberg speaks with Dr. Robert Brodell, Professor and Chair in the Department of Dermatology and Professor of Pathology at the University of Mississippi Medical Center.
Host: Robert J. Mentz, MD, FHFSA, FACC, FAHA
Guest: Peter van der Meer, MD, PhD
Iron deficiency is an extremely common comorbidity for 50% to 70% of our patients with heart failure in both the acute and chronic settings. It’s associated with poor exercise capacity, poor quality of life, and increased morbidity and mortality. In hospitalized patients with acute heart failure, iron deficiency is often present independent of anemia.
With that in mind, join Drs. Robert Mentz and Peter van der Meer as they discuss the impact of iron deficiency on patients with heart failure. Find out why it’s time to shift our perception of iron deficiency from a marker of disease outcome to a treatment target.
Host: George L. Bakris, MD
Guest: Rajiv Agarwal, MBBS, MD, FASN, BRCU
Guest: Bertram Pit, MD
Two HOT LINE sessions presented at the ESC Congress 2021 may change the way you manage your patients with diabetes and CKD as you work to prevent their progression to ESRD and improve their cardiovascular outcomes. Drs. Rajiv Agarwal, George Bakris, and Bertram Pitt review data from the FIGARO-DKD trial and the FIDELITY Analysis to explore the evolving role of mineralocorticoid receptor antagonists (MRAs) as part of the overall treatment plan for patients with diabetes and CKD. Don’t miss this potentially practice-changing session!
Guest: Arlene B. Chapman, MD
Guest: Michel Chonchol, MD
This Expert Exchange webcast aims to improve clinicians’ awareness of emerging agents in the treatment of patients with ADPKD.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Emily Carroll, JD, MSW
Guest: Heather McComas, PharmD
Guest: Chris Sherin
The prior authorization cost control process can be a burden on clinicians and lead to delayed treatment for patients. But the AMA’s recent advocacy efforts may help reform the process. Dr. Charles Turck meets with Emily Carroll, Heather McComas, and Chris Sherin to dive into these reforms and their impact at the state and federal levels.
Host: Arjun V. Balar, MD
Guest: Daniel P. Petrylak, MD
Bladder cancer is the sixth most common malignancy in the United States. Many of these patients present with multiple comorbidities which creates a considerable challenge for clinicians when determining an appropriate treatment plan. Until recently, platinum-based chemotherapy was the only viable systemic therapy option for patients with locally advanced or metastatic urothelial cancer (mUC); however, the majority of these patients eventually relapse and need subsequent lines of therapy. Patients are then left with limited treatment options and often poor outcomes, contributing to a largely unmet need that prompted investigation into new and promising therapeutic options.
This chapterized activity is designed to update clinicians who treat locally advanced or metastatic urothelial cancer on new clinical trials and the treatment guidelines that align with the identified unmet need of subsequent treatment options for this patient population. Drs. Arjun Balar and Daniel Petrylak focus on enhancing the knowledge and skills of clinicians through case-based content to demonstrate individualized patient treatment plans and enable participants to further incorporate changes into their clinical practice. Join us to find out why the future is bright for our patients with mUC.
Host: Jay Raman, MD, FACS
Guest: Oguz Akin, MD
Guest: Robert J. Motzer, MD
Guest: Elizabeth Plimack, MD, MS
Did you know that the current 5-year survival rate for patients diagnosed with metastatic RCC is only 12% despite advances in molecular research over the past decade? Are you familiar with recent treatment guidelines and clinical trial data showcasing the benefits of treating poor- and intermediate-risk ccRCC patients with immuno-oncology/tyrosine kinase inhibitor combination therapy? This virtual tumor board features a multidisciplinary expert panel presenting a poor-risk patient case and discussing treatment strategies and evidence-based therapy selection to optimize patient outcomes. Faculty additionally cover the importance of incorporating the patient perspective and adverse event profiles into treatment decisions.
After viewing the activity, visit the Related tab for supplemental resources.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Michelle Y. Owens, MD
OB-GYN clinicians can improve how they communicate with their patients about hemolytic disease of the fetus and newborn or HDFN. Strategies include encouraging patients to talk about their feelings when learning about this condition and communicating with them in terms that are not overly complex. In this program, Drs. Lee Shulman and Michelle Owens discuss how to break things down for the patient in front of you and explain how to use a read-back approach. This tactic ensures that your patient has absorbed what was discussed and also allows you to identify gaps in her understanding that can be addressed with further counseling.
Host: George L. Bakris, MD
Guest: Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACP
Guest: Robert Toto, MD
When treating patients with heart failure and chronic kidney disease, RAASi therapy should be continued if at all possible. One thing to keep in mind is that an elevation in serum creatinine does not always represent acute kidney injury. In this activity, Drs. George Bakris, Biykem Bozkurt, and Robert Toto examine a case study and discuss transient changes in serum creatinine with hyperkalemia. Join us to find out how and why you should avoid RAAS blockade interruption in these patients.
Host: Javed Butler, MD, MBA, MPH
Guest: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
It is well understood that RAASi therapy is critical in the management of patients with heart failure. However, hyperkalemia is common in these patients, and its presence often leads to suboptimal RAASi dosing, which in turn results in poorer patient outcomes. Join Drs. Javed Butler and Giuseppe Rosano as they look at a case presentation and discuss the hows and whys of optimal RAASi dosing in patients with heart failure and recurrent hyperkalemia.
Guest: Maria E. Arcila, MD
Guest: Alexander Drilon, MD
Capitalizing on the advances in identification of oncogenic driver mutations, genetic testing, and therapeutic approaches that target actionable mutations, targeted therapy is the current standard of care in NSCLC. The use of molecular testing and targeted therapies has yielded remarkable and practice-changing improvements for patients harboring these actionable mutations.
The current availability of multiple targeted agents, such as second- and third-generation ALK and ROS1 tyrosine kinase inhibitors, some of which are approved for use both in first-line and subsequent lines of therapy, coupled with the presence of concomitant actionable mutations, can make selection of the appropriate targeted treatment for eligible patients complicated.
This web-based, on-demand activity will feature an expert panel that will provide their interprofessional perspectives on the latest trends and emerging research regarding biomarker testing and evidence-based biomarker-guided targeted therapy for patients with NSCLC with ROS1 and ALK rearrangements.
Guest: Cheryl Pirozzi, MD, MS
Guest: Charlie Strange, MD
Alpha-1 antitrypsin deficiency (AATD) is a common yet underdiagnosed genetic disorder. Led by 2 AATD experts, this activity will address the most current information on the screening, diagnosis, and treatment of this potentially fatal disorder. AATD primarily affects the lungs and liver and requires a multidisciplinary care approach. Faculty will review patients who are at risk for AATD, its clinical manifestations (including similarities with COPD), and possible consequences to the lung and liver. Current treatment involves augmentation therapy with IV administration of AAT; there are ongoing investigations into other potential treatments. Patient cases will help clinicians apply the foundational information to clinical practice.
Host: John E. Anderson, MD
Guest: Simon Heller, MD
Dr. Simon Heller, a Professor of Clinical Diabetes at the University of Sheffield, discusses glucose-lowering studies and talks about the link between hypoglycemia and thrombosis in patients with diabetes.
Host: John E. Anderson, MD
Guest: Simon Heller, MD
What causes sudden death in patients with type 1 diabetes? Dr. Simon Heller, a Professor of Clinical Diabetes at the University of Sheffield, discusses severe hypoglycemia and cardiovascular risk in patients with both type 1 and type 2 diabetes and what clinicians to look for.
Host: Neilanjan Nandi, MD
Guest: Jordan E. Axelrad, MD, MPH
Many IBD patients and clinicians shy away from the topic of sexual health—and understandably so. Talking about sex in the clinic sadly remains a taboo, and there’s not many research studies exploring IBD and sexual health to use for guidance. But sexuality and intimacy are vital matters to discuss with our patients, which is why Dr. Jordan Axelrad joins Dr. Neil Nandi to share how we can facilitate an open and honest conversation with patients about their sexual health.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Alberto Augsten, PharmD
During the COVID-19 pandemic, many patients turned to alcohol as a way to cope with this sudden and unprecedented global health crisis, and the rates of alcohol dependency are only continuing to rise according to recent studies. That’s why Dr. Charles Turck speaks with board-certified clinical toxicologist Dr. Alberto Augsten to help us better understand the challenges in screening patients for alcohol dependency amid the COVID-19 pandemic and how we can overcome those barriers to get our patients the best—and necessary—treatment.
Published August 20, 2021
Host: John E. Anderson, MD
Guest: Simon Heller, MD
Dr. Simon Heller, a Professor of Clinical Diabetes at the University of Sheffield, and honorary consultant physician with the NHS Foundation Trust in the United Kingdom, reflects on the steps we can take to prevent severe hypoglycemia and reduce cardiovascular risk in diabetic patients.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Amanda Ayers, MD, FACS
Many patients undergo surgery to help manage their inflammatory bowel disease (IBD), but many questions still surround the surgical management of IBD. When should a patient receive surgery? How do we know which procedure is best? And what do we need to keep in mind before, during, and after a patient's surgery? Joining Dr. Peter Buch to help address those and other questions is colorectal surgeon Dr. Amanda Ayers.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Corey A. Siegel, MD, MS
Predicting which patients with IBD will develop complications allows for much better medication choices. But how do we go about predicting that risk? Joining Dr. Peter Buch to tackle this topic is Dr. Corey Siegel, Section Chief of Gastroenterology and Hepatology at Dartmouth-Hitchcock Medical Center.
Guest: Daniel Claassen, MD, MS
Neurogenic orthostatic hypotension (nOH) is a subset of orthostatic hypotension and is prevalent in patients with autonomic dysfunction.1,2 The cardinal symptoms of nOH include dizziness and lightheadedness,3 but frequently could include syncope, cognitive slowing, generalized weakness, coat-hanger (neck and shoulder) headache, fatigue, orthostatic dyspnea, blurred vision, and orthostatic angina.3 According to the Harris Poll conducted among nOH patients and their caregivers, the symptoms of nOH have a negative impact on activities of daily living. The symptoms are often minimized, poorly recognized/evaluated, or inadequately discussed and addressed.4
Patients with nOH may experience symptoms that can make daily tasks a challenge.1,5 The frequency and severity of symptomatic episodes can be unpredictable,6 and it is this unpredictability of events that contributes to a vicious cycle of nOH.1 In this cycle, fear of symptomatic events and falls may lead patients to reduce physical activity.1,5
References:
- Palma JA, Kaufmann H. Epidemiology, diagnosis, and management of neurogenic orthostatic hypotension. Mov Disord Clin Pract. 2017;4(3):298-308.
- Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21(2):69-72.
- Freeman R. Neurogenic orthostatic hypotension. N Engl J Med. 2008;358(6):615-624.
- Claassen DO, Adler …
Guest: Michel Chonchol, MD
Guest: Frederic Rahbari-Oskoui, MD, MS
This Expert Exchange webcast aims to improve clinicians’ ability to manage patients diagnosed with ADPKD.
Host: Matthew S. Keller MD
Guest: Omer Ibrahim, MD
In this episode, you’ll hear from board-certified dermatologist Dr. Omer Ibrahim about the rising prevalence of bed bug infestations, diagnostic and treatment strategies, and how we can help patients manage and prevent bed bug infestations.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Christopher J. DiMaio, MD
The approach to managing pancreatic necrosis has evolved over the past several years. To learn more, Dr. Peter Buch speaks with Dr. Christopher J. DiMaio, who’s one of the lead authors of the clinical practice update from the American Gastroenterological Association focusing on the management of pancreatic necrosis.
Host: John E. Anderson, MD
Host: John Buse, MD, PhD
Host: Carol Wysham, MD
John Anderson joins fellow Diabetes Discourse hosts John Buse and Carol Wysham to explore exciting clinical trial results presented at this year's Scientific Session of the American Diabetes Association.
Host: Hector O. Chapa, MD, FACOG
Guest: Susan Crowe, MD
Both UNICEF and WHO recommend exclusive breastfeeding for the first six months of life, starting within the very first hour of birth. But are we adhering to that recommendation? Joining Dr. Hector Chapa to discuss the importance of breastfeeding shortly after delivery and how we can help our patients and their newborns reap the benefits of this golden hour is Dr. Susan Crowe, Director of Outpatient Breastfeeding Medicine Consultative Services at Stanford Children's Health who recently spoke about this topic at the 2021 ACOG Annual Clinical and Scientific Meeting.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Yvonne Michael, ScD, SM
Dr. Yvonne Michael, an Associate Professor at the Dornsife School of Public Health at Drexel University, discusses risk factors that we should take into consideration when examining postmenopausal patients with coronary heart disease.
Guest: Garth W. Garrison, MD
Guest: Prema Menon, MD, PhD
The diagnosis and management of chronic cough can be challenging. In fact, only an estimated 50 percent of patients with chronic cough are accurately diagnosed. Recent advances in the understanding and management of refractory chronic cough have led to the development of novel therapies and ongoing clinical studies. In this two-part educational curriculum, pulmonary experts will discuss the prevalence, unmet clinical needs, and impact of chronic cough in patients who do not find relief from recommended management strategies. They will also review the clinical trial data and mechanisms of action of emerging therapies for patients with refractory chronic cough and summarize the current guidelines and emerging treatment strategies for the management of patients with chronic cough.
Host: Jacob Sands, MD
Guest: Brad McGregor, MD
Non-clear cell renal cell carcinoma is one of the rare diseases with limited treatment data, creating many challenges for oncologists. But could recent updates radically change the landscape? To find out, Dr. Jacob Sands speaks with Dr. Brad McGregor, the Clinical Director for the Lank Center for Genitourinary Oncology at the Dana-Farber Cancer Institute in Boston, to discuss developments in the management of non-clear cell renal cell carcinoma.
Guest: Matthew B. Lanktree, MD, PhD
Guest: Neera Dahl, MD, PhD
This Expert Exchange webcast aims to improve clinicians’ ability to properly monitor disease progression and make treatment decisions based on prognostic indicators.
Host: Michael Greenberg, MD
Guest: Joel Schlessinger, MD
Spa dermatology has morphed over the last 20 to 30 years, but not all of those changes benefited our patients. In fact, there are now several ethical and practical concerns when it comes to illegitimate med spas. Joining Dr. Matthew Keller to share those considerations and what we as dermatologists need to know so we can help guide our patients is board-certified dermatologist and cosmetic surgeon Dr. Joel Schlessinger.
Guest: Arlene B. Chapman, MD
Guest: Matthew B. Lanktree, MD, PhD
This Expert Exchange webcast aims to improve clinicians’ ability to detect and diagnose ADPKD in at-risk patients.
Host: John E. Anderson, MD
Guest: Michael Greenberg, MD
Dr. John Anderson joins Dr. Michael Greenberg, host of DermConsult, to discuss skin diseases that dermatologists should be aware of in patients with diabetes.
Host: Jacob Sands, MD
Guest: Derek Raghavan, MD, PhD, FACP, FRACP
CT scans have the potential to dramatically improve lung cancer outcomes, but are underserved communities receiving access to these types of screenings? Dr. Jacob Sands joins Dr. Derek Raghavan, President of Atrium Health Levine Cancer Institute in Charlotte, North Carolina, to discuss his research presented at the 2021 American Society of Clinical Oncology Annual Meeting.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Dustin Sulak, DO
Dr. Dustin Sulak, an integrative medicine physician specializing in osteopathy, mind-body medicine, and medical cannabis, talks about the impact of cannabis on the cardiovascular system.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Dustin Sulak, DO
The medical community continues to voice the medical benefits of cannabis. What do we need to know about them? Dr. Charles Turck discusses the benefits of medical cannabis with Dr. Dustin Sulak, an integrative medicine physician with a special focus on osteopathy, mind-body medicine, and medical cannabis.
Guest: Ami B. Bhatt, MD
The COVID-19 pandemic has brought a new level of understanding and optimizing telemedicine. Here to walk us through how telehealth can help us address unmet needs in direct outpatient cardiology, how it can be enhanced with wearable technology, and more is Dr. Ami Bhatt, Director of Outpatient Cardiology and Telecardiology at the Massachusetts General Hospital Heart Center.
6/21 121907
Host: David M. Simpson, MD
Guest: David R. Walega, MD
Guest: Eric J. Viel, MD, PhD
Find the full Prescribing Information here.
What are some of the current challenges in treating patients with painful diabetic peripheral neuropathy, and how can we overcome them? Explore those questions and more through the lens of patient case studies with Dr David M. Simpson, Dr Eric Viel, and Dr David Walega.
Here to walk us through the clinical trial data that led to the FDA approval of a treatment option for painful diabetic peripheral neuropathy of the feet is Dr David M. Simpson, a Professor of Neurology at the Icahn School of Medicine and Director of the Clinical Neurophysiology Laboratories and Neuromuscular Division at Mount Sinai in New York.
QUTENZA® is a registered trademark of Averitas Pharma, Inc.
Guest: Yehuda Handelsman, MD
Guest: Guy L. Mintz, MD
Guest: James A. Underberg, MD
Guest: Kari Uusinarkaus, MD
To learn more about the effect of persistent long-term exposure to LDL cholesterol on a patient’s risk of atherosclerotic cardiovascular disease, tune in to hear Drs Guy L. Mintz, James Underberg, Kari Uusinarkaus, and Yehuda Handelsman share their perspectives from four different specialties: cardiology, family medicine, internal medicine, and endocrinology.
6/21 121910